CHEBI ONTOLOGY - ANNOTATIONS |
|
The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
|
Term: | adjuvant |
|
Accession: | CHEBI:60809
|
browse the term
|
Definition: | Any pharmacological or immunological agent that modifies the effect of other agents such as drugs or vaccines while having few if any direct effects when given by itself. |
Synonyms: | related_synonym: | adjuvants |
|
|
|
G |
Cxcl10 |
C-X-C motif chemokine ligand 10 |
increases expression |
ISO |
KRN 7000 results in increased expression of CXCL10 protein |
CTD |
PMID:15867097 |
|
NCBI chr14:15,704,772...15,706,969
Ensembl chr14:15,704,758...15,706,975
|
|
G |
Il12b |
interleukin 12B |
increases expression |
ISO |
KRN 7000 results in increased expression of IL12B protein |
CTD |
PMID:15867097 |
|
NCBI chr10:28,888,832...28,903,796
Ensembl chr10:28,893,008...28,902,903
|
|
|
G |
Sult1a1 |
sulfotransferase family 1A member 1 |
multiple interactions |
ISO EXP |
Mefenamic Acid inhibits the reaction [SULT1A1 protein results in increased sulfation of 6-hydroxymelatonin] |
CTD |
PMID:11181495 |
|
NCBI chr 1:181,272,022...181,276,750
Ensembl chr 1:181,272,023...181,275,562
|
|
|
G |
Adora2a |
adenosine A2a receptor |
multiple interactions increases response to substance |
EXP ISO |
8-(3-chlorostyryl)caffeine binds to and results in decreased activity of ADORA2A protein; 8-(3-chlorostyryl)caffeine inhibits the reaction [2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine inhibits the reaction [Phenylephrine results in increased expression of ADORA2A mRNA]]; 8-(3-chlorostyryl)caffeine inhibits the reaction [2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine inhibits the reaction [Phenylephrine results in increased expression of ADORA2A protein]]; 8-(3-chlorostyryl)caffeine inhibits the reaction [[Oxidopamine co-treated with Levodopa] results in increased expression of ADORA2A protein] ADORA2A protein results in increased susceptibility to 8-(3-chlorostyryl)caffeine |
CTD |
PMID:11172060 PMID:15641640 PMID:18608257 PMID:19966059 PMID:21195062 |
|
NCBI chr20:13,315,848...13,333,386
Ensembl chr20:13,315,853...13,333,386
|
|
G |
Drd2 |
dopamine receptor D2 |
affects response to substance multiple interactions |
ISO |
DRD2 protein affects the susceptibility to 8-(3-chlorostyryl)caffeine DRD2 protein affects the susceptibility to [8-(3-chlorostyryl)caffeine co-treated with Reserpine] |
CTD |
PMID:11172060 |
|
NCBI chr 8:49,708,903...49,772,888
Ensembl chr 8:49,708,927...49,772,875
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
EXP |
8-(3-chlorostyryl)caffeine inhibits the reaction [Haloperidol results in increased expression of FOS mRNA]; 8-(3-chlorostyryl)caffeine promotes the reaction [Quinpirole inhibits the reaction [Reserpine results in increased expression of FOS protein]] |
CTD |
PMID:8577368 PMID:10199625 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Nppa |
natriuretic peptide A |
multiple interactions |
EXP |
8-(3-chlorostyryl)caffeine inhibits the reaction [[9-(2-hydroxy-3-nonyl)adenine co-treated with 4-nitrobenzylthioinosine] inhibits the reaction [Phenylephrine results in increased expression of NPPA mRNA]] |
CTD |
PMID:19966059 |
|
NCBI chr 5:158,429,042...158,430,351
Ensembl chr 5:158,429,042...158,430,351
|
|
G |
Nts |
neurotensin |
multiple interactions |
EXP |
8-(3-chlorostyryl)caffeine inhibits the reaction [Haloperidol results in increased expression of NTS mRNA] |
CTD |
PMID:10199625 |
|
NCBI chr 7:37,564,944...37,574,350
Ensembl chr 7:37,564,533...37,574,423
|
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
multiple interactions decreases activity |
ISO |
Atropine inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid] Atropine results in decreased activity of ABCB11 protein |
CTD |
PMID:24014644 |
|
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Abl1 |
ABL proto-oncogene 1, non-receptor tyrosine kinase |
multiple interactions |
ISO |
[Parathion co-treated with Atropine] results in increased expression of ABL1 mRNA |
CTD |
PMID:17390078 |
|
NCBI chr 3:14,979,853...15,083,065
Ensembl chr 3:14,979,853...15,083,065
|
|
G |
Ache |
acetylcholinesterase |
multiple interactions |
ISO EXP |
Atropine inhibits the reaction [[Organophosphorus Compounds results in decreased activity of ACHE protein] which results in increased abundance of Acetylcholine]; Atropine inhibits the reaction [Carbachol results in increased metabolism of and results in increased secretion of ACHE protein]; Atropine inhibits the reaction [Paraoxon results in increased expression of ACHE protein] [Atropine co-treated with Obidoxime Chloride] inhibits the reaction [Paraoxon results in decreased activity of ACHE protein]; [Methyl Parathion co-treated with pralidoxime co-treated with Atropine] results in decreased expression of ACHE protein; [Paraoxon co-treated with pralidoxime co-treated with Atropine] results in decreased activity of ACHE protein; [pralidoxime co-treated with Atropine] inhibits the reaction [Dichlorvos results in decreased activity of ACHE protein]; [tariquidar co-treated with asoxime chloride co-treated with Atropine] inhibits the reaction [Soman results in decreased activity of ACHE protein]; Atropine inhibits the reaction [Methyl Parathion results in decreased activity of ACHE protein]; Obidoxime Chloride inhibits the reaction [[Paraoxon co-treated with pralidoxime co-treated with Atropine] results in decreased activity of ACHE protein]; pralidoxime promotes the reaction [[Atropine co-treated with Curcumin] inhibits the reaction [Dichlorvos results in decreased activity of ACHE protein]] [1-(4-hydroxyiminomethylpyridinium)-3-(carbamoylpyridinium) propane dibromide co-treated with Atropine] inhibits the reaction [Sarin results in decreased activity of ACHE protein]; [[1-(4-hydroxyiminomethylpyridinium)-3-(carbamoylpyridinium) propane dibromide co-treated with cucurbit(7)uril] co-treated with Atropine] inhibits the reaction [Sarin results in decreased activity of ACHE protein]; Atropine inhibits the reaction [Sarin results in decreased activity of ACHE protein]; Atropine promotes the reaction [Dichlorvos results in increased phosphorylation of ACHE protein]; Atropine promotes the reaction [haloxon results in increased phosphorylation of ACHE protein]; Atropine promotes the reaction [Paraoxon results in increased phosphorylation of ACHE protein] |
CTD |
PMID:2241428 PMID:10421444 PMID:17963125 PMID:20105433 PMID:21600273 PMID:21787676 PMID:22783142 PMID:23047022 PMID:24881594 PMID:26751814 PMID:31794810 More...
|
|
NCBI chr12:19,407,359...19,413,713
Ensembl chr12:19,407,360...19,413,651
|
|
G |
Adcy5 |
adenylate cyclase 5 |
increases response to substance |
ISO |
ADCY5 protein results in increased susceptibility to Atropine |
CTD |
PMID:12869393 |
|
NCBI chr11:65,471,612...65,618,877
Ensembl chr11:65,471,612...65,618,974
|
|
G |
Aqp5 |
aquaporin 5 |
multiple interactions |
ISO |
Atropine inhibits the reaction [Pilocarpine affects the localization of AQP5 protein] |
CTD |
PMID:26208470 |
|
NCBI chr 7:130,722,675...130,726,207
Ensembl chr 7:130,721,748...130,726,209
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
EXP |
[asoxime chloride co-treated with Atropine co-treated with Diazepam] affects the reaction [Soman affects the expression of BAX mRNA] |
CTD |
PMID:21971501 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcar1 |
BCAR1 scaffold protein, Cas family member |
multiple interactions |
ISO |
Atropine inhibits the reaction [[oxotremorine M co-treated with wortmannin] inhibits the reaction [oxophenylarsine results in increased phosphorylation of BCAR1 protein]] |
CTD |
PMID:10537051 |
|
NCBI chr19:39,679,218...39,713,952
Ensembl chr19:39,679,204...39,713,907
|
|
G |
Bche |
butyrylcholinesterase |
multiple interactions |
EXP ISO |
[Atropine co-treated with pralidoxime] results in decreased expression of BCHE protein; [Methyl Parathion co-treated with pralidoxime co-treated with Atropine] results in decreased expression of BCHE protein [BCHE protein co-treated with asoxime chloride co-treated with pro-diazepam co-treated with Atropine] results in decreased susceptibility to VX |
CTD |
PMID:17963125 PMID:22981459 |
|
NCBI chr 2:158,308,674...158,401,148
Ensembl chr 2:158,307,584...158,401,148
|
|
G |
Bdkrb2 |
bradykinin receptor B2 |
multiple interactions |
ISO |
BDKRB2 affects the susceptibility to [Propranolol co-treated with Atropine] |
CTD |
PMID:10614985 |
|
NCBI chr 6:124,472,317...124,502,497
Ensembl chr 6:124,472,566...124,502,497
|
|
G |
Bmp6 |
bone morphogenetic protein 6 |
multiple interactions |
EXP |
Atropine inhibits the reaction [Carbon Tetrachloride results in increased expression of BMP6 mRNA] |
CTD |
PMID:18472332 |
|
NCBI chr17:26,318,121...26,469,034
Ensembl chr17:26,318,569...26,470,365
|
|
G |
Cacna1e |
calcium voltage-gated channel subunit alpha1 E |
multiple interactions |
EXP |
Atropine inhibits the reaction [Methacholine Chloride affects the reaction [CACNA1E protein results in increased transport of Barium]] |
CTD |
PMID:12663092 |
|
NCBI chr13:66,574,659...67,063,443
Ensembl chr13:66,581,920...66,894,450
|
|
G |
Calca |
calcitonin-related polypeptide alpha |
affects activity |
EXP |
Atropine affects the activity of CALCA protein |
CTD |
PMID:7906887 PMID:10075105 |
|
NCBI chr 1:168,878,212...168,883,176
Ensembl chr 1:168,878,214...168,883,105
|
|
G |
Casp3 |
caspase 3 |
increases expression |
EXP |
Atropine results in increased expression of CASP3 mRNA |
CTD |
PMID:19815060 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
multiple interactions |
ISO |
[Ketamine co-treated with Atropine] inhibits the reaction [Soman results in increased expression of CCL5 mRNA]; [Ketamine co-treated with Atropine] inhibits the reaction [Soman results in increased expression of CCL5 protein] |
CTD |
PMID:22245128 |
|
NCBI chr10:68,322,826...68,327,365
Ensembl chr10:68,322,829...68,327,377
|
|
G |
Ccna1 |
cyclin A1 |
increases expression multiple interactions |
ISO |
Atropine results in increased expression of CCNA1 mRNA [Parathion co-treated with Atropine] results in increased expression of CCNA1 mRNA |
CTD |
PMID:17390078 |
|
NCBI chr 2:139,231,738...139,278,066
Ensembl chr 2:139,201,074...139,243,157
|
|
G |
Ccnd3 |
cyclin D3 |
multiple interactions |
ISO |
[Parathion co-treated with Atropine] results in increased expression of CCND3 mRNA |
CTD |
PMID:17390078 |
|
NCBI chr 9:13,394,161...13,400,341
Ensembl chr 9:13,394,169...13,489,371
|
|
G |
Ccne1 |
cyclin E1 |
increases expression multiple interactions |
ISO |
Atropine results in increased expression of CCNE1 mRNA [Parathion co-treated with Atropine] results in increased expression of CCNE1 mRNA |
CTD |
PMID:17390078 |
|
NCBI chr 1:90,781,947...90,791,188
Ensembl chr 1:90,781,949...90,791,101
|
|
G |
Ccne2 |
cyclin E2 |
multiple interactions increases expression |
ISO |
[Parathion co-treated with Atropine] results in increased expression of CCNE2 mRNA Atropine results in increased expression of CCNE2 mRNA |
CTD |
PMID:17390078 |
|
NCBI chr 5:24,285,078...24,298,258
Ensembl chr 5:24,284,922...24,297,632
|
|
G |
Cd40 |
CD40 molecule |
multiple interactions |
ISO |
Atropine inhibits the reaction [Carbachol results in increased expression of CD40 protein] |
CTD |
PMID:16879495 |
|
NCBI chr 3:153,790,372...153,805,279
Ensembl chr 3:153,790,449...153,805,534
|
|
G |
Cdc20 |
cell division cycle 20 |
multiple interactions increases expression |
ISO |
[Parathion co-treated with Atropine] results in increased expression of CDC20 mRNA Atropine results in increased expression of CDC20 mRNA |
CTD |
PMID:17390078 |
|
NCBI chr 5:131,966,203...131,970,406
Ensembl chr 5:131,966,215...131,970,512
|
|
G |
Cdc6 |
cell division cycle 6 |
multiple interactions |
ISO |
[Parathion co-treated with Atropine] results in increased expression of CDC6 mRNA |
CTD |
PMID:17390078 |
|
NCBI chr10:83,864,189...83,878,011
Ensembl chr10:83,864,638...83,878,011
|
|
G |
Cdk1 |
cyclin-dependent kinase 1 |
multiple interactions increases expression |
ISO |
[Parathion co-treated with Atropine] results in increased expression of CDK1 mRNA Atropine results in increased expression of CDK1 mRNA |
CTD |
PMID:17390078 |
|
NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408
|
|
G |
Ces1d |
carboxylesterase 1D |
multiple interactions |
ISO |
Atropine inhibits the reaction [CES1 protein results in increased hydrolysis of 4-methylumbelliferyl acetate] |
CTD |
PMID:9311626 |
|
NCBI chr19:13,873,490...13,912,035
Ensembl chr19:13,796,623...13,912,035
|
|
G |
Chrm1 |
cholinergic receptor, muscarinic 1 |
multiple interactions decreases activity |
ISO |
Atropine binds to and results in decreased activity of CHRM1 protein; Atropine inhibits the reaction [[Carbachol results in increased activity of CHRM1 protein] which results in increased abundance of Calcium] Atropine results in decreased activity of CHRM1 protein Atropine affects the reaction [muscarinic toxin 7 binds to CHRM1 protein] |
CTD |
PMID:16439611 PMID:18316702 PMID:31830555 |
|
NCBI chr 1:205,567,046...205,583,001
Ensembl chr 1:205,567,220...205,582,356
|
|
G |
Chrm2 |
cholinergic receptor, muscarinic 2 |
multiple interactions |
ISO |
Atropine binds to and results in decreased activity of CHRM2 protein |
CTD |
PMID:15140916 |
|
NCBI chr 4:65,015,408...65,149,104
Ensembl chr 4:65,014,144...65,149,103
|
|
G |
Chrm3 |
cholinergic receptor, muscarinic 3 |
multiple interactions decreases activity |
ISO |
Atropine binds to and results in decreased activity of CHRM3 protein; Atropine inhibits the reaction [Carbachol results in increased activity of CHRM3 protein] Atropine results in decreased activity of CHRM3 protein |
CTD |
PMID:15140916 PMID:20708676 PMID:31830555 |
|
NCBI chr17:60,005,137...60,467,250
Ensembl chr17:60,005,202...60,467,278
|
|
G |
Chrm4 |
cholinergic receptor, muscarinic 4 |
multiple interactions affects binding |
ISO |
[WIN 62577 co-treated with Quinuclidinyl Benzilate] inhibits the reaction [Atropine binds to CHRM4 protein] |
CTD |
PMID:16709648 |
|
NCBI chr 3:77,893,425...77,901,166
Ensembl chr 3:77,893,425...77,901,159
|
|
G |
Chrm5 |
cholinergic receptor, muscarinic 5 |
multiple interactions |
ISO |
Atropine inhibits the reaction [Acetylcholine results in increased activity of CHRM5 protein] |
CTD |
PMID:31323226 |
|
NCBI chr 3:99,284,846...99,337,252
Ensembl chr 3:99,284,846...99,337,252
|
|
G |
Chrna4 |
cholinergic receptor nicotinic alpha 4 subunit |
multiple interactions affects binding |
ISO EXP |
Atropine promotes the reaction [Acetylcholine affects the activity of [CHRNA4 protein binds to CHRNB2 protein]] Atropine promotes the reaction [Mecamylamine inhibits the reaction [Paraoxon results in decreased expression of CHRNA4 mRNA]]; Atropine promotes the reaction [Mecamylamine inhibits the reaction [Paraoxon results in decreased expression of CHRNA4 protein]] Atropine binds to [CHRNA4 protein binds to CHRNB2 protein] |
CTD |
PMID:15733544 PMID:21791372 |
|
NCBI chr 3:168,136,246...168,157,839
Ensembl chr 3:168,136,266...168,156,957
|
|
G |
Chrnb2 |
cholinergic receptor nicotinic beta 2 subunit |
affects binding multiple interactions |
ISO EXP |
Atropine binds to [CHRNA4 protein binds to CHRNB2 protein] Atropine promotes the reaction [Mecamylamine inhibits the reaction [Paraoxon results in decreased expression of CHRNB2 mRNA]]; Atropine promotes the reaction [Mecamylamine inhibits the reaction [Paraoxon results in decreased expression of CHRNB2 protein]] Atropine promotes the reaction [Acetylcholine affects the activity of [CHRNA4 protein binds to CHRNB2 protein]] |
CTD |
PMID:15733544 PMID:21791372 |
|
NCBI chr 2:175,181,402...175,189,619
Ensembl chr 2:175,181,402...175,189,619
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
multiple interactions |
EXP |
[asoxime chloride co-treated with Atropine co-treated with Diazepam] affects the reaction [Soman affects the phosphorylation of CREB1 protein] |
CTD |
PMID:21971501 |
|
NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816
|
|
G |
Crh |
corticotropin releasing hormone |
multiple interactions |
EXP ISO |
Atropine inhibits the reaction [acephate results in increased expression of CRH mRNA]; Atropine inhibits the reaction [acephate results in increased secretion of CRH protein]; Atropine inhibits the reaction [methamidophos results in increased expression of CRH mRNA]; Atropine inhibits the reaction [methamidophos results in increased secretion of CRH protein] [Atropine co-treated with SR 140333 co-treated with SR 48968] results in decreased activity of CRH protein |
CTD |
PMID:12039681 PMID:12906840 |
|
NCBI chr 2:102,143,055...102,144,919
Ensembl chr 2:102,143,055...102,144,919
|
|
G |
Ctnnb1 |
catenin beta 1 |
multiple interactions |
ISO |
Atropine inhibits the reaction [Parathion results in increased expression of CTNNB1 protein mutant form]; Atropine inhibits the reaction [Parathion results in increased expression of CTNNB1 protein] |
CTD |
PMID:17390078 |
|
NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111
|
|
G |
Cxcl3 |
C-X-C motif chemokine ligand 3 |
multiple interactions |
ISO |
[Ketamine co-treated with Atropine] inhibits the reaction [Soman results in increased expression of CXCL1 mRNA]; [Ketamine co-treated with Atropine] inhibits the reaction [Soman results in increased expression of CXCL1 protein] |
CTD |
PMID:22245128 |
|
NCBI chr14:17,270,146...17,289,458
Ensembl chr14:17,270,146...17,289,511
|
|
G |
Dvl2 |
dishevelled segment polarity protein 2 |
multiple interactions |
ISO |
Atropine inhibits the reaction [Parathion results in increased expression of DVL2 protein] |
CTD |
PMID:17390078 |
|
NCBI chr10:54,723,356...54,732,823
Ensembl chr10:54,723,411...54,732,820
|
|
G |
Edn1 |
endothelin 1 |
multiple interactions |
ISO |
EDN1 protein results in decreased activity of [Atropine co-treated with Histamine] |
CTD |
PMID:12906840 |
|
NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions |
ISO |
Atropine inhibits the reaction [Parathion results in increased expression of EGFR protein] |
CTD |
PMID:17390078 |
|
NCBI chr14:91,176,931...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Egr1 |
early growth response 1 |
multiple interactions |
EXP |
Atropine inhibits the reaction [Pilocarpine results in increased expression of EGR1 mRNA] |
CTD |
PMID:7968354 |
|
NCBI chr18:26,463,333...26,465,531
Ensembl chr18:26,462,981...26,466,766
|
|
G |
Egr2 |
early growth response 2 |
multiple interactions |
EXP |
Atropine inhibits the reaction [Pilocarpine results in increased expression of EGR2 mRNA] |
CTD |
PMID:7968354 |
|
NCBI chr20:21,051,270...21,056,322
Ensembl chr20:21,051,277...21,055,562
|
|
G |
Ezr |
ezrin |
multiple interactions |
ISO |
Atropine inhibits the reaction [Parathion results in increased expression of EZR protein] |
CTD |
PMID:17390078 |
|
NCBI chr 1:46,967,961...47,011,505
Ensembl chr 1:46,967,658...47,011,505
|
|
G |
F2 |
coagulation factor II |
multiple interactions |
ISO |
[Paraoxon co-treated with Atropine co-treated with Obidoxime Chloride] results in decreased expression of F2 mRNA; [Paraoxon co-treated with Atropine co-treated with Obidoxime Chloride] results in increased activity of F2 protein |
CTD |
PMID:30515700 |
|
NCBI chr 3:77,596,196...77,609,486
Ensembl chr 3:77,596,198...77,609,486
|
|
G |
F2r |
coagulation factor II (thrombin) receptor |
multiple interactions |
ISO |
[Paraoxon co-treated with Atropine co-treated with Obidoxime Chloride] results in increased expression of F2R protein |
CTD |
PMID:30515700 |
|
NCBI chr 2:26,869,343...26,885,856
Ensembl chr 2:26,868,404...26,885,870
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
increases expression multiple interactions |
EXP ISO |
Atropine results in increased expression of FOS protein Atropine inhibits the reaction [Paraoxon results in increased expression of FOS mRNA] [asoxime chloride co-treated with Atropine co-treated with Diazepam] affects the reaction [Soman results in increased expression of FOS protein]; Atropine inhibits the reaction [Pilocarpine results in increased expression of FOS mRNA] |
CTD |
PMID:7968354 PMID:8281324 PMID:21787676 PMID:21971501 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Ghrl |
ghrelin and obestatin prepropeptide |
multiple interactions |
EXP |
Atropine inhibits the reaction [[Pentobarbital co-treated with L-pyroglutamyl-L-histidyl-3,3-dimethylprolinamide] results in increased expression of GHRL protein] |
CTD |
PMID:16959836 |
|
NCBI chr 4:146,865,712...146,869,621
Ensembl chr 4:146,865,712...146,869,621
|
|
G |
Glra1 |
glycine receptor, alpha 1 |
multiple interactions |
ISO |
Atropine binds to and results in decreased activity of GLRA1 protein |
CTD |
PMID:15081878 |
|
NCBI chr10:39,625,853...39,727,897
Ensembl chr10:39,629,459...39,727,162
|
|
G |
Grm4 |
glutamate metabotropic receptor 4 |
multiple interactions |
ISO |
Atropine inhibits the reaction [[Carbachol results in increased activity of [GRM4 protein binds to KCNJ3 protein]] which results in increased import of Thallium] |
CTD |
PMID:18171729 |
|
NCBI chr20:5,484,172...5,572,821
Ensembl chr20:5,481,124...5,572,821
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions |
ISO |
[Ketamine co-treated with Atropine] inhibits the reaction [Soman results in increased expression of ICAM1 mRNA]; [Ketamine co-treated with Atropine] inhibits the reaction [Soman results in increased expression of ICAM1 protein] |
CTD |
PMID:22245128 |
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
[Ketamine co-treated with Atropine] inhibits the reaction [Soman results in increased expression of IL1B mRNA]; [Ketamine co-treated with Atropine] inhibits the reaction [Soman results in increased expression of IL1B protein] |
CTD |
PMID:22245128 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
[Atropine co-treated with Ketamine] inhibits the reaction [Soman results in increased expression of IL6 mRNA]; [Atropine co-treated with Ketamine] inhibits the reaction [Soman results in increased expression of IL6 protein] |
CTD |
PMID:22245128 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
EXP |
[asoxime chloride co-treated with Atropine co-treated with Diazepam] affects the reaction [Soman affects the phosphorylation of JUN protein] |
CTD |
PMID:21971501 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Junb |
JunB proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
EXP |
Atropine inhibits the reaction [Pilocarpine results in increased expression of JUNB mRNA] |
CTD |
PMID:7968354 |
|
NCBI chr19:23,176,265...23,178,049
Ensembl chr19:23,176,294...23,178,035
|
|
G |
Kcnj3 |
potassium inwardly-rectifying channel, subfamily J, member 3 |
multiple interactions |
ISO |
Atropine inhibits the reaction [[Carbachol results in increased activity of [GRM4 protein binds to KCNJ3 protein]] which results in increased import of Thallium] |
CTD |
PMID:18171729 |
|
NCBI chr 3:39,944,896...40,106,646
Ensembl chr 3:39,945,351...40,109,124
|
|
G |
Kit |
KIT proto-oncogene receptor tyrosine kinase |
multiple interactions |
ISO |
Atropine inhibits the reaction [Parathion results in increased expression of KIT protein] |
CTD |
PMID:17390078 |
|
NCBI chr14:32,547,459...32,624,694
Ensembl chr14:32,548,877...32,624,652
|
|
G |
Ltf |
lactotransferrin |
multiple interactions |
ISO |
Atropine inhibits the reaction [methylcholine results in increased secretion of LTF protein] |
CTD |
PMID:11112886 |
|
NCBI chr 8:110,999,948...111,022,795
Ensembl chr 8:110,999,948...111,022,795
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
EXP |
[asoxime chloride co-treated with Atropine co-treated with Diazepam] affects the reaction [Soman results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:21971501 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk14 |
mitogen activated protein kinase 14 |
multiple interactions |
EXP |
[asoxime chloride co-treated with Atropine co-treated with Diazepam] affects the reaction [Soman results in increased phosphorylation of MAPK14 protein] |
CTD |
PMID:21971501 |
|
NCBI chr20:6,749,646...6,810,590
Ensembl chr20:6,749,670...6,810,589
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
EXP |
[asoxime chloride co-treated with Atropine co-treated with Diazepam] affects the reaction [Soman results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:21971501 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions |
EXP |
[asoxime chloride co-treated with Atropine co-treated with Diazepam] affects the reaction [Soman results in increased phosphorylation of MAPK8 protein] |
CTD |
PMID:21971501 |
|
NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Mcm4 |
minichromosome maintenance complex component 4 |
multiple interactions increases expression |
ISO |
[Parathion co-treated with Atropine] results in increased expression of MCM4 mRNA Atropine results in increased expression of MCM4 mRNA |
CTD |
PMID:17390078 |
|
NCBI chr11:85,258,443...85,272,144
Ensembl chr11:85,258,443...85,272,144
|
|
G |
Mcm6 |
minichromosome maintenance complex component 6 |
increases expression multiple interactions |
ISO |
Atropine results in increased expression of MCM6 mRNA [Parathion co-treated with Atropine] results in increased expression of MCM6 mRNA |
CTD |
PMID:17390078 |
|
NCBI chr13:39,826,745...39,851,937
Ensembl chr13:39,826,763...39,851,960
|
|
G |
Nefh |
neurofilament heavy chain |
affects expression |
EXP |
Atropine affects the expression of NEFH mRNA |
CTD |
PMID:22954530 |
|
NCBI chr14:79,830,362...79,840,347
Ensembl chr14:79,830,362...79,840,351
|
|
G |
Nlrp3 |
NLR family, pyrin domain containing 3 |
increases expression |
ISO |
Atropine results in increased expression of NLRP3 mRNA |
CTD |
PMID:28138970 |
|
NCBI chr10:44,326,770...44,353,814
Ensembl chr10:44,328,566...44,352,811
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
EXP |
Atropine inhibits the reaction [Indomethacin results in increased activity of NOS2 protein]; Atropine inhibits the reaction [Indomethacin results in increased expression of NOS2 mRNA] |
CTD |
PMID:15610444 PMID:16944022 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Notch4 |
notch receptor 4 |
multiple interactions |
ISO |
Atropine inhibits the reaction [Parathion results in increased expression of NOTCH4 protein] |
CTD |
PMID:17390078 |
|
NCBI chr20:4,160,362...4,184,466
Ensembl chr20:4,160,445...4,184,465
|
|
G |
Nppa |
natriuretic peptide A |
affects activity |
EXP |
Atropine affects the activity of NPPA protein modified form |
CTD |
PMID:1363893 |
|
NCBI chr 5:158,429,042...158,430,351
Ensembl chr 5:158,429,042...158,430,351
|
|
G |
Oprl1 |
opioid related nociceptin receptor 1 |
multiple interactions |
EXP |
Atropine inhibits the reaction [PNOC protein binds to and results in increased activity of OPRL1 protein] |
CTD |
PMID:12007927 |
|
NCBI chr 3:168,831,934...168,839,920
Ensembl chr 3:168,834,003...168,839,920
|
|
G |
Pcna |
proliferating cell nuclear antigen |
multiple interactions |
ISO |
Atropine inhibits the reaction [Malathion results in increased expression of PCNA]; Atropine inhibits the reaction [Parathion results in increased expression of PCNA] |
CTD |
PMID:12762645 |
|
NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995
|
|
G |
Pnoc |
prepronociceptin |
multiple interactions |
EXP |
Atropine inhibits the reaction [PNOC protein binds to and results in increased activity of OPRL1 protein] |
CTD |
PMID:12007927 |
|
NCBI chr15:39,624,635...39,652,463
Ensembl chr15:39,624,641...39,651,867
|
|
G |
Pomc |
proopiomelanocortin |
multiple interactions |
EXP |
Atropine inhibits the reaction [Acetylcholine results in increased expression of POMC protein] |
CTD |
PMID:7588217 |
|
NCBI chr 6:26,939,844...26,945,666
Ensembl chr 6:26,939,837...26,945,664
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions |
ISO |
[Atropine co-treated with Glucose] binds to PPARA protein; Atropine inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]] |
CTD |
PMID:18812576 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
EXP |
Atropine affects the reaction [Indomethacin results in increased expression of PTGS2]; Atropine inhibits the reaction [Indomethacin results in increased expression of PTGS2 mRNA]; Atropine inhibits the reaction [Indomethacin results in increased expression of PTGS2]; Atropine inhibits the reaction [SC 560 results in increased expression of PTGS2 mRNA] |
CTD |
PMID:15104355 PMID:15610444 PMID:16259740 PMID:16804302 |
|
NCBI chr13:62,164,080...62,169,770
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Ptk2 |
protein tyrosine kinase 2 |
multiple interactions |
ISO |
Atropine inhibits the reaction [oxotremorine M inhibits the reaction [[wortmannin co-treated with lysophosphatidic acid] results in increased phosphorylation of PTK2 protein]]; Atropine inhibits the reaction [oxotremorine M inhibits the reaction [[wortmannin co-treated with oxophenylarsine] results in increased phosphorylation of PTK2 protein]]; Atropine inhibits the reaction [oxotremorine M promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with wortmannin] results in increased phosphorylation of PTK2 protein]] |
CTD |
PMID:10537051 |
|
NCBI chr 7:105,126,725...105,331,848
Ensembl chr 7:105,126,728...105,331,783
|
|
G |
Pxn |
paxillin |
multiple interactions |
ISO |
Atropine inhibits the reaction [[oxotremorine M co-treated with wortmannin] inhibits the reaction [oxophenylarsine results in increased phosphorylation of PXN protein]] |
CTD |
PMID:10537051 |
|
NCBI chr12:41,060,791...41,107,962
Ensembl chr12:41,060,791...41,107,931
|
|
G |
Rac3 |
Rac family small GTPase 3 |
multiple interactions |
ISO |
Atropine inhibits the reaction [Parathion results in increased expression of RAC3 protein] |
CTD |
PMID:17390078 |
|
NCBI chr10:106,002,808...106,005,244
Ensembl chr10:105,993,087...106,005,260
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
EXP |
[asoxime chloride co-treated with Atropine co-treated with Diazepam] affects the reaction [Soman affects the phosphorylation of RELA protein] |
CTD |
PMID:21971501 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Rhoa |
ras homolog family member A |
multiple interactions |
ISO |
Atropine inhibits the reaction [Parathion results in increased expression of RHOA protein] |
CTD |
PMID:17390078 |
|
NCBI chr 8:108,991,926...109,025,746
Ensembl chr 8:108,991,954...109,025,746
|
|
G |
Slc22a1 |
solute carrier family 22 member 1 |
multiple interactions |
ISO |
Atropine inhibits the reaction [SLC22A1 protein results in increased transport of 1-Methyl-4-phenylpyridinium]; Atropine inhibits the reaction [SLC22A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium] |
CTD |
PMID:16263091 PMID:21641380 |
|
NCBI chr 1:48,076,657...48,103,679
Ensembl chr 1:48,076,666...48,103,678
|
|
G |
Slc22a2 |
solute carrier family 22 member 2 |
multiple interactions |
ISO |
Atropine inhibits the reaction [SLC22A2 protein results in increased transport of 1-Methyl-4-phenylpyridinium]; Atropine inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium]; Atropine inhibits the reaction [SLC22A2 protein results in increased uptake of Tetraethylammonium] |
CTD |
PMID:16263091 PMID:21599003 PMID:23770354 |
|
NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268
|
|
G |
Slc22a3 |
solute carrier family 22 member 3 |
increases uptake multiple interactions |
ISO |
SLC22A3 protein results in increased uptake of Atropine Atropine inhibits the reaction [SLC22A3 protein results in increased transport of 1-Methyl-4-phenylpyridinium] |
CTD |
PMID:16263091 |
|
NCBI chr 1:48,235,476...48,324,617
Ensembl chr 1:48,235,476...48,324,612
|
|
G |
Slc22a4 |
solute carrier family 22 member 4 |
multiple interactions |
ISO |
Atropine inhibits the reaction [SLC22A4 protein results in increased uptake of Tetraethylammonium] |
CTD |
PMID:21641380 |
|
NCBI chr10:38,133,333...38,179,932
Ensembl chr10:38,133,322...38,179,720
|
|
G |
Slc47a1 |
solute carrier family 47 member 1 |
multiple interactions |
ISO |
Atropine inhibits the reaction [SLC47A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium] |
CTD |
PMID:22419765 |
|
NCBI chr10:46,034,115...46,088,617
Ensembl chr10:46,034,122...46,087,637
|
|
G |
Slc47a2 |
solute carrier family 47 member 2 |
multiple interactions |
ISO |
Atropine inhibits the reaction [SLC47A2 protein results in increased uptake of 1-Methyl-4-phenylpyridinium] |
CTD |
PMID:22419765 |
|
NCBI chr10:45,990,806...46,033,937
Ensembl chr10:45,991,095...46,033,904
|
|
G |
Slpi |
secretory leukocyte peptidase inhibitor |
increases expression |
ISO |
Atropine results in increased expression of SLPI mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 3:153,082,208...153,084,457
Ensembl chr 3:153,082,369...153,084,453
|
|
G |
Socs3 |
suppressor of cytokine signaling 3 |
multiple interactions |
ISO |
[Ketamine co-treated with Atropine] inhibits the reaction [Soman results in increased expression of SOCS3 mRNA] |
CTD |
PMID:22245128 |
|
NCBI chr10:103,193,909...103,197,322
Ensembl chr10:103,193,537...103,197,787
|
|
G |
Spn |
sialophorin |
increases response to substance |
ISO |
SPN protein results in increased susceptibility to Atropine |
CTD |
PMID:18711009 |
|
NCBI chr 1:181,746,937...181,759,564
Ensembl chr 1:181,746,429...181,759,628
|
|
G |
Tat |
tyrosine aminotransferase |
multiple interactions |
EXP |
[Atropine co-treated with Obidoxime Chloride co-treated with Diazepam] inhibits the reaction [Dichlorvos results in increased expression of TAT protein] |
CTD |
PMID:7761789 |
|
NCBI chr19:37,947,153...37,957,717
Ensembl chr19:37,947,112...37,958,031
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
EXP |
Atropine inhibits the reaction [Carbon Tetrachloride results in increased expression of TGFB1 mRNA] |
CTD |
PMID:18472332 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
[Ketamine co-treated with Atropine] inhibits the reaction [Soman results in increased expression of TNF mRNA]; [Ketamine co-treated with Atropine] inhibits the reaction [Soman results in increased expression of TNF protein] |
CTD |
PMID:22245128 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions |
ISO |
Atropine inhibits the reaction [Malathion results in increased expression of TP53 protein]; Atropine inhibits the reaction [Parathion results in increased expression of TP53 protein] |
CTD |
PMID:12762645 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Trio |
trio Rho guanine nucleotide exchange factor |
multiple interactions |
ISO |
Atropine inhibits the reaction [Parathion results in increased expression of TRIO protein] |
CTD |
PMID:17390078 |
|
NCBI chr 2:78,505,069...78,801,384
Ensembl chr 2:78,505,070...78,803,135
|
|
G |
Trpa1 |
transient receptor potential cation channel, subfamily A, member 1 |
decreases response to substance |
ISO |
TRPA1 gene mutant form results in decreased susceptibility to Atropine |
CTD |
PMID:29627347 |
|
NCBI chr 5:4,379,999...4,433,243
Ensembl chr 5:4,379,999...4,433,570
|
|
G |
Tshb |
thyroid stimulating hormone subunit beta |
multiple interactions |
EXP |
[pralidoxime co-treated with Atropine] inhibits the reaction [methamidophos results in decreased expression of TSHB protein] |
CTD |
PMID:15891268 |
|
NCBI chr 2:190,224,676...190,229,559
Ensembl chr 2:190,224,676...190,229,559
|
|
G |
Tspo |
translocator protein |
multiple interactions |
EXP |
[Ketamine co-treated with Midazolam co-treated with Valproic Acid] inhibits the reaction [[Sarin co-treated with [Atropine co-treated with trimethylene-bis(4-hydroxyiminomethylpyridinium)]] results in increased expression of TSPO protein]; [Sarin co-treated with [Atropine co-treated with trimethylene-bis(4-hydroxyiminomethylpyridinium)]] results in increased expression of TSPO protein |
CTD |
PMID:33823148 |
|
NCBI chr 7:114,720,188...114,730,450
Ensembl chr 7:114,720,188...114,730,450
|
|
G |
Vcam1 |
vascular cell adhesion molecule 1 |
multiple interactions |
ISO |
[Ketamine co-treated with Atropine] inhibits the reaction [Soman results in increased expression of VCAM1 mRNA] |
CTD |
PMID:22245128 |
|
NCBI chr 2:204,038,120...204,057,852
Ensembl chr 2:204,038,114...204,057,958
|
|
|
G |
Gclm |
glutamate cysteine ligase, modifier subunit |
multiple interactions increases expression |
ISO |
NFE2L2 protein affects the reaction [benphothiamine metabolite results in increased expression of GCLM mRNA]; NFE2L2 protein affects the reaction [benphothiamine results in increased expression of GCLM mRNA] benphothiamine metabolite results in increased expression of GCLM mRNA; benphothiamine results in increased expression of GCLM mRNA |
CTD |
PMID:29860433 |
|
NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535
|
|
G |
Gsr |
glutathione-disulfide reductase |
multiple interactions increases expression |
ISO |
NFE2L2 protein affects the reaction [benphothiamine results in increased expression of GSR mRNA] |
CTD |
PMID:29860433 |
|
NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression multiple interactions |
ISO |
benphothiamine metabolite results in increased expression of HMOX1 mRNA; benphothiamine results in increased expression of HMOX1 mRNA benphothiamine inhibits the reaction [MAPT protein results in increased expression of HMOX1 mRNA]; NFE2L2 protein affects the reaction [benphothiamine metabolite results in increased expression of HMOX1 mRNA]; NFE2L2 protein affects the reaction [benphothiamine results in increased expression of HMOX1 mRNA] |
CTD |
PMID:29860433 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
[benphothiamine co-treated with MAPT protein] results in decreased expression of IL1B protein |
CTD |
PMID:29860433 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Mapt |
microtubule-associated protein tau |
decreases phosphorylation multiple interactions |
ISO |
benphothiamine results in decreased phosphorylation of MAPT protein [benphothiamine co-treated with MAPT protein] results in decreased expression of IL1B protein; [benphothiamine co-treated with MAPT protein] results in decreased expression of NOS2 protein; [benphothiamine co-treated with MAPT protein] results in decreased expression of PTGS2 protein; [benphothiamine co-treated with MAPT protein] results in decreased expression of RELA protein; [benphothiamine co-treated with MAPT protein] results in decreased expression of TNF protein; [benphothiamine co-treated with MAPT protein] results in increased expression of NQO1 mRNA; [benphothiamine co-treated with MAPT protein] results in increased expression of TXN mRNA; benphothiamine inhibits the reaction [MAPT protein results in decreased activity of TKT protein]; benphothiamine inhibits the reaction [MAPT protein results in decreased expression of NOS2 mRNA]; benphothiamine inhibits the reaction [MAPT protein results in decreased expression of PPARGC1A protein]; benphothiamine inhibits the reaction [MAPT protein results in decreased expression of SOD1 protein]; benphothiamine inhibits the reaction [MAPT protein results in increased expression of HMOX1 mRNA] |
CTD |
PMID:29860433 |
|
NCBI chr10:89,138,644...89,236,137
Ensembl chr10:89,138,627...89,236,129
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions |
ISO |
NFE2L2 protein affects the reaction [benphothiamine metabolite results in increased expression of GCLM mRNA]; NFE2L2 protein affects the reaction [benphothiamine metabolite results in increased expression of HMOX1 mRNA]; NFE2L2 protein affects the reaction [benphothiamine metabolite results in increased expression of NQO1 mRNA]; NFE2L2 protein affects the reaction [benphothiamine results in increased expression of GCLM mRNA]; NFE2L2 protein affects the reaction [benphothiamine results in increased expression of GSR mRNA]; NFE2L2 protein affects the reaction [benphothiamine results in increased expression of HMOX1 mRNA]; NFE2L2 protein affects the reaction [benphothiamine results in increased expression of NQO1 mRNA] |
CTD |
PMID:29860433 |
|
NCBI chr 3:60,594,239...60,621,785
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
[benphothiamine co-treated with MAPT protein] results in decreased expression of NOS2 protein; benphothiamine inhibits the reaction [MAPT protein results in decreased expression of NOS2 mRNA] |
CTD |
PMID:29860433 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
increases expression multiple interactions |
ISO |
benphothiamine metabolite results in increased expression of NQO1 mRNA; benphothiamine results in increased expression of NQO1 mRNA [benphothiamine co-treated with MAPT protein] results in increased expression of NQO1 mRNA; NFE2L2 protein affects the reaction [benphothiamine metabolite results in increased expression of NQO1 mRNA]; NFE2L2 protein affects the reaction [benphothiamine results in increased expression of NQO1 mRNA] |
CTD |
PMID:29860433 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
multiple interactions |
ISO |
benphothiamine inhibits the reaction [MAPT protein results in decreased expression of PPARGC1A protein] |
CTD |
PMID:29860433 |
|
NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
[benphothiamine co-treated with MAPT protein] results in decreased expression of PTGS2 protein |
CTD |
PMID:29860433 |
|
NCBI chr13:62,164,080...62,169,770
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
[benphothiamine co-treated with MAPT protein] results in decreased expression of RELA protein |
CTD |
PMID:29860433 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Sod1 |
superoxide dismutase 1 |
multiple interactions |
ISO |
benphothiamine inhibits the reaction [MAPT protein results in decreased expression of SOD1 protein] |
CTD |
PMID:29860433 |
|
NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249
|
|
G |
Tkt |
transketolase |
multiple interactions |
EXP ISO |
[benphothiamine co-treated with Streptozocin] results in increased activity of TKT protein benphothiamine inhibits the reaction [MAPT protein results in decreased activity of TKT protein] |
CTD |
PMID:12592403 PMID:29860433 |
|
NCBI chr16:5,723,764...5,748,702
Ensembl chr16:5,723,762...5,748,698
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
[benphothiamine co-treated with MAPT protein] results in decreased expression of TNF protein |
CTD |
PMID:29860433 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Txn1 |
thioredoxin 1 |
multiple interactions |
ISO |
[benphothiamine co-treated with MAPT protein] results in increased expression of TXN mRNA |
CTD |
PMID:29860433 |
|
NCBI chr 5:72,712,334...72,724,564
Ensembl chr 5:72,711,933...72,724,629
|
|
|
G |
Cdkn2a |
cyclin-dependent kinase inhibitor 2A |
multiple interactions |
EXP |
[Beryllium results in increased methylation of CDKN2A promoter] which results in decreased expression of CDKN2A mRNA |
CTD |
PMID:11872642 |
|
NCBI chr 5:103,984,949...103,992,143
Ensembl chr 5:103,984,949...104,003,149
|
|
G |
Esr1 |
estrogen receptor 1 |
increases methylation |
EXP |
Beryllium results in increased methylation of ESR1 gene |
CTD |
PMID:11872642 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Hras |
HRas proto-oncogene, GTPase |
increases mutagenesis |
EXP |
Beryllium results in increased mutagenesis of HRAS gene |
CTD |
PMID:7545909 |
|
NCBI chr 1:196,290,127...196,299,823
Ensembl chr 1:196,296,263...196,300,615
|
|
G |
Il1b |
interleukin 1 beta |
increases expression affects expression |
ISO |
Beryllium results in increased expression of IL1B mRNA Beryllium affects the expression of IL1B mRNA |
CTD |
PMID:8473757 PMID:8629860 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Tnf |
tumor necrosis factor |
increases response to substance increases secretion increases expression |
ISO |
TNF promoter polymorphism results in increased susceptibility to Beryllium Beryllium results in increased secretion of TNF protein Beryllium results in increased expression of TNF mRNA |
CTD |
PMID:8629860 PMID:12449171 PMID:15127972 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
|
G |
Apex1 |
apurinic/apyrimidinic endodeoxyribonuclease 1 |
affects expression |
ISO |
beryllium chloride affects the expression of APEX1 mRNA |
CTD |
PMID:23793613 |
|
NCBI chr15:24,144,595...24,146,785
Ensembl chr15:24,144,362...24,146,785
|
|
G |
Ogg1 |
8-oxoguanine DNA glycosylase |
affects expression |
ISO |
beryllium chloride affects the expression of OGG1 mRNA |
CTD |
PMID:23793613 |
|
NCBI chr 4:146,474,701...146,481,959
Ensembl chr 4:146,474,750...146,484,766
|
|
G |
Tp53 |
tumor protein p53 |
increases expression |
ISO |
beryllium chloride results in increased expression of TRP53 mRNA |
CTD |
PMID:23793613 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
multiple interactions |
ISO |
beryllium fluoride promotes the reaction [ABCB1 protein mutant form binds to 8-azidoadenosine 5'-triphosphate] |
CTD |
PMID:11027628 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcc6 |
ATP binding cassette subfamily C member 6 |
multiple interactions |
EXP |
beryllium fluoride promotes the reaction [8-azidoadenosine 5'-triphosphate binds to ABCC6 protein]; Cobalt promotes the reaction [beryllium fluoride promotes the reaction [8-azidoadenosine 5'-triphosphate binds to ABCC6 protein]]; Magnesium Chloride promotes the reaction [beryllium fluoride promotes the reaction [8-azidoadenosine 5'-triphosphate binds to ABCC6 protein]]; Manganese promotes the reaction [beryllium fluoride promotes the reaction [8-azidoadenosine 5'-triphosphate binds to ABCC6 protein]]; Nickel promotes the reaction [beryllium fluoride promotes the reaction [8-azidoadenosine 5'-triphosphate binds to ABCC6 protein]] |
CTD |
PMID:12069597 |
|
NCBI chr 1:96,447,224...96,501,464
Ensembl chr 1:96,447,251...96,501,464
|
|
G |
Abcc8 |
ATP binding cassette subfamily C member 8 |
decreases activity |
ISO EXP |
beryllium fluoride results in decreased activity of ABCC8 protein |
CTD |
PMID:17561960 PMID:18025464 |
|
NCBI chr 1:96,598,663...96,679,495
Ensembl chr 1:96,598,647...96,679,510
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
increases expression |
ISO |
beryllium fluoride results in increased expression of CREB1 protein |
CTD |
PMID:11867686 |
|
NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
increases expression |
ISO |
beryllium fluoride results in increased expression of FOS protein |
CTD |
PMID:11867686 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Map2k1 |
mitogen activated protein kinase kinase 1 |
increases phosphorylation |
ISO |
beryllium fluoride results in increased phosphorylation of MAP2K1 protein |
CTD |
PMID:11867686 |
|
NCBI chr 8:64,683,449...64,754,900
Ensembl chr 8:64,683,449...64,755,147
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
increases phosphorylation |
ISO |
beryllium fluoride results in increased phosphorylation of MAPK3 protein |
CTD |
PMID:11867686 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
increases expression |
ISO |
beryllium fluoride results in increased expression of MYC protein |
CTD |
PMID:11867686 |
|
NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
|
|
|
G |
Cdkn2a |
cyclin-dependent kinase inhibitor 2A |
multiple interactions |
EXP |
[Beryllium results in increased methylation of CDKN2A promoter] which results in decreased expression of CDKN2A mRNA |
CTD |
PMID:11872642 |
|
NCBI chr 5:103,984,949...103,992,143
Ensembl chr 5:103,984,949...104,003,149
|
|
G |
Esr1 |
estrogen receptor 1 |
increases methylation |
EXP |
Beryllium results in increased methylation of ESR1 gene |
CTD |
PMID:11872642 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Hras |
HRas proto-oncogene, GTPase |
increases mutagenesis |
EXP |
Beryllium results in increased mutagenesis of HRAS gene |
CTD |
PMID:7545909 |
|
NCBI chr 1:196,290,127...196,299,823
Ensembl chr 1:196,296,263...196,300,615
|
|
G |
Il1b |
interleukin 1 beta |
increases expression affects expression |
ISO |
Beryllium results in increased expression of IL1B mRNA Beryllium affects the expression of IL1B mRNA |
CTD |
PMID:8473757 PMID:8629860 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Tnf |
tumor necrosis factor |
increases expression increases response to substance increases secretion |
ISO |
Beryllium results in increased expression of TNF mRNA TNF promoter polymorphism results in increased susceptibility to Beryllium Beryllium results in increased secretion of TNF protein |
CTD |
PMID:8629860 PMID:12449171 PMID:15127972 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
increases expression |
ISO |
beryllium sulfate results in increased expression of ACTA2 mRNA |
CTD |
PMID:16314022 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Anxa5 |
annexin A5 |
increases expression |
ISO |
beryllium sulfate results in increased expression of ANXA5 mRNA |
CTD |
PMID:16314022 |
|
NCBI chr 2:119,314,007...119,344,703
Ensembl chr 2:119,314,007...119,353,369
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
multiple interactions increases secretion |
ISO |
beryllium sulfate promotes the reaction [RUNX1 protein binds to CCL3 promoter] beryllium sulfate results in increased secretion of CCL3 mRNA |
CTD |
PMID:16314022 |
|
NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938
|
|
G |
Ccl4 |
C-C motif chemokine ligand 4 |
increases secretion |
ISO |
beryllium sulfate results in increased secretion of CCL4 mRNA |
CTD |
PMID:16314022 |
|
NCBI chr10:68,466,469...68,467,941
Ensembl chr10:68,452,052...68,468,231
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
increases expression |
ISO |
beryllium sulfate results in increased expression of CCL5 mRNA |
CTD |
PMID:16314022 |
|
NCBI chr10:68,322,826...68,327,365
Ensembl chr10:68,322,829...68,327,377
|
|
G |
Cd44 |
CD44 molecule (Indian blood group) |
increases expression |
ISO |
beryllium sulfate results in increased expression of CD44 mRNA |
CTD |
PMID:16314022 |
|
NCBI chr 3:89,155,850...89,244,615
Ensembl chr 3:89,157,058...89,244,620
|
|
G |
Cd86 |
CD86 molecule |
increases expression |
ISO |
beryllium sulfate results in increased expression of CD86 protein |
CTD |
PMID:19665512 |
|
NCBI chr11:64,142,193...64,200,816
Ensembl chr11:64,163,828...64,200,818
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions increases expression |
ISO |
beryllium sulfate promotes the reaction [TP53 protein binds to CDKN1A promoter] beryllium sulfate results in increased expression of CDKN1A mRNA; beryllium sulfate results in increased expression of CDKN1A protein |
CTD |
PMID:17395767 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn2a |
cyclin-dependent kinase inhibitor 2A |
increases expression |
ISO |
beryllium sulfate results in increased expression of CDKN2A mRNA; beryllium sulfate results in increased expression of CDKN2A protein |
CTD |
PMID:17395767 |
|
NCBI chr 5:103,984,949...103,992,143
Ensembl chr 5:103,984,949...104,003,149
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
multiple interactions |
ISO |
[beryllium sulfate co-treated with IFNG protein] results in increased expression of CREB1 protein |
CTD |
PMID:10755711 |
|
NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816
|
|
G |
Ctsl |
cathepsin L |
increases expression |
ISO |
beryllium sulfate results in increased expression of CTSL mRNA |
CTD |
PMID:16314022 |
|
NCBI chr17:764,370...770,533
Ensembl chr17:764,309...770,548
|
|
G |
Cxcl1 |
C-X-C motif chemokine ligand 1 |
increases secretion |
ISO |
beryllium sulfate results in increased secretion of CXCL1 mRNA |
CTD |
PMID:16314022 |
|
NCBI chr14:17,193,364...17,195,143
Ensembl chr14:17,193,365...17,195,215
|
|
G |
Cxcl3 |
C-X-C motif chemokine ligand 3 |
increases secretion |
ISO |
beryllium sulfate results in increased secretion of CXCL1 mRNA |
CTD |
PMID:16314022 |
|
NCBI chr14:17,270,146...17,289,458
Ensembl chr14:17,270,146...17,289,511
|
|
G |
Egr2 |
early growth response 2 |
increases expression |
ISO |
beryllium sulfate results in increased expression of EGR2 mRNA |
CTD |
PMID:16314022 |
|
NCBI chr20:21,051,270...21,056,322
Ensembl chr20:21,051,277...21,055,562
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
increases expression multiple interactions |
ISO |
beryllium sulfate results in increased expression of FOS mRNA 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [beryllium sulfate results in increased expression of FOS mRNA]; Dactinomycin inhibits the reaction [beryllium sulfate results in increased expression of FOS mRNA]; Ro 31-8220 inhibits the reaction [beryllium sulfate results in increased expression of FOS mRNA] |
CTD |
PMID:11568973 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Hnrnpa1 |
heterogeneous nuclear ribonucleoprotein A1 |
increases expression |
ISO |
beryllium sulfate results in increased expression of HNRNPA1 mRNA |
CTD |
PMID:16314022 |
|
NCBI chr 7:134,375,318...134,381,610
Ensembl chr 7:134,375,150...134,381,609
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions increases secretion increases expression |
ISO |
3,3',4,5'-tetrahydroxystilbene inhibits the reaction [beryllium sulfate results in increased expression of ICAM1 mRNA]; 3,3',4,5'-tetrahydroxystilbene inhibits the reaction [beryllium sulfate results in increased secretion of ICAM1 protein]; Dimethyl Sulfoxide inhibits the reaction [beryllium sulfate results in increased secretion of ICAM1 protein] beryllium sulfate results in increased expression of ICAM1 mRNA; beryllium sulfate results in increased expression of ICAM1 protein |
CTD |
PMID:18539414 |
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Ifng |
interferon gamma |
increases expression multiple interactions |
ISO |
beryllium sulfate results in increased expression of IFNG protein [beryllium sulfate co-treated with IFNG protein] results in increased expression of CREB1 protein; [beryllium sulfate co-treated with IFNG protein] results in increased expression of JUN protein; [beryllium sulfate co-treated with IFNG protein] results in increased expression of JUNB protein; [beryllium sulfate co-treated with IFNG protein] results in increased expression of NFKB1 protein; beryllium sulfate promotes the reaction [IFNG protein results in increased expression of TNF protein] |
CTD |
PMID:10755710 PMID:10755711 PMID:20974702 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Il18 |
interleukin 18 |
increases expression |
ISO |
beryllium sulfate results in increased expression of IL18 mRNA; beryllium sulfate results in increased expression of IL18 protein |
CTD |
PMID:16100009 |
|
NCBI chr 8:50,904,630...50,932,887
Ensembl chr 8:50,906,960...50,932,887
|
|
G |
Il2 |
interleukin 2 |
increases expression |
ISO |
beryllium sulfate results in increased expression of IL2 mRNA |
CTD |
PMID:9328138 |
|
NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566
|
|
G |
Il5 |
interleukin 5 |
increases expression |
ISO |
beryllium sulfate results in increased expression of IL5 mRNA |
CTD |
PMID:9328138 |
|
NCBI chr10:37,874,342...37,877,213
Ensembl chr10:37,874,342...37,877,213
|
|
G |
Il6 |
interleukin 6 |
increases expression |
ISO |
beryllium sulfate results in increased expression of IL6 mRNA |
CTD |
PMID:9328138 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Itgb3 |
integrin subunit beta 3 |
increases expression |
ISO |
beryllium sulfate results in increased expression of ITGB3 mRNA |
CTD |
PMID:16314022 |
|
NCBI chr10:89,509,917...89,564,679
Ensembl chr10:89,509,989...89,564,679
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions increases expression |
ISO |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [beryllium sulfate results in increased expression of JUN mRNA]; [beryllium sulfate co-treated with IFNG protein] results in increased expression of JUN protein; Dactinomycin inhibits the reaction [beryllium sulfate results in increased expression of JUN mRNA]; Ro 31-8220 inhibits the reaction [beryllium sulfate results in increased expression of JUN mRNA] |
CTD |
PMID:10755711 PMID:11568973 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Junb |
JunB proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
[beryllium sulfate co-treated with IFNG protein] results in increased expression of JUNB protein |
CTD |
PMID:10755711 |
|
NCBI chr19:23,176,265...23,178,049
Ensembl chr19:23,176,294...23,178,035
|
|
G |
LOC100910577 |
zinc finger protein 709-like |
increases expression |
ISO |
beryllium sulfate results in increased expression of ZNF77 mRNA |
CTD |
PMID:16314022 |
|
NCBI chr 7:7,269,879...7,316,286
Ensembl chr 7:7,269,927...7,286,051
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
increases expression |
EXP |
beryllium sulfate results in increased expression of MYC protein |
CTD |
PMID:2009323 |
|
NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
|
|
G |
Nedd8 |
NEDD8 ubiquitin like modifier |
increases expression |
ISO |
beryllium sulfate results in increased expression of NEDD8 mRNA |
CTD |
PMID:16314022 |
|
NCBI chr15:29,153,556...29,165,575
Ensembl chr15:29,153,556...29,166,160
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions |
ISO |
[beryllium sulfate co-treated with IFNG protein] results in increased expression of NFKB1 protein |
CTD |
PMID:10755711 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nova1 |
NOVA alternative splicing regulator 1 |
increases expression |
ISO |
beryllium sulfate results in increased expression of NOVA1 mRNA |
CTD |
PMID:16314022 |
|
NCBI chr 6:63,780,105...63,905,950
Ensembl chr 6:63,783,489...63,906,289
|
|
G |
Rhoa |
ras homolog family member A |
increases expression |
ISO |
beryllium sulfate results in increased expression of RHOA mRNA |
CTD |
PMID:16314022 |
|
NCBI chr 8:108,991,926...109,025,746
Ensembl chr 8:108,991,954...109,025,746
|
|
G |
Rpl22 |
ribosomal protein L22 |
increases expression |
ISO |
beryllium sulfate results in increased expression of RPL22 mRNA |
CTD |
PMID:16314022 |
|
NCBI chr 5:162,835,251...162,841,977
Ensembl chr 5:162,833,740...162,843,368
|
|
G |
Rpl30 |
ribosomal protein L30 |
increases expression |
ISO |
beryllium sulfate results in increased expression of RPL30 mRNA |
CTD |
PMID:16314022 |
|
NCBI chr 7:65,648,470...65,651,363
Ensembl chr 7:65,645,991...65,651,363 Ensembl chr10:65,645,991...65,651,363
|
|
G |
Rpl37a |
ribosomal protein L37A |
increases expression |
ISO |
beryllium sulfate results in increased expression of RPL37A mRNA |
CTD |
PMID:16314022 |
|
|
|
G |
Rps7 |
ribosomal protein S7 |
increases expression |
ISO |
beryllium sulfate results in increased expression of RPS7 mRNA |
CTD |
PMID:16314022 |
|
NCBI chr 6:45,266,200...45,271,064
Ensembl chr 6:45,223,980...45,271,145
|
|
G |
RT1-Db1 |
RT1 class II, locus Db1 |
increases response to substance increases expression |
ISO |
HLA-DRB1 protein mutant form results in increased susceptibility to beryllium sulfate beryllium sulfate results in increased expression of HLA-DRB1 mRNA |
CTD |
PMID:16272364 PMID:16314022 |
|
NCBI chr20:4,548,664...4,558,237
Ensembl chr20:4,548,666...4,558,258
|
|
G |
Runx1 |
RUNX family transcription factor 1 |
multiple interactions |
ISO |
beryllium sulfate promotes the reaction [RUNX1 protein binds to CCL3 promoter] |
CTD |
PMID:16314022 |
|
NCBI chr11:31,839,880...32,074,427
Ensembl chr11:31,843,764...32,074,542
|
|
G |
Serpinb2 |
serpin family B member 2 |
increases expression |
ISO |
beryllium sulfate results in increased expression of SERPINB2 mRNA |
CTD |
PMID:16314022 |
|
NCBI chr13:23,537,312...23,551,823
Ensembl chr13:23,541,400...23,550,408
|
|
G |
Sftpd |
surfactant protein D |
increases expression |
ISO |
beryllium sulfate results in increased expression of SFTPD mRNA |
CTD |
PMID:16314022 |
|
NCBI chr16:17,046,491...17,058,968
Ensembl chr16:17,046,483...17,059,927
|
|
G |
Tat |
tyrosine aminotransferase |
multiple interactions |
EXP |
beryllium sulfate inhibits the reaction [Hydrocortisone results in increased expression of TAT protein] |
CTD |
PMID:6120038 |
|
NCBI chr19:37,947,153...37,957,717
Ensembl chr19:37,947,112...37,958,031
|
|
G |
Tmsb4x |
thymosin beta 4, X-linked |
increases expression |
ISO |
beryllium sulfate results in increased expression of TMSB4X mRNA |
CTD |
PMID:16314022 |
|
NCBI chr X:27,144,677...27,146,667
Ensembl chr X:27,128,610...27,146,667
|
|
G |
Tnf |
tumor necrosis factor |
increases expression multiple interactions |
ISO |
beryllium sulfate results in increased expression of TNF mRNA; beryllium sulfate results in increased expression of TNF protein beryllium sulfate promotes the reaction [IFNG protein results in increased expression of TNF protein] |
CTD |
PMID:10755710 PMID:10755711 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions increases expression |
ISO |
beryllium sulfate promotes the reaction [TP53 protein binds to CDKN1A promoter] beryllium sulfate results in increased expression of TP53 protein |
CTD |
PMID:17395767 PMID:20974702 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Wnt4 |
Wnt family member 4 |
increases expression |
ISO |
beryllium sulfate results in increased expression of WNT4 mRNA |
CTD |
PMID:16314022 |
|
NCBI chr 5:149,513,573...149,535,415
Ensembl chr 5:149,514,018...149,532,859
|
|
|
G |
Cdkn2a |
cyclin-dependent kinase inhibitor 2A |
multiple interactions |
EXP |
[Beryllium results in increased methylation of CDKN2A promoter] which results in decreased expression of CDKN2A mRNA |
CTD |
PMID:11872642 |
|
NCBI chr 5:103,984,949...103,992,143
Ensembl chr 5:103,984,949...104,003,149
|
|
G |
Esr1 |
estrogen receptor 1 |
increases methylation |
EXP |
Beryllium results in increased methylation of ESR1 gene |
CTD |
PMID:11872642 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Hras |
HRas proto-oncogene, GTPase |
increases mutagenesis |
EXP |
Beryllium results in increased mutagenesis of HRAS gene |
CTD |
PMID:7545909 |
|
NCBI chr 1:196,290,127...196,299,823
Ensembl chr 1:196,296,263...196,300,615
|
|
G |
Il1b |
interleukin 1 beta |
increases expression affects expression |
ISO |
Beryllium results in increased expression of IL1B mRNA Beryllium affects the expression of IL1B mRNA |
CTD |
PMID:8473757 PMID:8629860 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Tnf |
tumor necrosis factor |
increases response to substance increases secretion increases expression |
ISO |
TNF promoter polymorphism results in increased susceptibility to Beryllium Beryllium results in increased secretion of TNF protein Beryllium results in increased expression of TNF mRNA |
CTD |
PMID:8629860 PMID:12449171 PMID:15127972 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
|
G |
Abcb4 |
ATP binding cassette subfamily B member 4 |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of ABCB4 mRNA |
CTD |
PMID:28843594 |
|
NCBI chr 4:25,150,998...25,209,489
Ensembl chr 4:25,151,953...25,209,202
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of ABCC2 mRNA |
CTD |
PMID:28843594 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Abcc3 |
ATP binding cassette subfamily C member 3 |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of ABCC3 mRNA |
CTD |
PMID:28843594 |
|
NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595
|
|
G |
Acaca |
acetyl-CoA carboxylase alpha |
multiple interactions |
EXP |
Caffeine inhibits the reaction [Dietary Fats results in increased expression of ACACA mRNA] |
CTD |
PMID:29249184 |
|
NCBI chr10:69,014,261...69,276,453
Ensembl chr10:69,014,170...69,276,457
|
|
G |
Acan |
aggrecan |
decreases expression |
EXP |
Caffeine results in decreased expression of ACAN mRNA |
CTD |
PMID:29966748 PMID:32663519 |
|
NCBI chr 1:132,981,034...133,044,416
Ensembl chr 1:132,981,582...133,043,627
|
|
G |
Acat2 |
acetyl-CoA acetyltransferase 2 |
decreases expression |
ISO |
Caffeine results in decreased expression of ACAT2 mRNA |
CTD |
PMID:11793227 |
|
NCBI chr 1:47,695,833...47,713,879
Ensembl chr 1:47,695,788...47,752,821
|
|
G |
Ace |
angiotensin I converting enzyme |
increases expression decreases methylation |
EXP |
Caffeine results in increased expression of ACE mRNA; Caffeine results in increased expression of ACE protein Caffeine results in decreased methylation of ACE promoter |
CTD |
PMID:30423288 |
|
NCBI chr10:90,910,316...90,930,437
Ensembl chr10:90,910,316...90,931,131
|
|
G |
Ache |
acetylcholinesterase |
multiple interactions decreases activity |
EXP |
caffeic acid inhibits the reaction [Caffeine results in decreased activity of ACHE protein]; Caffeine promotes the reaction [caffeic acid results in decreased activity of ACHE protein] |
CTD |
PMID:28465162 |
|
NCBI chr12:19,407,359...19,413,713
Ensembl chr12:19,407,360...19,413,651
|
|
G |
Acin1 |
apoptotic chromatin condensation inducer 1 |
increases expression |
ISO |
Caffeine results in increased expression of ACIN1 mRNA |
CTD |
PMID:11793227 |
|
NCBI chr15:28,102,112...28,147,001
Ensembl chr15:28,102,112...28,147,001
|
|
G |
Acly |
ATP citrate lyase |
increases expression |
EXP |
Caffeine results in increased expression of ACLY mRNA |
CTD |
PMID:30776459 |
|
NCBI chr10:85,412,045...85,464,253
Ensembl chr10:85,412,049...85,463,320
|
|
G |
Acsl3 |
acyl-CoA synthetase long-chain family member 3 |
increases expression |
ISO |
Caffeine results in increased expression of ACSL3 mRNA |
CTD |
PMID:11793227 |
|
NCBI chr 9:80,140,996...80,164,636
Ensembl chr 9:80,115,112...80,164,627
|
|
G |
Acsl4 |
acyl-CoA synthetase long-chain family member 4 |
decreases expression |
ISO |
Caffeine results in decreased expression of ACSL4 protein |
CTD |
PMID:31195006 |
|
NCBI chr X:105,942,794...106,006,573
Ensembl chr X:105,942,799...106,006,427
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
increases expression |
EXP |
Caffeine results in increased expression of ACTA2 mRNA |
CTD |
PMID:29055810 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Actb |
actin, beta |
decreases expression |
ISO |
Caffeine results in decreased expression of ACTB protein |
CTD |
PMID:31195006 |
|
NCBI chr12:11,663,112...11,666,697
Ensembl chr12:11,663,109...11,672,877
|
|
G |
Actbl2 |
actin, beta-like 2 |
increases expression |
ISO |
Caffeine results in increased expression of ACTBL2 protein |
CTD |
PMID:31195006 |
|
NCBI chr 2:42,858,020...42,860,767
Ensembl chr 2:42,858,020...42,860,767
|
|
G |
Actl6b |
actin-like 6B |
increases expression |
ISO |
Caffeine results in increased expression of ACTL6B protein |
CTD |
PMID:31195006 |
|
NCBI chr12:19,124,887...19,141,419
Ensembl chr12:19,124,916...19,141,376
|
|
G |
Actr1a |
actin related protein 1A |
multiple interactions |
ISO |
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of ACTR1A mRNA; Caffeine promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of ACTR1A mRNA] |
CTD |
PMID:20230807 |
|
NCBI chr 1:245,237,821...245,256,618
Ensembl chr 1:245,237,826...245,256,495
|
|
G |
Ada |
adenosine deaminase |
increases expression |
EXP |
Caffeine results in increased expression of ADA protein |
CTD |
PMID:6149265 |
|
NCBI chr 3:152,398,745...152,422,854
Ensembl chr 3:152,398,747...152,447,088
|
|
G |
Adamts5 |
ADAM metallopeptidase with thrombospondin type 1 motif, 5 |
increases expression |
EXP |
Caffeine results in increased expression of ADAMTS5 mRNA |
CTD |
PMID:31874197 |
|
NCBI chr11:25,000,627...25,047,205
Ensembl chr11:25,000,637...25,047,205
|
|
G |
Adarb1 |
adenosine deaminase, RNA-specific, B1 |
decreases expression |
EXP |
Caffeine results in decreased expression of ADARB1 mRNA |
CTD |
PMID:20864626 |
|
NCBI chr20:11,222,569...11,350,854
Ensembl chr20:11,222,583...11,350,852
|
|
G |
Adcy5 |
adenylate cyclase 5 |
decreases expression |
EXP |
Caffeine results in decreased expression of ADCY5 mRNA |
CTD |
PMID:26367767 |
|
NCBI chr11:65,471,612...65,618,877
Ensembl chr11:65,471,612...65,618,974
|
|
G |
Adcy7 |
adenylate cyclase 7 |
multiple interactions |
ISO |
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of ADCY7 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ADCY7 mRNA] |
CTD |
PMID:20230807 |
|
NCBI chr19:18,740,875...18,798,924
Ensembl chr19:18,740,875...18,776,311
|
|
G |
Adgrl1 |
adhesion G protein-coupled receptor L1 |
multiple interactions |
ISO |
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of ADGRL1 mRNA; Caffeine promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of ADGRL1 mRNA] |
CTD |
PMID:20230807 |
|
NCBI chr19:24,202,405...24,244,137
Ensembl chr19:24,204,360...24,244,139
|
|
G |
Adipor2 |
adiponectin receptor 2 |
increases expression |
EXP |
Caffeine results in increased expression of ADIPOR2 mRNA |
CTD |
PMID:22583948 |
|
NCBI chr 4:152,524,604...152,588,848
Ensembl chr 4:152,524,623...152,559,355
|
|
G |
Adora1 |
adenosine A1 receptor |
multiple interactions decreases expression decreases activity increases expression |
ISO EXP |
[8-cyclopentyl-1,3-dimethylxanthine binds to and results in decreased activity of ADORA1 protein] inhibits the reaction [[Caffeine co-treated with [N(6)-cyclopentyladenosine binds to and results in increased activity of ADORA1 protein]] results in decreased susceptibility to Methamphetamine]; [Caffeine co-treated with [N(6)-cyclopentyladenosine binds to and results in increased activity of ADORA1 protein]] results in decreased susceptibility to Methamphetamine; [Caffeine co-treated with Mianserin] results in decreased expression of ADORA1 mRNA; [Citalopram co-treated with Caffeine deficiency] results in increased expression of ADORA1 mRNA; [Citalopram co-treated with Caffeine] results in decreased expression of ADORA1 mRNA; [Fluoxetine co-treated with Caffeine deficiency] results in increased expression of ADORA1 mRNA Caffeine deficiency results in decreased expression of ADORA1 mRNA Caffeine results in decreased activity of ADORA1 protein Caffeine results in decreased expression of ADORA1 mRNA Caffeine inhibits the reaction [N(6)-cyclopentyladenosine binds to and results in increased activity of ADORA1 protein]; Caffeine promotes the reaction [Phenylisopropyladenosine binds to and results in increased activity of ADORA1 protein] Caffeine results in increased expression of ADORA1 protein |
CTD |
PMID:3003150 PMID:7996441 PMID:10401785 PMID:12153486 PMID:15708489 PMID:22164264 PMID:23611293 PMID:29107002 PMID:29882086 More...
|
|
NCBI chr13:45,658,872...45,695,821
Ensembl chr13:45,658,872...45,695,801
|
|
G |
Adora2a |
adenosine A2a receptor |
affects response to substance decreases expression multiple interactions decreases activity increases response to substance affects binding |
ISO EXP |
ADORA2A protein affects the susceptibility to Caffeine Caffeine results in decreased expression of ADORA2A mRNA Caffeine results in decreased expression of ADORA2A mRNA; Caffeine results in decreased expression of ADORA2A protein 2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine inhibits the reaction [Caffeine results in decreased expression of ADORA2A mRNA]; 2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine inhibits the reaction [Caffeine results in decreased expression of ADORA2A protein] ADORA2A polymorphism affects the susceptibility to Caffeine Caffeine results in decreased activity of ADORA2A protein ADORA2A polymorphism results in increased susceptibility to Caffeine; ADORA2A SNP results in increased susceptibility to Caffeine Caffeine analog binds to and results in decreased activity of ADORA2A protein Caffeine analog binds to and results in decreased activity of ADORA2A protein; Caffeine binds to and results in decreased activity of ADORA2A protein Caffeine analog binds to ADORA2A protein ADORA2A protein results in increased susceptibility to Caffeine |
CTD |
PMID:10214707 PMID:11172060 PMID:12077927 PMID:12825092 PMID:15452191 PMID:16221767 PMID:16470403 PMID:16771831 PMID:18305461 PMID:20520601 PMID:21950736 PMID:23611293 PMID:26367767 PMID:30555576 PMID:30825513 More...
|
|
NCBI chr20:13,315,848...13,333,386
Ensembl chr20:13,315,853...13,333,386
|
|
G |
Adora2b |
adenosine A2B receptor |
multiple interactions decreases expression |
ISO EXP |
ADORA2B mutant form inhibits the reaction [Caffeine results in decreased expression of and results in decreased activity of HSD11B2 protein]; ADORA2B mutant form inhibits the reaction [Caffeine results in decreased expression of HSD11B2 mRNA] Caffeine results in decreased expression of ADORA2B mRNA |
CTD |
PMID:22701600 PMID:26367767 |
|
NCBI chr10:46,940,394...46,956,772
Ensembl chr10:46,940,384...46,956,772
|
|
G |
Agt |
angiotensinogen |
increases expression |
EXP |
Caffeine results in increased expression of AGT protein |
CTD |
PMID:30423288 |
|
NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977
|
|
G |
Agtr1a |
angiotensin II receptor, type 1a |
increases expression decreases expression |
EXP |
Caffeine results in increased expression of AGTR1A Caffeine results in decreased expression of AGTR1A mRNA |
CTD |
PMID:25986755 PMID:30423288 |
|
NCBI chr17:34,173,446...34,226,892
Ensembl chr17:34,174,429...34,226,946
|
|
G |
Agtr2 |
angiotensin II receptor, type 2 |
decreases expression |
EXP |
Caffeine results in decreased expression of AGTR2 mRNA; Caffeine results in decreased expression of AGTR2 protein |
CTD |
PMID:25986755 PMID:30423288 |
|
NCBI chr X:112,119,673...112,124,060
Ensembl chr X:112,120,228...112,124,057
|
|
G |
Ahcy |
adenosylhomocysteinase |
decreases expression |
ISO |
Caffeine results in decreased expression of AHCY protein |
CTD |
PMID:31195006 |
|
NCBI chr 3:143,569,134...143,584,359
Ensembl chr 3:143,569,094...143,584,393
|
|
G |
Akap9 |
A-kinase anchoring protein 9 |
decreases expression |
ISO |
Caffeine results in decreased expression of AKAP9 protein |
CTD |
PMID:31195006 |
|
NCBI chr 4:30,056,738...30,192,716
Ensembl chr 4:30,056,738...30,192,606
|
|
G |
Akr1a1 |
aldo-keto reductase family 1 member A1 |
multiple interactions |
ISO |
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of AKR1A1 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of AKR1A1 mRNA] |
CTD |
PMID:20230807 |
|
NCBI chr 5:130,092,945...130,130,277
Ensembl chr 5:130,092,732...130,113,674
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions affects expression decreases expression decreases phosphorylation increases phosphorylation decreases response to substance |
ISO EXP |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Caffeine results in increased phosphorylation of AKT1 protein]; Caffeine inhibits the reaction [INS protein results in increased phosphorylation of AKT1 protein]; wortmannin inhibits the reaction [Caffeine results in increased phosphorylation of AKT1 protein] Caffeine affects the expression of AKT1 mRNA Caffeine inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of AKT1 protein] Caffeine results in decreased expression of AKT1 mRNA; Caffeine results in decreased expression of AKT1 protein modified form Caffeine results in decreased phosphorylation of AKT1 protein AKT1 results in decreased susceptibility to Caffeine |
CTD |
PMID:15126379 PMID:18201823 PMID:21081844 PMID:21561856 PMID:22974838 PMID:29966748 PMID:30528684 More...
|
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Alb |
albumin |
multiple interactions |
EXP |
Caffeine inhibits the reaction [Dietary Fats results in decreased expression of ALB protein] |
CTD |
PMID:29249184 |
|
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Aldh18a1 |
aldehyde dehydrogenase 18 family, member A1 |
decreases expression |
ISO |
Caffeine results in decreased expression of ALDH18A1 mRNA |
CTD |
PMID:11793227 |
|
NCBI chr 1:239,375,657...239,407,967
Ensembl chr 1:239,375,669...239,407,890
|
|
G |
Aldh1a1 |
aldehyde dehydrogenase 1 family, member A1 |
multiple interactions |
ISO |
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of ALDH1A1 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ALDH1A1 mRNA] |
CTD |
PMID:20230807 |
|
NCBI chr 1:218,000,470...218,152,962
Ensembl chr 1:218,042,127...218,152,961
|
|
G |
Aldh9a1 |
aldehyde dehydrogenase 9 family, member A1 |
increases expression |
EXP |
Caffeine results in increased expression of ALDH9A1 mRNA |
CTD |
PMID:20864626 |
|
NCBI chr13:79,505,738...79,522,539
Ensembl chr13:79,505,695...79,540,568
|
|
G |
Aldoc |
aldolase, fructose-bisphosphate C |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of ALDOA mRNA |
CTD |
PMID:28843594 |
|
NCBI chr10:63,217,477...63,221,066
Ensembl chr10:63,217,451...63,221,066
|
|
G |
Alms1 |
ALMS1, centrosome and basal body associated protein |
decreases expression |
EXP |
Caffeine results in decreased expression of ALMS1 mRNA |
CTD |
PMID:25868845 |
|
NCBI chr 4:118,125,581...118,226,005
Ensembl chr 4:118,125,607...118,226,005
|
|
G |
Alpl |
alkaline phosphatase, biomineralization associated |
decreases expression |
EXP |
Caffeine results in decreased expression of ALPL mRNA |
CTD |
PMID:30423288 PMID:31874197 |
|
NCBI chr 5:149,951,397...150,006,424
Ensembl chr 5:149,951,409...150,006,446
|
|
G |
Ang |
angiogenin |
decreases expression |
ISO |
Caffeine results in decreased expression of ANG mRNA |
CTD |
PMID:11793227 |
|
NCBI chr15:24,317,733...24,323,361
|
|
G |
Ankrd37 |
ankyrin repeat domain 37 |
decreases expression |
EXP |
Caffeine results in decreased expression of ANKRD37 mRNA |
CTD |
PMID:20864626 |
|
NCBI chr16:46,269,025...46,271,971
Ensembl chr16:46,268,443...46,271,963
|
|
G |
Anxa11 |
annexin A11 |
decreases expression |
ISO |
Caffeine results in decreased expression of ANXA11 protein |
CTD |
PMID:31195006 |
|
NCBI chr16:1,412,373...1,457,814
Ensembl chr16:1,410,756...1,457,797
|
|
G |
Anxa4 |
annexin A4 |
decreases expression |
ISO |
Caffeine results in decreased expression of ANXA4 protein |
CTD |
PMID:31195006 |
|
NCBI chr 4:119,184,378...119,241,183
Ensembl chr 4:119,184,374...119,241,161
|
|
G |
Apex1 |
apurinic/apyrimidinic endodeoxyribonuclease 1 |
multiple interactions |
ISO |
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of APEX1 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of APEX1 mRNA] |
CTD |
PMID:20230807 |
|
NCBI chr15:24,144,595...24,146,785
Ensembl chr15:24,144,362...24,146,785
|
|
G |
Apoa1 |
apolipoprotein A1 |
multiple interactions decreases expression |
ISO EXP |
[Ephedrine co-treated with Caffeine] results in increased expression of APOA1 protein Caffeine results in decreased expression of APOA1 mRNA |
CTD |
PMID:16324916 PMID:25868845 |
|
NCBI chr 8:46,527,251...46,529,035
Ensembl chr 8:46,527,144...46,529,035
|
|
G |
Apoa2 |
apolipoprotein A2 |
multiple interactions decreases expression |
ISO EXP |
[Ephedrine co-treated with Caffeine] results in decreased expression of APOA2 protein Caffeine results in decreased expression of APOA2 mRNA |
CTD |
PMID:16324916 PMID:25868845 |
|
NCBI chr13:83,644,460...83,646,358
Ensembl chr13:83,644,470...83,646,355
|
|
G |
Apob |
apolipoprotein B |
multiple interactions decreases expression |
ISO EXP |
[Ephedrine co-treated with Caffeine] results in decreased expression of APOB protein [Caffeine co-treated with Dietary Fats] results in increased expression of APOB mRNA Caffeine results in decreased expression of APOB mRNA |
CTD |
PMID:16324916 PMID:25868845 PMID:29800656 |
|
NCBI chr 6:30,844,386...30,883,983
Ensembl chr 6:30,844,368...30,892,497
|
|
G |
Apoc1 |
apolipoprotein C1 |
multiple interactions decreases expression |
ISO EXP |
[Ephedrine co-treated with Caffeine co-treated with pioglitazone] results in increased expression of APOC1 protein Caffeine results in decreased expression of APOC1 mRNA |
CTD |
PMID:16324916 PMID:25868845 |
|
NCBI chr 1:79,347,057...79,350,340
Ensembl chr 1:79,346,136...79,350,375
|
|
G |
Apoc2 |
apolipoprotein C2 |
multiple interactions decreases expression |
ISO EXP |
[Ephedrine co-treated with Caffeine co-treated with pioglitazone] results in decreased expression of APOC2 protein Caffeine results in decreased expression of APOC2 mRNA |
CTD |
PMID:16324916 PMID:25868845 |
|
NCBI chr 1:79,329,429...79,334,397
Ensembl chr 1:79,329,428...79,334,476
|
|
G |
Apoc3 |
apolipoprotein C3 |
multiple interactions |
ISO |
[Ephedrine co-treated with Caffeine co-treated with pioglitazone] results in decreased expression of APOC3 protein |
CTD |
PMID:16324916 |
|
NCBI chr 8:46,531,478...46,533,658
Ensembl chr 8:46,531,478...46,533,583
|
|
G |
Apom |
apolipoprotein M |
decreases expression |
EXP |
Caffeine results in decreased expression of APOM mRNA |
CTD |
PMID:25868845 |
|
NCBI chr20:3,690,950...3,693,550
Ensembl chr20:3,688,413...3,693,550
|
|
G |
Arcn1 |
archain 1 |
decreases expression |
ISO |
Caffeine results in decreased expression of ARCN1 protein |
CTD |
PMID:31195006 |
|
NCBI chr 8:45,057,617...45,082,224
Ensembl chr 8:45,057,619...45,082,247
|
|
G |
Arf1 |
ADP-ribosylation factor 1 |
multiple interactions |
ISO |
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of ARF1 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ARF1 mRNA] |
CTD |
PMID:20230807 |
|
NCBI chr10:43,997,983...44,014,543
Ensembl chr10:43,997,986...44,014,434
|
|
G |
Arl6ip1 |
ADP-ribosylation factor like GTPase 6 interacting protein 1 |
increases expression |
ISO |
Caffeine results in increased expression of ARL6IP1 mRNA |
CTD |
PMID:11793227 |
|
NCBI chr 1:172,430,475...172,439,990
Ensembl chr 1:172,430,489...172,439,994
|
|
G |
Arrb2 |
arrestin, beta 2 |
increases expression |
EXP |
Caffeine results in increased expression of ARRB2 mRNA |
CTD |
PMID:20864626 |
|
NCBI chr10:55,146,887...55,154,854
Ensembl chr10:55,146,818...55,154,850
|
|
G |
Asns |
asparagine synthetase (glutamine-hydrolyzing) |
decreases expression |
ISO |
Caffeine results in decreased expression of ASNS mRNA |
CTD |
PMID:18444173 |
|
NCBI chr 4:35,784,995...35,803,474
Ensembl chr 4:35,785,237...35,803,423
|
|
G |
Atg7 |
autophagy related 7 |
increases response to substance |
ISO |
ATG7 protein results in increased susceptibility to Caffeine; ATG7 results in increased susceptibility to Caffeine |
CTD |
PMID:21081844 |
|
NCBI chr 4:147,718,663...147,925,656
Ensembl chr 4:147,718,752...147,925,593
|
|
G |
Atm |
ATM serine/threonine kinase |
multiple interactions decreases activity |
ISO |
[[Caffeine results in decreased activity of ATR protein] co-treated with [Caffeine results in decreased activity of ATM protein]] results in decreased susceptibility to Acrylamide; Caffeine inhibits the reaction [[Resveratrol results in increased activity of [ATM protein co-treated with ATR protein]] results in increased activity of [CHEK1 protein co-treated with CHEK2 protein]]; Caffeine inhibits the reaction [Acetaminophen results in increased phosphorylation of ATM protein]; Caffeine inhibits the reaction [dorsomorphin results in increased phosphorylation of ATM protein]; Caffeine inhibits the reaction [Doxorubicin results in increased activity of ATM protein]; Caffeine inhibits the reaction [Doxorubicin results in increased phosphorylation of and results in decreased activity of ATM protein]; Caffeine inhibits the reaction [Genistein results in increased phosphorylation of ATM protein]; Caffeine inhibits the reaction [kaempferol results in increased phosphorylation of ATM protein]; Caffeine inhibits the reaction [polyhexamethyleneguanidine results in increased phosphorylation of ATM protein]; Caffeine inhibits the reaction [Resveratrol results in increased activity of [ATM protein co-treated with ATR protein]] ATM protein affects the susceptibility to [Caffeine co-treated with Benzo(a)pyrene] |
CTD |
PMID:10531013 PMID:11507241 PMID:15975956 PMID:18347191 PMID:19028473 PMID:19038232 PMID:20734998 PMID:20888899 PMID:22927544 PMID:23274516 PMID:31168028 PMID:33971260 More...
|
|
NCBI chr 8:53,828,741...53,932,773
Ensembl chr 8:53,831,093...53,932,437
|
|
G |
Atp2a2 |
ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 2 |
affects response to substance |
ISO |
ATP2A2 protein affects the susceptibility to Caffeine |
CTD |
PMID:19328205 |
|
NCBI chr12:34,072,710...34,122,142
Ensembl chr12:34,072,683...34,122,101
|
|
G |
Atp5mf |
ATP synthase membrane subunit f |
decreases expression |
ISO |
Caffeine results in decreased expression of ATP5MF mRNA |
CTD |
PMID:11793227 |
|
NCBI chr12:9,421,665...9,428,236
Ensembl chr12:9,421,579...9,428,236
|
|
G |
Atp6v0c |
ATPase H+ transporting V0 subunit C |
multiple interactions |
ISO |
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of ATP6V0C mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ATP6V0C mRNA] |
CTD |
PMID:20230807 |
|
NCBI chr10:13,196,204...13,202,580
Ensembl chr10:13,196,204...13,201,500
|
|
G |
Atp6v1b2 |
ATPase H+ transporting V1 subunit B2 |
multiple interactions |
ISO |
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of ATP6V1B2 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ATP6V1B2 mRNA] |
CTD |
PMID:20230807 |
|
NCBI chr16:20,617,515...20,641,651
Ensembl chr16:20,617,518...20,641,745
|
|
G |
Atpaf1 |
ATP synthase mitochondrial F1 complex assembly factor 1 |
decreases expression |
EXP |
Caffeine results in decreased expression of ATPAF1 mRNA |
CTD |
PMID:20864626 |
|
NCBI chr 5:129,265,789...129,293,556
Ensembl chr 5:129,266,404...129,293,556
|
|
G |
Atr |
ATR serine/threonine kinase |
multiple interactions affects activity |
ISO |
[[Caffeine results in decreased activity of ATR protein] co-treated with [Caffeine results in decreased activity of ATM protein]] results in decreased susceptibility to Acrylamide; Caffeine inhibits the reaction [[resveratrol results in increased activity of [ATM protein co-treated with ATR protein]] results in increased activity of [CHEK1 protein co-treated with CHEK2 protein]]; Caffeine inhibits the reaction [Hydroxyurea promotes the reaction [ATR protein results in increased phosphorylation of and results in increased activity of CHEK1 protein]]; Caffeine inhibits the reaction [resveratrol results in increased activity of [ATM protein co-treated with ATR protein]] Caffeine affects the activity of ATR protein |
CTD |
PMID:11507241 PMID:15975956 PMID:18158334 PMID:20734998 |
|
NCBI chr 8:96,426,704...96,524,152
Ensembl chr 8:96,426,724...96,524,136
|
|
G |
Atrn |
attractin |
multiple interactions |
ISO |
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of ATRN mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of ATRN mRNA] |
CTD |
PMID:20230807 |
|
NCBI chr 3:118,110,320...118,244,326
Ensembl chr 3:118,110,229...118,244,322
|
|
G |
Avpr1a |
arginine vasopressin receptor 1A |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of AVPR1A mRNA |
CTD |
PMID:28843594 |
|
NCBI chr 7:58,114,306...58,118,230
Ensembl chr 7:58,114,284...58,122,215
|
|
G |
Basp1 |
brain abundant, membrane attached signal protein 1 |
increases expression |
ISO |
Caffeine results in increased expression of BASP1 protein |
CTD |
PMID:31195006 |
|
NCBI chr 2:75,816,130...75,863,801
Ensembl chr 2:75,816,122...75,864,043
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression multiple interactions |
ISO |
Caffeine results in increased expression of BAX protein [Caffeine co-treated with bisphenol A] results in increased expression of BAX mRNA |
CTD |
PMID:12811820 PMID:12907610 PMID:31756439 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bbc3 |
Bcl-2 binding component 3 |
multiple interactions |
ISO |
Caffeine inhibits the reaction [kaempferol results in increased expression of BBC3 protein] |
CTD |
PMID:19028473 |
|
NCBI chr 1:77,013,281...77,022,509
Ensembl chr 1:77,014,543...77,022,509
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
multiple interactions |
ISO |
[Caffeine co-treated with bisphenol A] results in decreased expression of BCL2L1 mRNA |
CTD |
PMID:31756439 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
multiple interactions |
EXP |
Caffeine inhibits the reaction [aluminum chloride results in decreased expression of BDNF mRNA] |
CTD |
PMID:26339337 |
|
NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615
|
|
G |
Becn1 |
beclin 1 |
multiple interactions increases expression |
ISO |
3-(2,4-dichloro-5-methoxyphenyl)-2-sulfanyl-4(3H)-quinazolinone inhibits the reaction [Caffeine results in increased expression of BECN1 protein]; 3-methyladenine inhibits the reaction [Caffeine results in increased expression of BECN1 protein] 2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine inhibits the reaction [Caffeine results in increased expression of BECN1 protein]; 3-methyladenine inhibits the reaction [Caffeine results in increased expression of BECN1 protein]; Sirolimus promotes the reaction [Caffeine results in increased expression of BECN1 protein]; SIRT3 protein promotes the reaction [Caffeine results in increased expression of BECN1 protein] |
CTD |
PMID:30555576 |
|
NCBI chr10:86,231,387...86,246,742
Ensembl chr10:86,231,388...86,246,742
|
|
G |
Bglap |
bone gamma-carboxyglutamate protein |
decreases expression |
EXP |
Caffeine results in decreased expression of BGLAP mRNA |
CTD |
PMID:30423288 PMID:31874197 |
|
NCBI chr 2:173,838,518...173,839,495
Ensembl chr 2:173,838,518...173,839,495
|
|
G |
Bhmt |
betaine-homocysteine S-methyltransferase |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of BHMT mRNA |
CTD |
PMID:28843594 |
|
NCBI chr 2:24,859,871...24,879,449
Ensembl chr 2:24,859,873...24,879,742
|
|
G |
Bid |
BH3 interacting domain death agonist |
multiple interactions |
ISO |
Caffeine inhibits the reaction [silybin results in increased cleavage of BID protein] |
CTD |
PMID:16777994 |
|
NCBI chr 4:154,113,198...154,136,353
Ensembl chr 4:154,113,198...154,134,720
|
|
G |
Bnip3 |
BCL2 interacting protein 3 |
multiple interactions |
ISO |
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of BNIP3 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of BNIP3 mRNA] |
CTD |
PMID:20230807 |
|
NCBI chr 1:193,708,164...193,725,348
Ensembl chr 1:193,708,167...193,725,359
|
|
G |
Bub1 |
BUB1 mitotic checkpoint serine/threonine kinase |
multiple interactions |
ISO |
[Nocodazole co-treated with Caffeine] results in increased expression of BUB1 protein modified form |
CTD |
PMID:21670593 |
|
NCBI chr 3:115,020,254...115,051,650
Ensembl chr 3:115,020,254...115,051,650
|
|
G |
C1r |
complement C1r |
multiple interactions |
ISO |
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of C1R mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of C1R mRNA] |
CTD |
PMID:20230807 |
|
NCBI chr 4:157,412,718...157,423,483
Ensembl chr 4:157,412,692...157,423,484
|
|
G |
C2cd5 |
C2 calcium-dependent domain containing 5 |
increases expression |
EXP |
Caffeine results in increased expression of C2CD5 mRNA |
CTD |
PMID:20864626 |
|
NCBI chr 4:175,969,544...176,055,597
Ensembl chr 4:175,969,545...176,055,558
|
|
G |
Cad |
carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, and dihydroorotase |
increases expression |
EXP |
Caffeine results in increased expression of CAD protein |
CTD |
PMID:6149265 |
|
NCBI chr 6:25,292,133...25,315,176
Ensembl chr 6:25,292,133...25,319,861
|
|
G |
Calm1 |
calmodulin 1 |
multiple interactions |
ISO |
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of CALM1 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CALM1 mRNA] |
CTD |
PMID:20230807 |
|
NCBI chr 6:119,487,691...119,495,759
Ensembl chr 6:119,487,621...119,498,227
|
|
G |
Calu |
calumenin |
decreases expression |
ISO |
Caffeine results in decreased expression of CALU mRNA |
CTD |
PMID:11793227 |
|
NCBI chr 4:57,949,086...57,976,589
Ensembl chr 4:57,948,997...57,976,593
|
|
G |
Cand1 |
cullin-associated and neddylation-dissociated 1 |
decreases expression |
ISO |
Caffeine results in decreased expression of CAND1 protein |
CTD |
PMID:31195006 |
|
NCBI chr 7:54,681,114...54,719,002
Ensembl chr 7:54,680,900...54,718,993
|
|
G |
Capn1 |
calpain 1 |
multiple interactions |
ISO |
[Caffeine co-treated with Alprazolam] promotes the reaction [Calcium results in increased activity of CAPN1 protein] |
CTD |
PMID:19490937 |
|
NCBI chr 1:203,275,912...203,300,848
Ensembl chr 1:203,277,344...203,300,177
|
|
G |
Capn2 |
calpain 2 |
decreases expression |
ISO |
Caffeine results in decreased expression of CAPN2 protein |
CTD |
PMID:31195006 |
|
NCBI chr13:94,150,244...94,200,969
Ensembl chr13:94,150,240...94,200,969
|
|
G |
Casp2 |
caspase 2 |
multiple interactions |
ISO |
Caffeine inhibits the reaction [silybin results in increased cleavage of and results in increased activity of CASP2 protein] |
CTD |
PMID:16777994 |
|
NCBI chr 4:71,149,632...71,167,388
Ensembl chr 4:71,149,669...71,167,379
|
|
G |
Casp3 |
caspase 3 |
multiple interactions decreases expression increases expression increases cleavage increases activity affects cleavage |
ISO EXP |
[Caffeine co-treated with Alprazolam] results in increased cleavage of CASP3 protein; Caffeine inhibits the reaction [Oxidopamine results in increased activity of CASP3 protein]; Caffeine inhibits the reaction [Silybin results in increased cleavage of and results in increased activity of CASP3 protein]; Caffeine promotes the reaction [[Doxorubicin co-treated with Nocodazole co-treated with Hydroxyurea] results in increased cleavage of CASP3 protein]; Caffeine results in increased cleavage of and results in increased expression of CASP3 protein; NOTCH1 protein mutant form inhibits the reaction [Caffeine promotes the reaction [[Doxorubicin co-treated with Nocodazole co-treated with Hydroxyurea] results in increased cleavage of CASP3 protein]] Caffeine results in decreased expression of CASP3 protein modified form Caffeine results in increased expression of CASP3 mRNA Caffeine results in increased cleavage of CASP3 protein Caffeine results in increased activity of CASP3 protein [Caffeine co-treated with Ephedrine] results in increased cleavage of CASP3 protein Caffeine affects the cleavage of CASP3 protein |
CTD |
PMID:12378022 PMID:12395097 PMID:12907610 PMID:15537744 PMID:16522534 PMID:16777994 PMID:18201823 PMID:18283038 PMID:19242509 PMID:19490937 PMID:19815060 PMID:21081844 PMID:21229324 PMID:31597699 PMID:31874197 More...
|
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp9 |
caspase 9 |
multiple interactions |
ISO |
Caffeine inhibits the reaction [silybin results in increased cleavage of and results in increased activity of CASP9 protein]; Caffeine results in increased cleavage of and results in increased expression of CASP9 protein [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of CASP9 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CASP9 mRNA] |
CTD |
PMID:16522534 PMID:16777994 PMID:20230807 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
multiple interactions decreases expression increases expression |
ISO EXP |
Caffeine inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in decreased activity of CAT protein] Caffeine results in decreased expression of CAT mRNA Caffeine results in increased expression of CAT protein [Caffeine co-treated with Cadmium Chloride] results in decreased activity of CAT protein; [Caffeine co-treated with Cadmium Chloride] results in increased expression of CAT protein |
CTD |
PMID:22154906 PMID:23099337 PMID:25868845 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Cav1 |
caveolin 1 |
increases expression |
ISO |
Caffeine results in increased expression of CAV1 protein |
CTD |
PMID:31195006 |
|
NCBI chr 4:45,640,624...45,673,708
Ensembl chr 4:45,634,918...45,673,705
|
|
G |
Cav3 |
caveolin 3 |
decreases expression |
EXP |
Caffeine results in decreased expression of CAV3 mRNA |
CTD |
PMID:25868845 |
|
NCBI chr 4:145,582,168...145,598,142
Ensembl chr 4:145,582,060...145,598,137
|
|
G |
Cbx5 |
chromobox 5 |
multiple interactions |
ISO |
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of CBX5 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CBX5 mRNA] |
CTD |
PMID:20230807 |
|
NCBI chr 7:134,333,165...134,376,102
Ensembl chr 7:134,331,335...134,375,022
|
|
G |
Ccdc124 |
coiled-coil domain containing 124 |
increases expression |
ISO |
Caffeine results in increased expression of CCDC124 protein |
CTD |
PMID:31195006 |
|
NCBI chr16:18,566,745...18,572,564
Ensembl chr16:18,566,745...18,572,564
|
|
G |
Ccdc174 |
coiled-coil domain containing 174 |
decreases expression |
EXP |
Caffeine results in decreased expression of CCDC174 mRNA |
CTD |
PMID:20864626 |
|
NCBI chr 4:124,392,183...124,419,035
Ensembl chr 4:124,392,274...124,419,035
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
increases expression decreases expression |
ISO |
Caffeine results in increased expression of CCL3 mRNA Caffeine results in decreased expression of CCL3 mRNA |
CTD |
PMID:28089782 |
|
NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938
|
|
G |
Ccnb1 |
cyclin B1 |
multiple interactions increases expression |
ISO |
Caffeine inhibits the reaction [Cisplatin results in increased expression of CCNB1 protein] Caffeine inhibits the reaction [Genistein results in increased expression of CCNB1 protein] Caffeine results in increased expression of CCNB1 protein |
CTD |
PMID:9098629 PMID:19038232 PMID:20025956 |
|
NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172
|
|
G |
Ccnd1 |
cyclin D1 |
multiple interactions |
ISO |
Caffeine results in decreased activity of [CCND1 protein binds to CDK4 protein] |
CTD |
PMID:15126379 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Ccnf |
cyclin F |
multiple interactions |
ISO |
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of CCNF mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CCNF mRNA] |
CTD |
PMID:20230807 |
|
NCBI chr10:13,253,073...13,279,140
Ensembl chr10:13,253,380...13,279,101
|
|
G |
Ccng1 |
cyclin G1 |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of CCNG1 mRNA |
CTD |
PMID:28843594 |
|
NCBI chr10:25,176,231...25,182,604
Ensembl chr10:25,176,234...25,181,641
|
|
G |
Ccnl2 |
cyclin L2 |
multiple interactions |
ISO |
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of CCNL2 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CCNL2 mRNA] |
CTD |
PMID:20230807 |
|
NCBI chr 5:166,416,940...166,428,997
Ensembl chr 5:166,417,508...166,436,882
|
|
G |
Cct8 |
chaperonin containing TCP1 subunit 8 |
decreases expression |
ISO |
Caffeine results in decreased expression of CCT8 protein |
CTD |
PMID:31195006 |
|
NCBI chr11:26,710,370...26,722,079
Ensembl chr11:26,710,370...26,722,079
|
|
G |
Ccz1b |
CCZ1 homolog B, vacuolar protein trafficking and biogenesis associated |
decreases expression |
EXP |
Caffeine results in decreased expression of CCZ1 mRNA |
CTD |
PMID:20864626 |
|
NCBI chr12:10,601,066...10,624,608
Ensembl chr12:10,601,056...10,624,608
|
|
G |
Cd36 |
CD36 molecule |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of CD36 mRNA |
CTD |
PMID:28843594 |
|
NCBI chr 4:17,317,343...17,410,084
Ensembl chr 4:17,354,466...17,513,903
|
|
G |
Cd59 |
CD59 molecule |
increases expression |
ISO |
Caffeine results in increased expression of CD59 protein |
CTD |
PMID:31195006 |
|
NCBI chr 3:90,459,085...90,477,571
Ensembl chr 3:90,459,162...90,478,847
|
|
G |
Cd9 |
CD9 molecule |
decreases expression |
ISO |
Caffeine results in decreased expression of CD9 protein |
CTD |
PMID:31195006 |
|
NCBI chr 4:158,256,328...158,289,136
Ensembl chr 4:158,256,328...158,289,222
|
|
G |
Cdc14b |
cell division cycle 14B |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of CDC14B mRNA |
CTD |
PMID:28843594 |
|
NCBI chr17:844,731...934,787
Ensembl chr17:844,685...933,235
|
|
G |
Cdc25b |
cell division cycle 25B |
increases expression |
EXP |
Caffeine results in increased expression of CDC25B mRNA |
CTD |
PMID:20864626 |
|
NCBI chr 3:118,407,127...118,417,272
Ensembl chr 3:118,407,128...118,417,272
|
|
G |
Cdc25c |
cell division cycle 25C |
decreases expression multiple interactions |
ISO |
Caffeine results in decreased expression of CDC25C protein Caffeine inhibits the reaction [CDC25C protein binds to YWHAQ protein]; Caffeine inhibits the reaction [resveratrol results in increased phosphorylation of CDC25C protein] |
CTD |
PMID:11835680 PMID:15975956 |
|
NCBI chr18:26,335,156...26,356,199
Ensembl chr18:26,335,834...26,356,185
|
|
G |
Cdh1 |
cadherin 1 |
increases expression |
EXP |
Caffeine results in increased expression of CDH1 mRNA |
CTD |
PMID:20864626 |
|
NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775
|
|
G |
Cdh11 |
cadherin 11 |
multiple interactions |
ISO |
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of CDH11 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CDH11 mRNA] |
CTD |
PMID:20230807 |
|
NCBI chr19:2,148,447...2,305,754
Ensembl chr19:2,148,458...2,304,272
|
|
G |
Cdk1 |
cyclin-dependent kinase 1 |
multiple interactions |
ISO |
Caffeine inhibits the reaction [Genistein results in increased phosphorylation of CDK1 protein]; Caffeine inhibits the reaction [Resveratrol results in increased phosphorylation of CDK1 protein]; Caffeine results in decreased phosphorylation of and results in increased activity of CDK1 protein Caffeine inhibits the reaction [Cisplatin results in increased expression of CDK1 protein] |
CTD |
PMID:9098629 PMID:11835680 PMID:15975956 PMID:19038232 |
|
NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
decreases activity |
ISO |
Caffeine results in decreased activity of CDK2 protein |
CTD |
PMID:11835680 |
|
NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403
|
|
G |
Cdk4 |
cyclin-dependent kinase 4 |
multiple interactions decreases expression |
ISO |
Caffeine results in decreased activity of [CCND1 protein binds to CDK4 protein] Caffeine results in decreased expression of CDK4 mRNA |
CTD |
PMID:11793227 PMID:15126379 |
|
NCBI chr 7:62,885,647...62,889,562
Ensembl chr 7:62,883,105...62,942,403
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions |
ISO |
2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine inhibits the reaction [Caffeine inhibits the reaction [2,2'-azobis(2-amidinopropane) results in increased expression of CDKN1A protein]]; 3-methyladenine inhibits the reaction [Caffeine inhibits the reaction [2,2'-azobis(2-amidinopropane) results in increased expression of CDKN1A protein]]; [PARP1 protein results in decreased susceptibility to Caffeine] promotes the reaction [N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride results in increased expression of CDKN1A mRNA]; Caffeine inhibits the reaction [2,2'-azobis(2-amidinopropane) results in increased expression of CDKN1A protein]; Caffeine inhibits the reaction [Cytarabine results in increased expression of CDKN1A protein]; Caffeine inhibits the reaction [Decitabine results in increased expression of CDKN1A protein]; Caffeine inhibits the reaction [dorsomorphin results in increased expression of CDKN1A protein]; Caffeine inhibits the reaction [Doxorubicin results in increased expression of CDKN1A protein]; Caffeine inhibits the reaction [entinostat results in increased expression of CDKN1A protein]; Caffeine inhibits the reaction [Oxaliplatin results in increased expression of CDKN1A protein]; Sirolimus promotes the reaction [Caffeine inhibits the reaction [2,2'-azobis(2-amidinopropane) results in increased expression of CDKN1A protein]]; SIRT3 protein promotes the reaction [Caffeine inhibits the reaction [2,2'-azobis(2-amidinopropane) results in increased expression of CDKN1A protein]] 3-(2,4-dichloro-5-methoxyphenyl)-2-sulfanyl-4(3H)-quinazolinone inhibits the reaction [Caffeine inhibits the reaction [2,2'-azobis(2-amidinopropane) results in increased expression of CDKN1A protein]]; 3-methyladenine inhibits the reaction [Caffeine inhibits the reaction [2,2'-azobis(2-amidinopropane) results in increased expression of CDKN1A protein]]; Caffeine inhibits the reaction [2,2'-azobis(2-amidinopropane) results in increased expression of CDKN1A protein] |
CTD |
PMID:17977830 PMID:18223691 PMID:18347191 PMID:19735649 PMID:21840268 PMID:22927544 PMID:23274516 PMID:30555576 More...
|
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cebpa |
CCAAT/enhancer binding protein alpha |
decreases expression affects expression increases expression |
EXP |
Caffeine results in decreased expression of CEBPA mRNA Caffeine affects the expression of CEBPA mRNA Caffeine results in increased expression of CEBPA mRNA |
CTD |
PMID:23727198 PMID:30423288 PMID:30528684 PMID:30776459 |
|
NCBI chr 1:87,759,631...87,762,303
Ensembl chr 1:87,759,433...87,762,412
|
|
G |
Cebpb |
CCAAT/enhancer binding protein beta |
decreases expression |
EXP |
Caffeine results in decreased expression of CEBPB mRNA |
CTD |
PMID:30528684 |
|
NCBI chr 3:156,398,035...156,399,466
Ensembl chr 3:156,397,052...156,399,473
|
|
G |
Cemip2 |
cell migration inducing hyaluronidase 2 |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of CEMIP2 mRNA |
CTD |
PMID:28843594 |
|
NCBI chr 1:219,330,295...219,407,760
Ensembl chr 1:219,337,985...219,407,760
|
|
G |
Cetn3 |
centrin 3 |
multiple interactions |
ISO |
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of CETN3 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CETN3 mRNA] |
CTD |
PMID:20230807 |
|
NCBI chr 2:12,089,025...12,101,828
Ensembl chr 2:12,089,226...12,101,828
|
|
G |
Cfd |
complement factor D |
multiple interactions |
ISO |
[Caffeine co-treated with Ephedrine] affects the reaction [Sodium Glutamate results in decreased expression of CFD mRNA]; [Caffeine co-treated with Ephedrine] affects the reaction [Sodium Glutamate results in decreased expression of CFD protein] |
CTD |
PMID:2307116 |
|
NCBI chr 7:9,813,148...9,814,871
Ensembl chr 7:9,813,150...9,815,053
|
|
G |
Chek1 |
checkpoint kinase 1 |
multiple interactions increases phosphorylation decreases expression decreases phosphorylation |
ISO |
Caffeine inhibits the reaction [[resveratrol results in increased activity of [ATM protein co-treated with ATR protein]] results in increased activity of [CHEK1 protein co-treated with CHEK2 protein]]; Caffeine inhibits the reaction [Carmustine results in increased phosphorylation of and results in increased activity of CHEK1 protein]; Caffeine inhibits the reaction [Hydroxyurea promotes the reaction [ATR protein results in increased phosphorylation of and results in increased activity of CHEK1 protein]]; Caffeine inhibits the reaction [resveratrol results in increased activity of [CHEK1 protein co-treated with CHEK2 protein]]; xanthatin inhibits the reaction [Caffeine results in increased phosphorylation of CHEK1 protein] Caffeine inhibits the reaction [Camptothecin results in increased expression of CHEK1 mRNA]; Caffeine inhibits the reaction [Camptothecin results in increased phosphorylation of CHEK1 protein] Caffeine results in decreased expression of CHEK1 protein modified form Caffeine results in decreased phosphorylation of CHEK1 protein |
CTD |
PMID:15975956 PMID:18158334 PMID:19261750 PMID:21505179 PMID:21561856 PMID:22403396 PMID:29074359 More...
|
|
NCBI chr 8:36,420,565...36,443,477
Ensembl chr 8:36,420,569...36,441,009
|
|
G |
Chek2 |
checkpoint kinase 2 |
multiple interactions decreases activity |
ISO |
Caffeine inhibits the reaction [[Resveratrol results in increased activity of [ATM protein co-treated with ATR protein]] results in increased activity of [CHEK1 protein co-treated with CHEK2 protein]]; Caffeine inhibits the reaction [dorsomorphin results in increased phosphorylation of CHEK2 protein]; Caffeine inhibits the reaction [Genistein results in increased phosphorylation of CHEK2 protein]; Caffeine inhibits the reaction [Resveratrol results in increased activity of [CHEK1 protein co-treated with CHEK2 protein]]; Caffeine inhibits the reaction [Silybin results in increased phosphorylation of CHEK2 protein]; Caffeine promotes the reaction [Aphidicolin promotes the reaction [PRKDC protein results in increased phosphorylation of and results in increased activity of CHEK2 protein]] Caffeine results in decreased activity of CHEK2 protein |
CTD |
PMID:10531013 PMID:15975956 PMID:16777994 PMID:18158334 PMID:19038232 PMID:23274516 More...
|
|
NCBI chr12:45,788,823...45,821,382
Ensembl chr12:45,788,827...45,821,286
|
|
G |
Ckmt1 |
creatine kinase, mitochondrial 1 |
multiple interactions |
ISO |
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of CKMT1 mRNA; Caffeine promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CKMT1 mRNA] |
CTD |
PMID:20230807 |
|
NCBI chr 3:108,329,859...108,335,760
Ensembl chr 3:108,330,705...108,335,758
|
|
G |
Clic1 |
chloride intracellular channel 1 |
increases expression |
ISO |
Caffeine results in increased expression of CLIC1 protein |
CTD |
PMID:31195006 |
|
NCBI chr20:3,764,867...3,773,711
Ensembl chr20:3,761,461...3,773,712
|
|
G |
Clstn1 |
calsyntenin 1 |
multiple interactions |
ISO |
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of CLSTN1 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CLSTN1 mRNA] |
CTD |
PMID:20230807 |
|
NCBI chr 5:160,031,235...160,094,585
Ensembl chr 5:160,031,308...160,094,583
|
|
G |
Cnn2 |
calponin 2 |
multiple interactions |
ISO |
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of CNN2 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CNN2 mRNA] |
CTD |
PMID:20230807 |
|
NCBI chr 7:9,712,505...9,719,711
Ensembl chr 7:9,712,516...9,719,656
|
|
G |
Cobl |
cordon-bleu WH2 repeat protein |
affects expression |
EXP |
Caffeine affects the expression of COBL mRNA |
CTD |
PMID:20864626 |
|
NCBI chr14:86,828,137...87,060,682
Ensembl chr14:86,828,139...87,060,800
|
|
G |
Coch |
cochlin |
decreases expression |
EXP |
Caffeine results in decreased expression of COCH mRNA |
CTD |
PMID:20864626 |
|
NCBI chr 6:69,031,139...69,045,124
Ensembl chr 6:69,031,167...69,045,109
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
multiple interactions decreases expression |
ISO EXP |
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of COL1A1 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of COL1A1 mRNA] Caffeine results in decreased expression of COL1A1 mRNA |
CTD |
PMID:20230807 PMID:24275088 |
|
NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
|
|
G |
Col2a1 |
collagen type II alpha 1 chain |
decreases expression |
EXP |
Caffeine results in decreased expression of COL2A1 mRNA; Caffeine results in decreased expression of COL2A1 protein |
CTD |
PMID:29966748 PMID:32663519 |
|
NCBI chr 7:129,098,489...129,127,620
Ensembl chr 7:129,098,786...129,127,546
|
|
G |
Comt |
catechol-O-methyltransferase |
multiple interactions |
ISO |
[Caffeine co-treated with Mianserin] results in decreased expression of COMT mRNA |
CTD |
PMID:29882086 |
|
NCBI chr11:82,568,052...82,587,642
Ensembl chr11:82,568,025...82,587,642
|
|
G |
Coq8a |
coenzyme Q8A |
multiple interactions |
ISO |
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of COQ8A mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of COQ8A mRNA] |
CTD |
PMID:20230807 |
|
NCBI chr13:91,904,731...91,933,588
Ensembl chr13:91,904,739...91,931,431
|
|
G |
Cort |
cortistatin |
decreases expression |
EXP |
Caffeine results in decreased expression of CORT protein |
CTD |
PMID:25868845 |
|
NCBI chr 5:159,560,591...159,562,032
|
|
G |
Cox7a2l |
cytochrome c oxidase subunit 7A2 like |
multiple interactions |
ISO |
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of COX7A2L mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of COX7A2L mRNA] |
CTD |
PMID:20230807 |
|
NCBI chr 6:11,184,284...11,198,287
Ensembl chr 6:11,184,285...11,198,273
|
|
G |
Cox7c |
cytochrome c oxidase subunit 7C |
multiple interactions |
ISO |
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of COX7C mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of COX7C mRNA] |
CTD |
PMID:20230807 |
|
NCBI chr 2:16,841,771...16,843,796
Ensembl chr 2:16,840,837...16,843,760
|
|
G |
Cpt1a |
carnitine palmitoyltransferase 1A |
decreases expression multiple interactions |
EXP |
Caffeine results in decreased expression of CPT1A mRNA Caffeine inhibits the reaction [Dietary Fats results in decreased expression of CPT1A mRNA] |
CTD |
PMID:29249184 PMID:30776459 |
|
NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
decreases expression |
ISO EXP |
Caffeine results in decreased expression of CREB1 mRNA |
CTD |
PMID:26367767 |
|
NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816
|
|
G |
Crtc2 |
CREB regulated transcription coactivator 2 |
decreases expression |
ISO |
Caffeine results in decreased expression of CRTC2 protein |
CTD |
PMID:31195006 |
|
NCBI chr 2:175,709,603...175,719,768
Ensembl chr 2:175,709,644...175,719,763
|
|
G |
Csnk2a2 |
casein kinase 2 alpha 2 |
decreases expression |
EXP |
Caffeine results in decreased expression of CSNK2A2 mRNA |
CTD |
PMID:20864626 |
|
NCBI chr19:9,556,443...9,596,080
Ensembl chr19:9,556,260...9,596,080
|
|
G |
Cst3 |
cystatin C |
multiple interactions |
ISO |
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of CST3 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CST3 mRNA] |
CTD |
PMID:20230807 |
|
NCBI chr 3:136,336,923...136,340,796
Ensembl chr 3:136,336,920...136,340,822
|
|
G |
Cth |
cystathionine gamma-lyase |
multiple interactions |
EXP |
[Isoproterenol co-treated with Caffeine] results in decreased expression of CTH mRNA |
CTD |
PMID:29447158 |
|
NCBI chr 2:246,975,888...247,002,234
Ensembl chr 2:246,975,894...247,002,234
|
|
G |
Ctnnb1 |
catenin beta 1 |
increases mutagenesis multiple interactions |
EXP |
Caffeine results in increased mutagenesis of CTNNB1 gene Caffeine inhibits the reaction [Doxorubicin results in decreased expression of CTNNB1 protein] |
CTD |
PMID:18283038 PMID:30377735 |
|
NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111
|
|
G |
Ctsb |
cathepsin B |
multiple interactions |
ISO |
[Caffeine co-treated with Alprazolam] results in increased secretion of CTSB protein [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of CTSB mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CTSB mRNA] |
CTD |
PMID:19490937 PMID:20230807 |
|
NCBI chr15:37,389,636...37,410,508
Ensembl chr15:37,389,629...37,410,500
|
|
G |
Ctsd |
cathepsin D |
increases expression |
ISO |
Caffeine results in increased expression of CTSD protein |
CTD |
PMID:31195006 |
|
NCBI chr 1:197,527,467...197,539,343
Ensembl chr 1:197,527,467...197,539,488
|
|
G |
Ctsl |
cathepsin L |
multiple interactions |
ISO |
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of CTSL mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CTSL mRNA] |
CTD |
PMID:20230807 |
|
NCBI chr17:764,370...770,533
Ensembl chr17:764,309...770,548
|
|
G |
Cwc25 |
CWC25 spliceosome-associated protein homolog |
decreases expression |
ISO |
Caffeine results in decreased expression of CWC25 protein |
CTD |
PMID:31195006 |
|
NCBI chr10:82,735,698...82,760,373
Ensembl chr10:82,736,995...82,760,354
|
|
G |
Cxcl12 |
C-X-C motif chemokine ligand 12 |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of CXCL12 mRNA |
CTD |
PMID:28843594 |
|
NCBI chr 4:150,388,326...150,401,173
Ensembl chr 4:150,388,325...150,401,168
|
|
G |
Cyc1 |
cytochrome c-1 |
decreases expression |
ISO |
Caffeine results in decreased expression of CYC1 mRNA |
CTD |
PMID:11793227 |
|
NCBI chr 7:108,067,106...108,069,483
Ensembl chr 7:108,067,115...108,069,479
|
|
G |
Cycs |
cytochrome c, somatic |
multiple interactions |
ISO |
Caffeine inhibits the reaction [kaempferol affects the localization of CYCS protein] |
CTD |
PMID:19028473 |
|
NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054
|
|
G |
Cyp11a1 |
cytochrome P450, family 11, subfamily a, polypeptide 1 |
decreases expression |
EXP |
Caffeine results in decreased expression of CYP11A1 mRNA |
CTD |
PMID:24717552 PMID:25868845 |
|
NCBI chr 8:58,422,807...58,434,342
Ensembl chr 8:58,404,669...58,434,338
|
|
G |
Cyp11b2 |
cytochrome P450, family 11, subfamily b, polypeptide 2 |
decreases expression |
EXP |
Caffeine results in decreased expression of CYP11B1 mRNA |
CTD |
PMID:25868845 PMID:29343424 PMID:30528684 |
|
NCBI chr 7:106,838,590...106,845,004
Ensembl chr 7:106,838,590...106,845,004
|
|
G |
Cyp11b3 |
cytochrome P450, family 11, subfamily b, polypeptide 3 |
decreases expression |
EXP |
Caffeine results in decreased expression of CYP11B2 mRNA |
CTD |
PMID:25868845 PMID:29343424 |
|
NCBI chr 7:106,808,559...106,814,048
Ensembl chr 7:106,808,559...106,814,048
|
|
G |
Cyp17a1 |
cytochrome P450, family 17, subfamily a, polypeptide 1 |
increases expression |
EXP |
Caffeine results in increased expression of CYP17A1 mRNA |
CTD |
PMID:25868845 |
|
NCBI chr 1:245,535,462...245,543,148
Ensembl chr 1:245,535,462...245,541,573
|
|
G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
increases expression |
EXP |
Caffeine results in increased expression of CYP19A1 mRNA; Caffeine results in increased expression of CYP19A1 protein |
CTD |
PMID:28111094 |
|
NCBI chr 8:54,553,165...54,580,758
Ensembl chr 8:54,553,165...54,580,758
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
decreases activity |
ISO |
Caffeine results in decreased activity of CYP1A1 protein |
CTD |
PMID:18420780 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
affects binding multiple interactions increases metabolic processing decreases activity affects metabolic processing increases activity decreases methylation |
ISO EXP |
CYP1A2 protein binds to Caffeine [Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of CYP1A2 mRNA [CYP1A2 protein binds to and results in increased metabolism of Caffeine] which results in increased chemical synthesis of 1,3,7-trimethyluric acid; [CYP1A2 protein binds to and results in increased metabolism of Caffeine] which results in increased chemical synthesis of 1,7-dimethylxanthine; [CYP1A2 protein binds to and results in increased metabolism of Caffeine] which results in increased chemical synthesis of Theobromine; [CYP1A2 protein binds to and results in increased metabolism of Caffeine] which results in increased chemical synthesis of Theophylline; [CYP1A2 protein results in increased metabolism of Caffeine] which results in increased chemical synthesis of 1,7-dimethylxanthine; Ciprofloxacin inhibits the reaction [CYP1A2 protein results in decreased methylation of Caffeine]; CYP1A2 protein binds to and affects the metabolism of Caffeine; CYP1A2 protein binds to and results in increased metabolism of Caffeine; GH1 protein promotes the reaction [CYP1A2 protein results in increased metabolism of Caffeine]; Resveratrol promotes the reaction [CYP1A2 protein results in increased metabolism of Caffeine]; rofecoxib inhibits the reaction [CYP1A2 protein results in increased metabolism of Caffeine] Caffeine results in decreased activity of CYP1A2 protein CYP1A2 protein affects the metabolism of Caffeine; CYP1A2 protein affects the metabolism of Caffeine metabolite [Fluvoxamine results in decreased activity of CYP1A2 protein] which results in decreased metabolism of Caffeine; [N,N-diallyl-5-methoxytryptamine results in decreased activity of CYP1A2 protein] which results in decreased metabolism of Caffeine; Caffeine promotes the reaction [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of CYP1A2 mRNA]; CYP1A2 protein binds to and affects the metabolism of Caffeine Caffeine results in increased activity of CYP1A2 protein |
CTD |
PMID:1302044 PMID:9334905 PMID:11145498 PMID:11376689 PMID:11465391 PMID:11907490 PMID:12433797 PMID:12706856 PMID:14586384 PMID:14586387 PMID:15022032 PMID:15199075 PMID:15286053 PMID:15327588 PMID:15619608 PMID:15659567 PMID:15822860 PMID:15856409 PMID:15980104 PMID:16934051 PMID:18420780 PMID:19215233 PMID:20716633 PMID:24211539 PMID:26599973 PMID:28843594 PMID:31132250 More...
|
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
decreases activity |
ISO |
Caffeine results in decreased activity of CYP1B1 protein |
CTD |
PMID:18420780 |
|
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Cyp21a1 |
cytochrome P450, family 21, subfamily a, polypeptide 1 |
increases expression decreases expression |
EXP |
Caffeine results in increased expression of CYP21A1 mRNA Caffeine results in decreased expression of CYP21A1 mRNA; Caffeine results in decreased expression of CYP21A2 mRNA |
CTD |
PMID:24717552 PMID:25868845 PMID:30528684 |
|
NCBI chr20:4,020,217...4,026,923
Ensembl chr20:4,023,767...4,026,923
|
|
G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
affects metabolic processing |
ISO |
CYP2D6 protein affects the metabolism of Caffeine |
CTD |
PMID:15199075 |
|
NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
affects metabolic processing |
ISO |
CYP2E1 protein affects the metabolism of Caffeine |
CTD |
PMID:1302044 PMID:14586387 |
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
decreases activity |
ISO |
Caffeine results in decreased activity of CYP3A4 protein |
CTD |
PMID:24211539 |
|
NCBI chr12:9,207,986...9,230,038
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Cyp4b1 |
cytochrome P450, family 4, subfamily b, polypeptide 1 |
increases expression |
ISO |
Caffeine results in increased expression of CYP4B1 mRNA |
CTD |
PMID:18444173 |
|
NCBI chr 5:129,139,019...129,176,860
Ensembl chr 5:129,139,038...129,156,348
|
|
G |
Cyp7b1 |
cytochrome P450 family 7 subfamily B member 1 |
decreases expression |
EXP |
Caffeine results in decreased expression of CYP7B1 mRNA |
CTD |
PMID:20864626 |
|
NCBI chr 2:100,502,791...100,669,713
Ensembl chr 2:100,502,791...100,669,698
|
|
G |
Dad1 |
defender against cell death 1 |
decreases expression |
ISO |
Caffeine results in decreased expression of DAD1 mRNA |
CTD |
PMID:11793227 |
|
NCBI chr15:27,677,285...27,697,275
Ensembl chr15:27,677,268...27,697,347
|
|
G |
Dcaf11 |
DDB1 and CUL4 associated factor 11 |
decreases expression |
EXP |
Caffeine results in decreased expression of DCAF11 mRNA |
CTD |
PMID:20864626 |
|
NCBI chr15:29,046,744...29,057,450
Ensembl chr15:29,046,826...29,057,669
|
|
G |
Dct |
dopachrome tautomerase |
increases expression |
ISO |
Caffeine results in increased expression of DCT mRNA |
CTD |
PMID:18444173 |
|
NCBI chr15:95,062,006...95,100,863
Ensembl chr15:95,062,003...95,100,836
|
|
G |
Dcxr |
dicarbonyl and L-xylulose reductase |
multiple interactions |
ISO |
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of DCXR mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of DCXR mRNA] |
CTD |
PMID:20230807 |
|
NCBI chr10:106,006,404...106,008,294
|
|
G |
Ddhd1 |
DDHD domain containing 1 |
increases expression |
EXP |
Caffeine results in increased expression of DDHD1 mRNA |
CTD |
PMID:20864626 |
|
NCBI chr15:18,824,389...18,891,036
Ensembl chr15:18,824,394...18,890,952
|
|
G |
Ddx31 |
DEAD-box helicase 31 |
decreases expression |
EXP |
Caffeine results in decreased expression of DDX31 mRNA |
CTD |
PMID:20864626 |
|
NCBI chr 3:12,172,829...12,238,392
Ensembl chr 3:12,172,836...12,238,873
|
|
G |
Ddx39a |
DExD-box helicase 39A |
decreases expression |
ISO |
Caffeine results in decreased expression of DDX39A protein |
CTD |
PMID:31195006 |
|
NCBI chr19:24,418,743...24,427,422
Ensembl chr19:24,418,114...24,426,954
|
|
G |
Dhcr24 |
24-dehydrocholesterol reductase |
decreases expression |
EXP |
Caffeine results in decreased expression of DHCR24 mRNA |
CTD |
PMID:20864626 |
|
NCBI chr 5:121,344,637...121,368,853
Ensembl chr 5:121,344,575...121,371,137
|
|
G |
Dhcr7 |
7-dehydrocholesterol reductase |
decreases expression |
EXP |
Caffeine results in decreased expression of DHCR7 mRNA |
CTD |
PMID:25868845 |
|
NCBI chr 1:199,015,081...199,031,055
Ensembl chr 1:199,015,081...199,031,055
|
|
G |
Dhodh |
dihydroorotate dehydrogenase (quinone) |
increases expression |
EXP |
Caffeine results in increased expression of DHODH protein |
CTD |
PMID:6149265 |
|
NCBI chr19:37,551,858...37,573,327
Ensembl chr19:37,558,177...37,591,654
|
|
G |
Dnaja1 |
DnaJ heat shock protein family (Hsp40) member A1 |
multiple interactions |
ISO |
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of DNAJA1 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of DNAJA1 mRNA] |
CTD |
PMID:20230807 |
|
NCBI chr 5:55,842,414...55,853,326
Ensembl chr 5:55,842,426...55,853,967
|
|
G |
Dnajb9 |
DnaJ heat shock protein family (Hsp40) member B9 |
multiple interactions |
ISO |
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of DNAJB9 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of DNAJB9 mRNA] |
CTD |
PMID:20230807 |
|
NCBI chr 6:61,270,385...61,276,795
Ensembl chr 6:61,269,913...61,275,063
|
|
G |
Dnajc12 |
DnaJ heat shock protein family (Hsp40) member C12 |
increases expression |
ISO |
Caffeine results in increased expression of DNAJC12 protein |
CTD |
PMID:31195006 |
|
NCBI chr20:25,246,744...25,267,508
Ensembl chr20:25,223,144...25,267,521
|
|
G |
Dnmt1 |
DNA methyltransferase 1 |
increases expression |
EXP |
Caffeine results in increased expression of DNMT1 mRNA |
CTD |
PMID:24717552 |
|
NCBI chr 8:19,440,611...19,486,659
Ensembl chr 8:19,440,611...19,486,659
|
|
G |
Dnmt3a |
DNA methyltransferase 3 alpha |
increases expression |
EXP |
Caffeine results in increased expression of DNMT3A mRNA |
CTD |
PMID:24717552 |
|
NCBI chr 6:26,791,517...26,902,161
Ensembl chr 6:26,822,609...26,896,687
|
|
G |
Dnmt3b |
DNA methyltransferase 3 beta |
increases expression |
EXP |
Caffeine results in increased expression of DNMT3B mRNA |
CTD |
PMID:25868845 PMID:30423288 |
|
NCBI chr 3:142,130,592...142,169,124
Ensembl chr 3:142,130,592...142,169,124
|
|
G |
Dpp4 |
dipeptidylpeptidase 4 |
multiple interactions |
ISO |
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of DPP4 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of DPP4 mRNA] |
CTD |
PMID:20230807 |
|
NCBI chr 3:46,962,243...47,043,870
Ensembl chr 3:46,962,243...47,043,901
|
|
G |
Drd2 |
dopamine receptor D2 |
affects response to substance increases response to substance multiple interactions |
ISO EXP |
DRD2 polymorphism affects the susceptibility to Caffeine DRD2 protein results in increased susceptibility to Caffeine Caffeine inhibits the reaction [N-Methyl-3,4-methylenedioxyamphetamine promotes the reaction [Spiperone binds to DRD2 protein]] |
CTD |
PMID:11172060 PMID:16889759 PMID:18305461 |
|
NCBI chr 8:49,708,903...49,772,888
Ensembl chr 8:49,708,927...49,772,875
|
|
G |
Dtx4 |
deltex E3 ubiquitin ligase 4 |
decreases expression |
EXP |
Caffeine results in decreased expression of DTX4 mRNA |
CTD |
PMID:20864626 |
|
NCBI chr 1:209,457,719...209,545,163
Ensembl chr 1:209,460,735...209,492,818
|
|
G |
Dusp8 |
dual specificity phosphatase 8 |
increases expression |
EXP |
Caffeine results in increased expression of DUSP8 mRNA |
CTD |
PMID:9813294 |
|
NCBI chr 1:197,167,392...197,184,285
Ensembl chr 1:197,169,422...197,182,921
|
|
G |
E2f1 |
E2F transcription factor 1 |
multiple interactions |
ISO |
Caffeine inhibits the reaction [Camptothecin results in increased expression of E2F1 mRNA] |
CTD |
PMID:22403396 |
|
NCBI chr 3:143,064,535...143,075,362
Ensembl chr 3:143,049,478...143,075,361
|
|
G |
Ebp |
EBP, cholestenol delta-isomerase |
increases expression |
EXP |
Caffeine results in increased expression of EBP mRNA |
CTD |
PMID:25868845 |
|
NCBI chr X:14,299,427...14,305,826
Ensembl chr X:14,299,448...14,305,826
|
|
G |
Ebpl |
EBP like |
decreases expression |
EXP |
Caffeine results in decreased expression of EBPL mRNA |
CTD |
PMID:20864626 |
|
NCBI chr15:35,508,074...35,531,472
Ensembl chr15:35,508,074...35,531,472
|
|
G |
Eci1 |
enoyl-CoA delta isomerase 1 |
decreases expression |
EXP |
Caffeine results in decreased expression of ECI1 mRNA |
CTD |
PMID:20864626 |
|
NCBI chr10:13,456,715...13,470,061
Ensembl chr10:13,456,563...13,470,061
|
|
G |
Ecm1 |
extracellular matrix protein 1 |
multiple interactions |
ISO |
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of ECM1 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ECM1 mRNA] |
CTD |
PMID:20230807 |
|
NCBI chr 2:183,287,491...183,292,729
Ensembl chr 2:183,287,322...183,292,671
|
|
G |
Edn1 |
endothelin 1 |
increases activity |
EXP |
Caffeine results in increased activity of EDN1 protein |
CTD |
PMID:1860718 |
|
NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885
|
|
G |
Eef1a1 |
eukaryotic translation elongation factor 1 alpha 1 |
multiple interactions increases expression |
ISO |
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of EEF1A1 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of EEF1A1 mRNA] Caffeine results in increased expression of EEF1A1 protein |
CTD |
PMID:20230807 PMID:31195006 |
|
NCBI chr 8:79,341,554...79,344,784
Ensembl chr 8:79,341,557...79,344,839
|
|
G |
Eef1d |
eukaryotic translation elongation factor 1 delta |
decreases expression |
ISO |
Caffeine results in decreased expression of EEF1D protein |
CTD |
PMID:31195006 |
|
NCBI chr 7:107,581,930...107,596,735
Ensembl chr 7:107,581,930...107,608,799
|
|
G |
Eef1g |
eukaryotic translation elongation factor 1 gamma |
increases expression |
ISO |
Caffeine results in increased expression of EEF1G protein |
CTD |
PMID:31195006 |
|
NCBI chr 1:205,860,713...205,871,319
Ensembl chr 1:205,860,698...205,872,382
|
|
G |
Eef2 |
eukaryotic translation elongation factor 2 |
multiple interactions |
ISO |
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of EEF2 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of EEF2 mRNA] |
CTD |
PMID:20230807 |
|
NCBI chr 7:8,533,248...8,538,518
Ensembl chr 7:8,533,116...8,559,183
|
|
G |
Efna1 |
ephrin A1 |
multiple interactions |
ISO |
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of EFNA1 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of EFNA1 mRNA] |
CTD |
PMID:20230807 |
|
NCBI chr 2:174,681,676...174,690,306
Ensembl chr 2:174,681,682...174,690,866
|
|
G |
Efnb3 |
ephrin B3 |
multiple interactions |
ISO |
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of EFNB3 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of EFNB3 mRNA] |
CTD |
PMID:20230807 |
|
NCBI chr10:54,274,506...54,281,951
Ensembl chr10:54,274,506...54,280,471
|
|
G |
Egr1 |
early growth response 1 |
increases expression decreases expression multiple interactions |
ISO EXP |
Caffeine results in increased expression of EGR1 mRNA Caffeine results in decreased expression of EGR1 mRNA [Cocaine co-treated with Caffeine] results in increased expression of EGR1 mRNA; Cocaine promotes the reaction [Caffeine results in increased expression of EGR1 mRNA] [Caffeine co-treated with Dextroamphetamine] affects the expression of EGR1 mRNA |
CTD |
PMID:10971643 PMID:16771831 |
|
NCBI chr18:26,463,333...26,465,531
Ensembl chr18:26,462,981...26,466,766
|
|
G |
Ehbp1 |
EH domain binding protein 1 |
increases expression |
ISO |
Caffeine results in increased expression of EHBP1 protein |
CTD |
PMID:31195006 |
|
NCBI chr14:96,093,327...96,380,502
Ensembl chr14:96,093,327...96,345,332
|
|
G |
Ehd1 |
EH-domain containing 1 |
decreases expression |
ISO |
Caffeine results in decreased expression of EHD1 protein |
CTD |
PMID:31195006 |
|
NCBI chr 1:203,579,850...203,602,226
Ensembl chr 1:203,579,869...203,602,212
|
|
G |
Ehd2 |
EH-domain containing 2 |
decreases expression |
ISO |
Caffeine results in decreased expression of EHD2 protein |
CTD |
PMID:31195006 |
|
NCBI chr 1:76,639,568...76,658,747
Ensembl chr 1:76,637,482...76,658,783
|
|
G |
Eif1 |
eukaryotic translation initiation factor 1 |
increases expression |
ISO |
Caffeine results in increased expression of EIF1 mRNA |
CTD |
PMID:11793227 |
|
NCBI chr10:85,246,751...85,248,842
Ensembl chr10:85,246,764...85,427,327
|
|
G |
Eif3b |
eukaryotic translation initiation factor 3, subunit B |
decreases expression |
ISO |
Caffeine results in decreased expression of EIF3B protein |
CTD |
PMID:31195006 |
|
NCBI chr12:14,196,403...14,220,865
Ensembl chr12:14,196,403...14,220,886
|
|
G |
Eif4e |
eukaryotic translation initiation factor 4E |
multiple interactions |
ISO |
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of EIF4E mRNA; Caffeine affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of EIF4E mRNA] |
CTD |
PMID:20230807 |
|
NCBI chr 2:227,066,519...227,099,261
Ensembl chr 2:227,066,673...227,098,683
|
|
G |
Eif4ebp1 |
eukaryotic translation initiation factor 4E binding protein 1 |
decreases expression increases expression |
ISO EXP |
Caffeine results in decreased expression of EIF4EBP1 protein modified form Caffeine results in increased expression of EIF4EBP1 protein |
CTD |
PMID:21081844 |
|
NCBI chr16:64,792,595...64,805,984
Ensembl chr16:64,790,226...64,805,984
|
|
G |
Eif5 |
eukaryotic translation initiation factor 5 |
multiple interactions |
ISO |
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of EIF5 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of EIF5 mRNA] |
CTD |
PMID:20230807 |
|
NCBI chr 6:130,589,200...130,597,656
Ensembl chr 6:130,589,143...130,597,656
|
|
G |
Ell |
elongation factor for RNA polymerase II |
decreases expression |
EXP |
Caffeine results in decreased expression of ELL mRNA |
CTD |
PMID:20864626 |
|
NCBI chr16:18,845,025...18,891,484
Ensembl chr16:18,843,780...18,891,118
|
|
G |
Emc6 |
ER membrane protein complex subunit 6 |
decreases expression |
EXP |
Caffeine results in decreased expression of EMC6 mRNA |
CTD |
PMID:20864626 |
|
NCBI chr10:57,794,072...57,795,671
Ensembl chr10:57,793,685...57,796,217
|
|
G |
Endod1 |
endonuclease domain containing 1 |
decreases expression |
EXP |
Caffeine results in decreased expression of ENDOD1 mRNA |
CTD |
PMID:20864626 |
|
NCBI chr 8:11,209,123...11,238,680
Ensembl chr 8:11,211,110...11,238,892
|
|
G |
Eno1 |
enolase 1 |
multiple interactions |
ISO |
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of ENO1 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ENO1 mRNA] |
CTD |
PMID:20230807 |
|
NCBI chr 5:160,719,951...160,731,337
Ensembl chr 5:160,719,951...160,731,336
|
|
G |
Eppk1 |
epiplakin 1 |
decreases expression |
ISO |
Caffeine results in decreased expression of EPPK1 protein |
CTD |
PMID:31195006 |
|
NCBI chr 7:107,816,919...107,842,946
Ensembl chr 7:107,817,693...107,831,159
|
|
G |
Ern1 |
endoplasmic reticulum to nucleus signaling 1 |
multiple interactions |
ISO |
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of ERN1 mRNA; Caffeine promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of ERN1 mRNA] |
CTD |
PMID:20230807 |
|
NCBI chr10:91,326,889...91,421,201
Ensembl chr10:91,330,654...91,421,029
|
|
G |
Erp44 |
endoplasmic reticulum protein 44 |
multiple interactions |
ISO |
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of ERP44 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of ERP44 mRNA] |
CTD |
PMID:20230807 |
|
NCBI chr 5:62,516,550...62,610,762
Ensembl chr 5:62,516,551...62,610,761
|
|
G |
Esyt2 |
extended synaptotagmin 2 |
decreases expression |
EXP |
Caffeine results in decreased expression of ESYT2 mRNA |
CTD |
PMID:20864626 |
|
NCBI chr 6:137,219,653...137,312,590
Ensembl chr 6:137,219,707...137,312,590
|
|
G |
Etv3 |
ETS variant transcription factor 3 |
increases expression |
ISO |
Caffeine results in increased expression of ETV3 protein |
CTD |
PMID:31195006 |
|
NCBI chr 2:172,965,461...172,980,320
Ensembl chr 2:172,965,588...172,980,314
|
|
G |
Eya1 |
EYA transcriptional coactivator and phosphatase 1 |
decreases expression |
ISO |
Caffeine results in decreased expression of EYA1 mRNA |
CTD |
PMID:31711903 |
|
NCBI chr 5:4,863,501...5,101,483
Ensembl chr 5:4,955,543...5,101,483
|
|
G |
Ezr |
ezrin |
multiple interactions |
ISO |
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of EZR mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of EZR mRNA] |
CTD |
PMID:20230807 |
|
NCBI chr 1:46,967,961...47,011,505
Ensembl chr 1:46,967,658...47,011,505
|
|
G |
Fabp4 |
fatty acid binding protein 4 |
decreases expression |
ISO EXP |
Caffeine results in decreased expression of FABP4 mRNA |
CTD |
PMID:23727198 |
|
NCBI chr 2:91,580,858...91,585,578
Ensembl chr 2:91,580,885...91,585,578
|
|
G |
Farsa |
phenylalanyl-tRNA synthetase subunit alpha |
increases expression |
ISO |
Caffeine results in increased expression of FARSA protein |
CTD |
PMID:31195006 |
|
NCBI chr19:23,291,409...23,300,985
Ensembl chr19:23,268,869...23,300,980
|
|
G |
Fas |
Fas cell surface death receptor |
decreases expression multiple interactions |
EXP |
Caffeine results in decreased expression of FAS mRNA Caffeine inhibits the reaction [Dietary Fats results in increased expression of FAS mRNA] |
CTD |
PMID:29249184 PMID:29343424 |
|
NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
|
|
G |
Fasn |
fatty acid synthase |
multiple interactions increases expression |
ISO EXP |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of FASN mRNA Caffeine results in increased expression of FASN mRNA; Caffeine results in increased expression of FASN protein |
CTD |
PMID:28843594 PMID:30776459 |
|
NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261
|
|
G |
Fastkd3 |
FAST kinase domains 3 |
decreases expression |
EXP |
Caffeine results in decreased expression of FASTKD3 mRNA |
CTD |
PMID:20864626 |
|
NCBI chr 1:34,858,342...34,866,988
Ensembl chr 1:34,858,219...34,866,973
|
|
G |
Fau |
FAU, ubiquitin like and ribosomal protein S30 fusion |
increases expression |
ISO |
Caffeine results in increased expression of FAU protein |
CTD |
PMID:31195006 |
|
NCBI chr 1:203,350,226...203,351,741
Ensembl chr 1:203,350,189...203,351,742
|
|
G |
Fbln2 |
fibulin 2 |
increases expression |
EXP |
Caffeine results in increased expression of FBLN2 mRNA |
CTD |
PMID:20864626 |
|
NCBI chr 4:123,704,289...123,763,857
Ensembl chr 4:123,704,373...123,763,948
|
|
G |
Fbrs |
fibrosin |
increases expression |
EXP |
Caffeine results in increased expression of FBRS mRNA |
CTD |
PMID:20864626 |
|
NCBI chr 1:182,090,741...182,104,026
Ensembl chr 1:182,089,844...182,103,828
|
|
G |
Fbxl12 |
F-box and leucine-rich repeat protein 12 |
multiple interactions |
ISO |
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of FBXL12 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of FBXL12 mRNA] |
CTD |
PMID:20230807 |
|
NCBI chr 8:19,175,864...19,183,373
Ensembl chr 8:19,160,352...19,183,607
|
|
G |
Fbxl19 |
F-box and leucine-rich repeat protein 19 |
decreases expression |
ISO |
Caffeine results in decreased expression of FBXL19 protein |
CTD |
PMID:31195006 |
|
NCBI chr 1:182,356,899...182,380,839
Ensembl chr 1:182,360,830...182,380,083
|
|
G |
Fcsk |
fucose kinase |
increases expression |
EXP |
Caffeine results in increased expression of FCSK mRNA |
CTD |
PMID:20864626 |
|
NCBI chr19:38,849,130...38,874,497
Ensembl chr19:38,854,762...38,874,418
|
|
G |
Fdft1 |
farnesyl diphosphate farnesyl transferase 1 |
decreases expression increases expression |
EXP |
Caffeine results in decreased expression of FDFT1 mRNA Caffeine results in increased expression of FDFT1 mRNA |
CTD |
PMID:20864626 PMID:25868845 |
|
NCBI chr15:37,412,143...37,440,198
Ensembl chr15:37,412,146...37,440,287
|
|
G |
Fdx1 |
ferredoxin 1 |
decreases expression |
EXP |
Caffeine results in decreased expression of FDX1 mRNA |
CTD |
PMID:20864626 PMID:25868845 |
|
NCBI chr 8:52,268,536...52,287,344
Ensembl chr 8:52,268,536...52,287,414
|
|
G |
Fhl1 |
four and a half LIM domains 1 |
increases expression |
EXP |
Caffeine results in increased expression of FHL1 mRNA |
CTD |
PMID:20864626 |
|
NCBI chr X:134,555,399...134,614,930
Ensembl chr X:134,555,479...134,614,928
|
|
G |
Filip1l |
filamin A interacting protein 1-like |
increases expression |
EXP |
Caffeine results in increased expression of FILIP1L mRNA |
CTD |
PMID:20864626 |
|
NCBI chr11:42,937,353...43,177,085
Ensembl chr11:42,940,467...43,177,415
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
increases expression multiple interactions |
ISO |
Caffeine results in increased expression of FOS mRNA [Cocaine co-treated with Caffeine] results in increased expression of FOS mRNA; Cocaine promotes the reaction [Caffeine results in increased expression of FOS mRNA] |
CTD |
PMID:10971643 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Fyn |
FYN proto-oncogene, Src family tyrosine kinase |
multiple interactions |
ISO |
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of FYN mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of FYN mRNA] |
CTD |
PMID:20230807 |
|
NCBI chr20:42,767,733...42,960,903
Ensembl chr20:42,766,369...42,959,911
|
|
G |
Gale |
UDP-galactose-4-epimerase |
multiple interactions |
ISO |
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of GALE mRNA; Caffeine promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GALE mRNA] |
CTD |
PMID:20230807 |
|
NCBI chr 5:148,193,886...148,198,392
Ensembl chr 5:148,194,791...148,198,388
|
|
G |
Ganab |
glucosidase II alpha subunit |
decreases expression |
ISO |
Caffeine results in decreased expression of GANAB protein |
CTD |
PMID:31195006 |
|
NCBI chr 1:205,793,810...205,813,701
Ensembl chr 1:205,793,895...205,813,695
|
|
G |
Gapdh |
glyceraldehyde-3-phosphate dehydrogenase |
multiple interactions |
ISO |
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of GAPDH mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of GAPDH mRNA] |
CTD |
PMID:20230807 |
|
NCBI chr 4:157,962,312...157,967,158
Ensembl chr 4:157,962,343...157,966,235
|
|
G |
Gast |
gastrin |
increases secretion |
EXP |
Caffeine results in increased secretion of GAST protein |
CTD |
PMID:19208342 |
|
NCBI chr10:85,264,832...85,269,393
Ensembl chr10:85,264,832...85,267,496
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of GCLC mRNA |
CTD |
PMID:28843594 |
|
NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544
|
|
G |
Gdf10 |
growth differentiation factor 10 |
decreases expression |
EXP |
Caffeine results in decreased expression of GDF10 mRNA |
CTD |
PMID:20864626 |
|
NCBI chr16:9,237,182...9,250,537
Ensembl chr16:9,237,261...9,249,343
|
|
G |
Gfap |
glial fibrillary acidic protein |
multiple interactions |
ISO EXP |
Caffeine promotes the reaction [N-Methyl-3,4-methylenedioxyamphetamine results in increased expression of GFAP protein] Caffeine inhibits the reaction [aluminum chloride results in increased expression of GFAP protein] |
CTD |
PMID:19882200 PMID:26339337 |
|
NCBI chr10:87,852,891...87,861,631
Ensembl chr10:87,852,890...87,861,589
|
|
G |
Gh1 |
growth hormone 1 |
multiple interactions |
ISO |
GH1 protein promotes the reaction [CYP1A2 protein results in increased metabolism of Caffeine] |
CTD |
PMID:11907490 |
|
NCBI chr10:91,228,102...91,230,079
Ensembl chr10:91,228,103...91,230,078
|
|
G |
Ghitm |
growth hormone inducible transmembrane protein |
multiple interactions |
ISO |
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of GHITM mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of GHITM mRNA] |
CTD |
PMID:20230807 |
|
NCBI chr16:12,885,551...12,897,887
Ensembl chr16:12,885,553...12,897,879
|
|
G |
Gja1 |
gap junction protein, alpha 1 |
decreases expression |
EXP |
Caffeine results in decreased expression of GJA1 mRNA |
CTD |
PMID:28087314 |
|
NCBI chr20:35,756,007...35,768,481
Ensembl chr20:35,755,991...35,768,582
|
|
G |
Glrx |
glutaredoxin |
decreases expression |
ISO |
Caffeine results in decreased expression of GLRX mRNA |
CTD |
PMID:11793227 |
|
NCBI chr 2:5,341,873...5,351,686
Ensembl chr 2:5,341,885...5,351,680
|
|
G |
Glt8d1 |
glycosyltransferase 8 domain containing 1 |
decreases expression |
ISO |
Caffeine results in decreased expression of GLT8D1 mRNA |
CTD |
PMID:11793227 |
|
NCBI chr16:6,192,269...6,207,227
Ensembl chr16:6,192,300...6,207,229
|
|
G |
Glud1 |
glutamate dehydrogenase 1 |
decreases expression |
ISO |
Caffeine results in decreased expression of GLUD1 mRNA |
CTD |
PMID:11793227 |
|
NCBI chr16:9,640,312...9,673,961
Ensembl chr16:9,640,312...9,673,957
|
|
G |
Gmfb |
glia maturation factor, beta |
multiple interactions |
ISO |
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of GMFB mRNA; Caffeine promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GMFB mRNA] |
CTD |
PMID:20230807 |
|
NCBI chr15:20,069,923...20,081,005
Ensembl chr15:20,067,263...20,080,331
|
|
G |
Gnai1 |
G protein subunit alpha i1 |
decreases expression increases expression |
EXP |
Caffeine results in decreased expression of GNAI1 protein Caffeine results in increased expression of GNAI1 mRNA |
CTD |
PMID:15708489 |
|
NCBI chr 4:16,813,941...16,898,111
Ensembl chr 4:16,814,001...16,896,417
|
|
G |
Gnai2 |
G protein subunit alpha i2 |
decreases expression |
EXP |
Caffeine results in decreased expression of GNAI2 protein |
CTD |
PMID:15708489 |
|
NCBI chr 8:108,288,401...108,309,009
Ensembl chr 8:108,288,401...108,308,979
|
|
G |
Gnal |
G protein subunit alpha L |
increases response to substance |
ISO |
GNAL protein results in increased susceptibility to Caffeine |
CTD |
PMID:11404425 |
|
NCBI chr18:60,622,311...60,762,599
Ensembl chr18:60,622,311...60,762,599
|
|
G |
Gnaq |
G protein subunit alpha q |
decreases expression |
EXP |
Caffeine results in decreased expression of GNAQ protein |
CTD |
PMID:15998294 |
|
NCBI chr 1:213,425,631...213,671,947
Ensembl chr 1:213,424,465...213,667,672
|
|
G |
Gnas |
GNAS complex locus |
decreases expression |
EXP |
Caffeine results in decreased expression of GNAS protein |
CTD |
PMID:15708489 |
|
NCBI chr 3:163,071,003...163,136,350
Ensembl chr 3:163,071,417...163,127,262 Ensembl chr 3:163,071,417...163,127,262
|
|
G |
Golt1b |
golgi transport 1B |
multiple interactions |
ISO |
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of GOLT1B mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GOLT1B mRNA] |
CTD |
PMID:20230807 |
|
NCBI chr 4:175,333,056...175,346,156
Ensembl chr 4:175,333,092...175,346,153
|
|
G |
Gosr1 |
golgi SNAP receptor complex member 1 |
decreases expression |
EXP |
Caffeine results in decreased expression of GOSR1 mRNA |
CTD |
PMID:20864626 |
|
NCBI chr10:61,570,499...61,607,287
Ensembl chr10:61,450,494...61,607,177 Ensembl chr10:61,450,494...61,607,177
|
|
G |
Got2 |
glutamic-oxaloacetic transaminase 2 |
decreases expression |
ISO |
Caffeine results in decreased expression of GOT2 protein |
CTD |
PMID:31195006 |
|
NCBI chr19:9,174,304...9,199,995
Ensembl chr19:9,174,311...9,199,994
|
|
G |
Gpc3 |
glypican 3 |
affects expression |
EXP |
Caffeine affects the expression of GPC3 mRNA |
CTD |
PMID:20864626 |
|
NCBI chr X:131,868,983...132,236,837
Ensembl chr X:131,868,990...132,236,798
|
|
G |
Gpi |
glucose-6-phosphate isomerase |
decreases expression |
ISO |
Caffeine results in decreased expression of GPI protein |
CTD |
PMID:31195006 |
|
NCBI chr 1:86,828,211...86,856,077
Ensembl chr 1:86,828,216...86,856,086
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions increases activity |
EXP |
Caffeine inhibits the reaction [Dietary Fats results in increased activity of GPT protein]; Caffeine promotes the reaction [allyl alcohol results in increased activity of GPT protein]; Fomepizole inhibits the reaction [Caffeine promotes the reaction [allyl alcohol results in increased activity of GPT protein]] Caffeine results in increased activity of GPT protein |
CTD |
PMID:11394713 PMID:29249184 PMID:30776459 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
multiple interactions |
ISO |
Caffeine promotes the reaction [bisphenol A results in decreased expression of GPX1 mRNA] |
CTD |
PMID:31756439 |
|
NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024
|
|
G |
Gpx3 |
glutathione peroxidase 3 |
multiple interactions |
ISO |
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of GPX3 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GPX3 mRNA] |
CTD |
PMID:20230807 |
|
NCBI chr10:39,028,624...39,036,695
Ensembl chr10:39,028,570...39,037,035
|
|
G |
Gpx4 |
glutathione peroxidase 4 |
multiple interactions |
ISO |
[Caffeine co-treated with bisphenol A] results in decreased expression of GPX4 mRNA |
CTD |
PMID:31756439 |
|
NCBI chr 7:9,650,186...9,652,982
Ensembl chr 7:9,650,185...9,652,982
|
|
G |
Grid2 |
glutamate ionotropic receptor delta type subunit 2 |
multiple interactions |
ISO |
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of GRID2 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GRID2 mRNA] |
CTD |
PMID:20230807 |
|
NCBI chr 4:92,415,019...93,892,472
Ensembl chr 4:92,415,230...93,889,355
|
|
G |
Grm1 |
glutamate metabotropic receptor 1 |
decreases expression |
EXP |
Caffeine results in decreased expression of GRM1 protein |
CTD |
PMID:15998294 |
|
NCBI chr 1:5,058,285...5,453,170
Ensembl chr 1:5,058,292...5,453,170
|
|
G |
Grpr |
gastrin releasing peptide receptor |
decreases expression |
EXP |
Caffeine results in decreased expression of GRPR mRNA |
CTD |
PMID:20864626 |
|
NCBI chr X:30,998,425...31,038,442
Ensembl chr X:30,998,416...31,038,442
|
|
G |
Grwd1 |
glutamate-rich WD repeat containing 1 |
decreases expression |
EXP |
Caffeine results in decreased expression of GRWD1 mRNA |
CTD |
PMID:20864626 |
|
NCBI chr 1:96,301,260...96,306,962
Ensembl chr 1:96,301,261...96,307,201
|
|
G |
Gsk3a |
glycogen synthase kinase 3 alpha |
increases expression |
EXP |
Caffeine results in increased expression of GSK3A mRNA |
CTD |
PMID:25868845 |
|
NCBI chr 1:80,815,843...80,825,732
Ensembl chr 1:80,815,850...80,825,802
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
increases phosphorylation decreases phosphorylation multiple interactions |
ISO |
Caffeine results in increased phosphorylation of GSK3B protein Caffeine results in decreased phosphorylation of GSK3B protein N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Caffeine results in increased phosphorylation of GSK3B protein] |
CTD |
PMID:15126379 PMID:21229324 |
|
NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
|
|
G |
Gsr |
glutathione-disulfide reductase |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of GSR mRNA |
CTD |
PMID:28843594 |
|
NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661
|
|
G |
Gsto1 |
glutathione S-transferase omega 1 |
decreases expression |
ISO |
Caffeine results in decreased expression of GSTO1 mRNA |
CTD |
PMID:11793227 |
|
NCBI chr 1:246,721,089...246,731,228
Ensembl chr 1:246,721,221...246,731,468
|
|
G |
H1f0 |
H1.0 linker histone |
decreases expression |
ISO |
Caffeine results in decreased expression of H1F0 protein |
CTD |
PMID:31195006 |
|
NCBI chr 7:110,592,834...110,594,694
Ensembl chr 7:110,592,208...110,594,694
|
|
G |
H1f4 |
H1.4 linker histone, cluster member |
increases expression |
ISO |
Caffeine results in increased expression of H1-4 protein |
CTD |
PMID:31195006 |
|
NCBI chr17:41,486,634...41,487,293
Ensembl chr17:41,486,560...41,487,403
|
|
G |
H1f5 |
H1.5 linker histone, cluster member |
increases expression |
ISO |
Caffeine results in increased expression of H1-5 protein |
CTD |
PMID:31195006 |
|
NCBI chr17:42,726,189...42,726,857
Ensembl chr17:42,726,127...42,769,160
|
|
G |
H1f6 |
H1.6 linker histone, cluster member |
increases expression |
ISO |
Caffeine results in increased expression of H1-6 protein |
CTD |
PMID:31195006 |
|
NCBI chr17:41,427,365...41,428,109
Ensembl chr17:41,427,323...41,428,119
|
|
G |
H2ax |
H2A.X variant histone |
multiple interactions |
ISO EXP |
Caffeine inhibits the reaction [4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone results in increased phosphorylation of H2AX protein]; Caffeine inhibits the reaction [Resveratrol results in increased phosphorylation of H2AX protein]; Caffeine inhibits the reaction [riccardin D results in increased phosphorylation of H2AX protein]; Caffeine inhibits the reaction [Silybin results in increased phosphorylation of H2AX protein]; Caffeine promotes the reaction [Acetaminophen results in increased expression of H2AX protein]; Caffeine promotes the reaction [Benzo(a)pyrene results in increased phosphorylation of H2AX protein] [Caffeine co-treated with Ephedrine] results in increased phosphorylation of H2AX protein |
CTD |
PMID:15537744 PMID:15975956 PMID:16777994 PMID:20888899 PMID:24069304 PMID:26231820 PMID:33971260 More...
|
|
NCBI chr 8:44,671,927...44,673,257
Ensembl chr 8:44,671,786...44,673,239
|
|
G |
Hacd1 |
3-hydroxyacyl-CoA dehydratase 1 |
decreases expression |
EXP |
Caffeine results in decreased expression of HACD1 mRNA |
CTD |
PMID:20864626 |
|
NCBI chr17:77,081,508...77,106,114
Ensembl chr17:77,083,740...77,106,073
|
|
G |
Hba-a1 |
hemoglobin alpha, adult chain 1 |
multiple interactions |
ISO |
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of HBA-A1 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of HBA-A1 mRNA] |
CTD |
PMID:20230807 |
|
NCBI chr10:15,337,265...15,338,121
Ensembl chr10:15,307,815...15,338,392
|
|
G |
Hdac1 |
histone deacetylase 1 |
increases expression |
EXP |
Caffeine results in increased expression of HDAC1 mRNA |
CTD |
PMID:24717552 |
|
NCBI chr 5:141,853,992...141,881,057
Ensembl chr 5:141,853,989...141,881,111
|
|
G |
Hdac2 |
histone deacetylase 2 |
increases expression |
EXP |
Caffeine results in increased expression of HDAC2 mRNA |
CTD |
PMID:24717552 |
|
NCBI chr20:40,548,250...40,571,609
Ensembl chr20:40,548,250...40,571,609
|
|
G |
Hdac7 |
histone deacetylase 7 |
increases expression |
EXP |
Caffeine results in increased expression of HDAC7 mRNA; Caffeine results in increased expression of HDAC7 protein |
CTD |
PMID:31306741 |
|
NCBI chr 7:128,923,918...128,962,025
Ensembl chr 7:128,923,920...128,962,072
|
|
G |
Hdlbp |
high density lipoprotein binding protein |
decreases expression |
EXP |
Caffeine results in decreased expression of HDLBP mRNA |
CTD |
PMID:25868845 |
|
NCBI chr 9:93,948,099...94,018,040
Ensembl chr 9:93,949,913...94,018,048
|
|
G |
Heca |
hdc homolog, cell cycle regulator |
increases expression |
EXP |
Caffeine results in increased expression of HECA mRNA |
CTD |
PMID:20864626 |
|
NCBI chr 1:12,525,135...12,575,358
Ensembl chr 1:12,525,135...12,576,427
|
|
G |
Hells |
helicase, lymphoid specific |
multiple interactions increases expression |
ISO |
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of HELLS mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of HELLS mRNA] Caffeine results in increased expression of HELLS protein |
CTD |
PMID:20025956 PMID:20230807 |
|
NCBI chr 1:236,701,704...236,748,239
Ensembl chr 1:236,701,758...236,746,844
|
|
G |
Hhipl2 |
HHIP like 2 |
decreases expression |
ISO |
Caffeine results in decreased expression of HHIPL2 protein |
CTD |
PMID:31195006 |
|
NCBI chr13:95,054,685...95,074,609
Ensembl chr13:95,054,694...95,074,608
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
multiple interactions |
ISO |
[Caffeine co-treated with bisphenol A] results in decreased expression of HIF1A mRNA |
CTD |
PMID:31756439 |
|
NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261
|
|
G |
Hint1 |
histidine triad nucleotide binding protein 1 |
multiple interactions |
ISO |
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of HINT1 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of HINT1 mRNA] |
CTD |
PMID:20230807 |
|
NCBI chr10:38,989,516...38,993,259
Ensembl chr 4:92,100,973...92,101,568
|
|
G |
Hist1h4b |
histone cluster 1 H4 family member B |
increases expression |
ISO |
Caffeine results in increased expression of H4C9 protein |
CTD |
PMID:31195006 |
|
NCBI chr17:42,480,467...42,484,912
Ensembl chr17:42,480,313...42,485,370
|
|
G |
Hmga1 |
high mobility group AT-hook 1 |
decreases expression |
ISO |
Caffeine results in decreased expression of HMGA1 protein |
CTD |
PMID:31195006 |
|
NCBI chr20:5,611,088...5,618,755
Ensembl chr20:5,611,694...5,618,752
|
|
G |
Hmga2 |
high mobility group AT-hook 2 |
decreases expression |
ISO |
Caffeine results in decreased expression of HMGA2 protein |
CTD |
PMID:31195006 |
|
NCBI chr 7:55,877,145...55,998,813
Ensembl chr 7:55,880,112...55,994,784
|
|
G |
Hmgb1 |
high mobility group box 1 |
decreases expression |
ISO |
Caffeine results in decreased expression of HMGB1 protein |
CTD |
PMID:31195006 |
|
NCBI chr12:5,973,062...5,978,565
Ensembl chr12:5,901,586...5,978,565
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
multiple interactions increases expression |
EXP ISO |
[Dietary Fats co-treated with Caffeine] results in decreased expression of HMGCR mRNA; Caffeine promotes the reaction [Lipopolysaccharides results in increased expression of HMGCR mRNA] Caffeine results in increased expression of HMGCR mRNA; Caffeine results in increased expression of HMGCR protein 2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine inhibits the reaction [Caffeine results in increased expression of HMGCR mRNA]; Colforsin inhibits the reaction [Caffeine results in increased expression of HMGCR mRNA]; Resveratrol inhibits the reaction [Caffeine results in increased expression of HMGCR mRNA] |
CTD |
PMID:29800656 PMID:29958987 PMID:30825513 |
|
NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703
|
|
G |
Hmgcs1 |
3-hydroxy-3-methylglutaryl-CoA synthase 1 |
decreases expression increases expression multiple interactions |
EXP ISO |
Caffeine results in decreased expression of HMGCS1 mRNA Caffeine results in increased expression of HMGCS1 mRNA 2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine inhibits the reaction [Caffeine results in increased expression of HMGCS1 mRNA]; Colforsin inhibits the reaction [Caffeine results in increased expression of HMGCS1 mRNA]; Resveratrol inhibits the reaction [Caffeine results in increased expression of HMGCS1 mRNA] |
CTD |
PMID:20864626 PMID:25868845 PMID:30825513 |
|
NCBI chr 2:51,649,368...51,667,100
Ensembl chr 2:51,649,497...51,667,100
|
|
G |
Hnrnpa1 |
heterogeneous nuclear ribonucleoprotein A1 |
decreases expression |
ISO |
Caffeine results in decreased expression of HNRNPA1 protein |
CTD |
PMID:31195006 |
|
NCBI chr 7:134,375,318...134,381,610
Ensembl chr 7:134,375,150...134,381,609
|
|
G |
Hnrnpc |
heterogeneous nuclear ribonucleoprotein C |
multiple interactions |
ISO |
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of HNRNPC mRNA; Caffeine promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of HNRNPC mRNA] |
CTD |
PMID:20230807 |
|
NCBI chr15:24,779,593...24,809,213
Ensembl chr15:24,779,450...24,809,183
|
|
G |
Hnrnpdl |
heterogeneous nuclear ribonucleoprotein D-like |
decreases expression |
ISO |
Caffeine results in decreased expression of HNRNPDL protein |
CTD |
PMID:31195006 |
|
NCBI chr14:9,558,079...9,563,654
Ensembl chr14:9,557,425...9,562,506
|
|
G |
Hnrnpf |
heterogeneous nuclear ribonucleoprotein F |
decreases expression |
ISO |
Caffeine results in decreased expression of HNRNPF protein |
CTD |
PMID:31195006 |
|
NCBI chr 4:151,083,262...151,104,464
Ensembl chr 4:151,083,062...151,109,038
|
|
G |
Hnrnph1 |
heterogeneous nuclear ribonucleoprotein H1 |
decreases expression |
ISO |
Caffeine results in decreased expression of HNRNPH1 protein |
CTD |
PMID:31195006 |
|
NCBI chr10:34,692,868...34,702,849
Ensembl chr10:34,693,555...34,702,846
|
|
G |
Hnrnpk |
heterogeneous nuclear ribonucleoprotein K |
decreases expression increases expression |
EXP ISO |
Caffeine results in decreased expression of HNRNPK mRNA Caffeine results in increased expression of HNRNPK protein |
CTD |
PMID:25868845 PMID:31195006 |
|
NCBI chr17:6,262,936...6,275,001
Ensembl chr17:6,262,998...6,274,997
|
|
G |
Homer1 |
homer scaffold protein 1 |
multiple interactions |
EXP |
HOMER1 protein alternative form inhibits the reaction [Caffeine promotes the reaction [RYR2 protein results in increased secretion of Calcium]] |
CTD |
PMID:12887973 |
|
NCBI chr 2:24,542,777...24,645,715
Ensembl chr 2:24,543,093...24,644,785
|
|
G |
Hoxb7 |
homeo box B7 |
increases expression |
ISO |
Caffeine results in increased expression of HOXB7 mRNA |
CTD |
PMID:31711903 |
|
NCBI chr10:81,252,616...81,256,034
Ensembl chr10:81,252,553...81,256,034
|
|
G |
Hprt1 |
hypoxanthine phosphoribosyltransferase 1 |
increases expression |
EXP |
Caffeine results in increased expression of HPRT1 protein |
CTD |
PMID:6149265 |
|
NCBI chr X:132,736,175...132,768,149
Ensembl chr X:132,736,096...132,768,154
|
|
G |
Hras |
HRas proto-oncogene, GTPase |
multiple interactions |
ISO |
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of HRAS mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of HRAS mRNA] |
CTD |
PMID:20230807 |
|
NCBI chr 1:196,290,127...196,299,823
Ensembl chr 1:196,296,263...196,300,615
|
|
G |
Hsd11b1 |
hydroxysteroid 11-beta dehydrogenase 1 |
increases expression |
EXP |
Caffeine results in increased expression of HSD11B1 mRNA |
CTD |
PMID:22583948 PMID:30423288 PMID:30528684 |
|
NCBI chr13:104,728,539...104,798,884
Ensembl chr13:104,728,539...104,788,687
|
|
G |
Hsd11b2 |
hydroxysteroid 11-beta dehydrogenase 2 |
decreases expression multiple interactions |
EXP ISO |
Caffeine results in decreased expression of HSD11B2 mRNA ADORA2B mutant form inhibits the reaction [Caffeine results in decreased expression of and results in decreased activity of HSD11B2 protein]; ADORA2B mutant form inhibits the reaction [Caffeine results in decreased expression of HSD11B2 mRNA]; Caffeine results in decreased expression of and results in decreased activity of HSD11B2 protein; Colforsin inhibits the reaction [Caffeine results in decreased expression of and results in decreased activity of HSD11B2 protein]; Colforsin inhibits the reaction [Caffeine results in decreased expression of HSD11B2 mRNA] |
CTD |
PMID:22583948 PMID:22701600 PMID:30423288 PMID:30528684 |
|
NCBI chr19:33,397,656...33,402,899
Ensembl chr19:33,397,656...33,402,899
|
|
G |
Hsd17b7 |
hydroxysteroid (17-beta) dehydrogenase 7 |
decreases expression |
EXP |
Caffeine results in decreased expression of HSD17B7 mRNA |
CTD |
PMID:20864626 |
|
NCBI chr13:82,170,079...82,190,018
Ensembl chr13:82,173,179...82,190,017
|
|
G |
Hsd3b1 |
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 |
increases expression decreases expression |
EXP |
Caffeine results in increased expression of HSD3B1 mRNA Caffeine results in decreased expression of HSD3B1 mRNA |
CTD |
PMID:25868845 PMID:30528684 |
|
NCBI chr 2:186,169,864...186,175,984
Ensembl chr 2:186,169,863...186,175,999
|
|
G |
Hsp90aa1 |
heat shock protein 90 alpha family class A member 1 |
multiple interactions |
ISO |
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of HSP90AA1 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of HSP90AA1 mRNA] |
CTD |
PMID:20230807 |
|
NCBI chr 6:129,702,376...129,707,907
Ensembl chr 6:129,702,383...129,707,268
|
|
G |
Hsp90b1 |
heat shock protein 90 beta family member 1 |
decreases expression |
EXP |
Caffeine results in decreased expression of HSP90B1 mRNA |
CTD |
PMID:25868845 |
|
NCBI chr 7:21,110,431...21,124,762
Ensembl chr 7:21,110,457...21,124,788
|
|
G |
Hspa4 |
heat shock protein family A (Hsp70) member 4 |
increases expression |
ISO |
Caffeine results in increased expression of HSPA4 protein |
CTD |
PMID:31195006 |
|
NCBI chr10:37,408,025...37,449,080
Ensembl chr10:37,408,025...37,449,001
|
|
G |
Hspa9 |
heat shock protein family A (Hsp70) member 9 |
decreases expression |
ISO |
Caffeine results in decreased expression of HSPA9 protein |
CTD |
PMID:31195006 |
|
NCBI chr18:26,536,131...26,554,294
Ensembl chr18:26,535,798...26,554,292
|
|
G |
Hspb1 |
heat shock protein family B (small) member 1 |
increases expression decreases expression |
EXP ISO |
Caffeine results in increased expression of HSPB1 mRNA Caffeine results in decreased expression of HSPB1 protein |
CTD |
PMID:20864626 PMID:31195006 |
|
NCBI chr12:20,794,014...20,795,675
Ensembl chr12:20,794,028...20,795,743
|
|
G |
Hspb6 |
heat shock protein family B (small) member 6 |
increases expression |
EXP |
Caffeine results in increased expression of HSPB6 mRNA |
CTD |
PMID:20864626 |
|
NCBI chr 1:85,806,898...85,809,072
Ensembl chr 1:85,806,146...85,809,071
|
|
G |
Hspe1 |
heat shock protein family E (Hsp10) member 1 |
multiple interactions |
ISO |
Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of HSPE1 mRNA] |
CTD |
PMID:20230807 |
|
NCBI chr 9:56,589,912...56,593,000
Ensembl chr 9:56,589,789...56,593,089
|
|
G |
Ibsp |
integrin-binding sialoprotein |
decreases expression |
EXP |
Caffeine results in decreased expression of IBSP mRNA |
CTD |
PMID:31874197 |
|
NCBI chr14:5,439,825...5,452,570
Ensembl chr14:5,439,829...5,452,693
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
decreases expression |
ISO |
Caffeine results in decreased expression of ICAM1 mRNA |
CTD |
PMID:28089782 |
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Id3 |
inhibitor of DNA binding 3, HLH protein |
increases expression |
EXP |
Caffeine results in increased expression of ID3 mRNA |
CTD |
PMID:20864626 |
|
NCBI chr 5:148,372,784...148,374,353
Ensembl chr 5:148,372,762...148,374,349
|
|
G |
Idi1 |
isopentenyl-diphosphate delta isomerase 1 |
decreases expression |
EXP |
Caffeine results in decreased expression of IDI1 mRNA |
CTD |
PMID:20864626 PMID:25868845 |
|
NCBI chr17:61,629,592...61,637,357
Ensembl chr17:61,629,594...61,637,357
|
|
G |
Igf1 |
insulin-like growth factor 1 |
decreases secretion multiple interactions affects expression decreases activity decreases expression |
ISO EXP |
Caffeine results in decreased secretion of IGF1 protein [Caffeine co-treated with bisphenol A] results in decreased expression of IGF1 mRNA Caffeine affects the expression of IGF1 protein Caffeine results in decreased activity of IGF1 protein Caffeine results in decreased expression of IGF1 mRNA; Caffeine results in decreased expression of IGF1 protein |
CTD |
PMID:1995187 PMID:22583948 PMID:24239806 PMID:29343424 PMID:29966748 PMID:30528684 PMID:31756439 More...
|
|
NCBI chr 7:22,282,895...22,361,972
Ensembl chr 7:22,282,930...22,359,296
|
|
G |
Igf1r |
insulin-like growth factor 1 receptor |
decreases expression affects expression |
EXP |
Caffeine results in decreased expression of IGF1R mRNA; Caffeine results in decreased expression of IGF1R protein Caffeine affects the expression of IGF1R mRNA |
CTD |
PMID:22583948 PMID:29343424 PMID:29966748 PMID:30528684 |
|
NCBI chr 1:121,549,839...121,838,545
Ensembl chr 1:121,550,743...121,831,777
|
|
G |
Igfbp1 |
insulin-like growth factor binding protein 1 |
increases expression |
ISO |
Caffeine results in increased expression of IGFBP1 mRNA |
CTD |
PMID:11793227 |
|
NCBI chr14:82,047,415...82,052,482
Ensembl chr14:82,047,415...82,052,482
|
|
G |
Ikbkb |
inhibitor of nuclear factor kappa B kinase subunit beta |
increases expression |
EXP |
Caffeine results in increased expression of IKBKB mRNA |
CTD |
PMID:20864626 |
|
NCBI chr16:69,319,487...69,373,251
Ensembl chr16:69,319,554...69,373,250
|
|
G |
Il10 |
interleukin 10 |
increases expression |
ISO |
Caffeine results in increased expression of IL10 mRNA |
CTD |
PMID:28089782 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il10rb |
interleukin 10 receptor subunit beta |
increases expression |
EXP |
Caffeine results in increased expression of IL10RB mRNA |
CTD |
PMID:20864626 |
|
NCBI chr11:30,646,494...30,668,081
Ensembl chr11:30,652,096...30,668,074
|
|
G |
Il12a |
interleukin 12A |
decreases expression |
ISO |
Caffeine results in decreased expression of IL12A mRNA |
CTD |
PMID:28089782 |
|
NCBI chr 2:152,965,769...152,973,035
Ensembl chr 2:152,965,769...152,972,734
|
|
G |
Il12b |
interleukin 12B |
multiple interactions |
ISO |
Caffeine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of IL12B mRNA] |
CTD |
PMID:26852703 |
|
NCBI chr10:28,888,832...28,903,796
Ensembl chr10:28,893,008...28,902,903
|
|
G |
Il1b |
interleukin 1 beta |
decreases expression increases expression |
ISO EXP |
Caffeine results in decreased expression of IL1B mRNA Caffeine results in increased expression of IL1B mRNA |
CTD |
PMID:28089782 PMID:29055810 PMID:30776459 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il1rl1 |
interleukin 1 receptor-like 1 |
increases expression |
ISO |
Caffeine results in increased expression of IL1RL1 protein |
CTD |
PMID:20025956 |
|
NCBI chr 9:42,661,694...42,727,266
Ensembl chr 9:42,697,192...42,727,256
|
|
G |
Il3 |
interleukin 3 |
multiple interactions |
ISO |
Caffeine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of IL3 mRNA] |
CTD |
PMID:26852703 |
|
NCBI chr10:38,405,716...38,408,066
Ensembl chr10:38,405,716...38,408,066
|
|
G |
Il4r |
interleukin 4 receptor |
increases expression multiple interactions |
EXP ISO |
Caffeine results in increased expression of IL4RA mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of IL4RA mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL4RA mRNA] |
CTD |
PMID:20230807 PMID:20864626 |
|
NCBI chr 1:180,115,061...180,139,981
Ensembl chr 1:180,115,120...180,139,980
|
|
G |
Il5 |
interleukin 5 |
increases expression |
ISO |
Caffeine results in increased expression of IL5 mRNA |
CTD |
PMID:28089782 |
|
NCBI chr10:37,874,342...37,877,213
Ensembl chr10:37,874,342...37,877,213
|
|
G |
Il6 |
interleukin 6 |
decreases expression increases expression multiple interactions |
EXP ISO |
Caffeine results in decreased expression of IL6 mRNA Caffeine results in increased expression of IL6 mRNA Caffeine promotes the reaction [Lipopolysaccharides results in increased expression of IL6 protein] Caffeine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of IL6 mRNA] |
CTD |
PMID:23727198 PMID:26852703 PMID:29055810 PMID:30776459 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Ilf3 |
interleukin enhancer binding factor 3 |
increases expression |
ISO |
Caffeine results in increased expression of ILF3 protein |
CTD |
PMID:31195006 |
|
NCBI chr 8:19,922,409...19,960,495
Ensembl chr 8:19,922,460...19,960,350
|
|
G |
Impdh2 |
inosine monophosphate dehydrogenase 2 |
decreases expression |
ISO |
Caffeine results in decreased expression of IMPDH2 protein |
CTD |
PMID:31195006 |
|
NCBI chr 8:109,256,705...109,261,365
Ensembl chr 8:109,256,728...109,261,359
|
|
G |
Ino80c |
INO80 complex subunit C |
decreases expression |
EXP |
Caffeine results in decreased expression of INO80C mRNA |
CTD |
PMID:20864626 |
|
NCBI chr18:15,378,764...15,398,574
Ensembl chr18:15,378,770...15,393,403
|
|
G |
Ins2 |
insulin 2 |
multiple interactions |
ISO |
Caffeine inhibits the reaction [INS protein results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:21081844 |
|
NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775
|
|
G |
Insig1 |
insulin induced gene 1 |
decreases expression |
EXP |
Caffeine results in decreased expression of INSIG1 mRNA |
CTD |
PMID:20864626 PMID:25868845 |
|
NCBI chr 4:7,315,494...7,323,972
Ensembl chr 4:7,315,495...7,323,952
|
|
G |
Insr |
insulin receptor |
decreases expression |
EXP |
Caffeine results in decreased expression of INSR mRNA |
CTD |
PMID:22583948 |
|
NCBI chr12:1,193,193...1,330,976
Ensembl chr12:1,197,100...1,330,883
|
|
G |
Irak1 |
interleukin-1 receptor-associated kinase 1 |
multiple interactions |
ISO |
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of IRAK1 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IRAK1 mRNA] |
CTD |
PMID:20230807 |
|
NCBI chr X:151,768,621...151,778,521
Ensembl chr X:151,768,777...151,778,521
|
|
G |
Irx3 |
iroquois homeobox 3 |
multiple interactions |
ISO |
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of IRX3 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of IRX3 mRNA] |
CTD |
PMID:20230807 |
|
NCBI chr19:15,211,882...15,215,323
Ensembl chr19:15,211,878...15,215,317
|
|
G |
Itgam |
integrin subunit alpha M |
multiple interactions |
ISO |
Caffeine promotes the reaction [N-Methyl-3,4-methylenedioxyamphetamine results in increased expression of ITGAM protein] |
CTD |
PMID:19882200 |
|
NCBI chr 1:182,659,047...182,709,495
Ensembl chr 1:182,659,000...182,709,503
|
|
G |
Itm2b |
integral membrane protein 2B |
multiple interactions |
ISO |
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of ITM2B mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ITM2B mRNA] |
CTD |
PMID:20230807 |
|
NCBI chr15:48,545,998...48,568,904
Ensembl chr15:48,546,001...48,568,917
|
|
G |
Itpr1 |
inositol 1,4,5-trisphosphate receptor, type 1 |
decreases expression |
ISO |
Caffeine results in decreased expression of ITPR1 mRNA |
CTD |
PMID:18444173 |
|
NCBI chr 4:141,187,377...141,554,240
Ensembl chr 4:141,187,418...141,510,491
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
decreases phosphorylation increases expression |
ISO |
Caffeine results in decreased phosphorylation of JUN protein Caffeine results in increased expression of JUN protein |
CTD |
PMID:17145898 PMID:20025956 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Kctd14 |
potassium channel tetramerization domain containing 14 |
decreases expression |
EXP |
Caffeine results in decreased expression of KCTD14 mRNA |
CTD |
PMID:20864626 |
|
NCBI chr 1:151,761,045...151,766,693
Ensembl chr 1:151,761,663...151,766,691
|
|
G |
Khsrp |
KH-type splicing regulatory protein |
increases expression |
ISO |
Caffeine results in increased expression of KHSRP protein |
CTD |
PMID:31195006 |
|
NCBI chr 9:1,862,555...1,872,301
Ensembl chr 9:1,862,899...1,872,451
|
|
G |
Kidins220 |
kinase D-interacting substrate 220 |
increases expression |
EXP |
Caffeine results in increased expression of KIDINS220 mRNA |
CTD |
PMID:20864626 |
|
NCBI chr 6:41,618,207...41,706,990
Ensembl chr 6:41,618,294...41,703,256
|
|
G |
Kif3b |
kinesin family member 3B |
multiple interactions |
ISO |
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of KIF3B mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of KIF3B mRNA] |
CTD |
PMID:20230807 |
|
NCBI chr 3:141,758,466...141,798,012
Ensembl chr 3:141,758,466...141,797,963
|
|
G |
Klf4 |
Kruppel like factor 4 |
multiple interactions decreases expression |
ISO EXP |
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of KLF4 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of KLF4 mRNA] Caffeine results in decreased expression of KLF4 mRNA; Caffeine results in decreased expression of KLF4 protein |
CTD |
PMID:20230807 PMID:31306741 |
|
NCBI chr 5:70,278,843...70,283,751
Ensembl chr 5:70,278,972...70,283,602
|
|
G |
Krt1 |
keratin 1 |
decreases expression |
ISO |
Caffeine results in decreased expression of KRT1 protein |
CTD |
PMID:31195006 |
|
NCBI chr 7:132,976,618...132,981,844
Ensembl chr 7:132,976,620...132,981,844
|
|
G |
Krt18 |
keratin 18 |
decreases expression |
ISO |
Caffeine results in decreased expression of KRT18 protein |
CTD |
PMID:31195006 |
|
NCBI chr 7:133,157,486...133,161,162
Ensembl chr 7:133,157,475...133,161,166
|
|
G |
Krt36 |
keratin 36 |
decreases expression |
ISO |
Caffeine results in decreased expression of KRT36 protein |
CTD |
PMID:31195006 |
|
NCBI chr10:85,036,594...85,039,959
Ensembl chr10:85,036,594...85,039,959
|
|
G |
Krt84 |
keratin 84 |
decreases expression |
ISO |
Caffeine results in decreased expression of KRT84 protein |
CTD |
PMID:31195006 |
|
NCBI chr 7:132,649,064...132,656,885
Ensembl chr 7:132,649,061...132,656,874
|
|
G |
Lamb1 |
laminin subunit beta 1 |
increases expression |
ISO |
Caffeine results in increased expression of LAMB1 protein |
CTD |
PMID:31195006 |
|
NCBI chr 6:47,835,492...47,902,585
Ensembl chr 6:47,835,525...47,902,585
|
|
G |
Ldha |
lactate dehydrogenase A |
decreases expression |
ISO |
Caffeine results in decreased expression of LDHA mRNA |
CTD |
PMID:11793227 |
|
NCBI chr 1:97,371,823...97,381,247
Ensembl chr 1:97,366,021...97,433,472
|
|
G |
Ldlr |
low density lipoprotein receptor |
multiple interactions |
EXP |
[Caffeine co-treated with Dietary Fats] results in decreased expression of LDLR mRNA; Caffeine promotes the reaction [Dietary Fats results in decreased expression of LDLR mRNA] |
CTD |
PMID:29800656 |
|
NCBI chr 8:20,270,020...20,292,981
Ensembl chr 8:20,270,041...20,294,580
|
|
G |
Lep |
leptin |
decreases expression multiple interactions |
ISO EXP |
Caffeine results in decreased expression of LEP mRNA Caffeine results in decreased expression of LEP mRNA; Caffeine results in decreased expression of LEP protein 2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine inhibits the reaction [Caffeine results in decreased expression of LEP mRNA]; Colforsin inhibits the reaction [Caffeine results in decreased expression of LEP mRNA] |
CTD |
PMID:23727198 PMID:26367767 |
|
NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262
|
|
G |
Lepr |
leptin receptor |
increases expression decreases expression |
EXP |
Caffeine results in increased expression of LEPR mRNA Caffeine results in decreased expression of LEPR mRNA |
CTD |
PMID:22583948 PMID:26367767 |
|
NCBI chr 5:116,294,409...116,477,904
Ensembl chr 5:116,289,823...116,475,908
|
|
G |
Lmnb1 |
lamin B1 |
decreases expression |
ISO |
Caffeine results in decreased expression of LMNB1 protein |
CTD |
PMID:31195006 |
|
NCBI chr18:50,175,861...50,215,210
Ensembl chr18:50,175,874...50,214,502
|
|
G |
LOC100125598 |
metallothionein 1a pseudogene |
increases expression |
ISO |
Caffeine results in increased expression of MT1G mRNA |
CTD |
PMID:11793227 |
|
NCBI chr17:74,786,652...74,787,040
Ensembl chr17:74,786,654...74,787,135
|
|
G |
LOC100361854 |
ribosomal protein S26-like |
increases expression |
ISO |
Caffeine results in increased expression of RPS26 protein |
CTD |
PMID:31195006 |
|
NCBI chr X:107,822,116...107,822,555
Ensembl chr X:107,822,178...107,822,525
|
|
G |
Lpar4 |
lysophosphatidic acid receptor 4 |
multiple interactions |
ISO |
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of LPAR4 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of LPAR4 mRNA] |
CTD |
PMID:20230807 |
|
NCBI chr X:72,033,486...72,046,978
Ensembl chr X:72,033,486...72,046,977
|
|
G |
Lpl |
lipoprotein lipase |
decreases expression multiple interactions |
EXP ISO |
Caffeine results in decreased expression of LPL mRNA [Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of LPL mRNA |
CTD |
PMID:23727198 PMID:28843594 |
|
NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249
|
|
G |
Lss |
lanosterol synthase |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] affects the expression of LSS mRNA |
CTD |
PMID:28843594 |
|
NCBI chr20:12,091,138...12,118,858
Ensembl chr20:12,092,774...12,118,762
|
|
G |
Lysmd2 |
LysM domain containing 2 |
decreases expression |
EXP |
Caffeine results in decreased expression of LYSMD2 mRNA |
CTD |
PMID:20864626 |
|
NCBI chr 8:76,378,984...76,394,395
Ensembl chr 8:76,379,219...76,394,654
|
|
G |
Mael |
maelstrom spermatogenic transposon silencer |
decreases expression |
ISO |
Caffeine results in decreased expression of MAEL protein |
CTD |
PMID:31195006 |
|
NCBI chr13:78,457,073...78,496,657
Ensembl chr13:78,457,073...78,496,657
|
|
G |
Maoa |
monoamine oxidase A |
multiple interactions |
ISO |
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of MAOA mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of MAOA mRNA] |
CTD |
PMID:20230807 |
|
NCBI chr X:6,032,172...6,098,308
Ensembl chr X:6,030,795...6,099,593
|
|
G |
Map1lc3b |
microtubule-associated protein 1 light chain 3 beta |
increases cleavage multiple interactions |
ISO |
Caffeine results in increased cleavage of MAP1LC3B protein 3-(2,4-dichloro-5-methoxyphenyl)-2-sulfanyl-4(3H)-quinazolinone inhibits the reaction [Caffeine results in increased cleavage of MAP1LC3B protein]; 3-methyladenine inhibits the reaction [Caffeine results in increased cleavage of MAP1LC3B protein] 2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine inhibits the reaction [Caffeine results in increased cleavage of MAP1LC3B protein]; 3-methyladenine inhibits the reaction [Caffeine results in increased cleavage of MAP1LC3B protein]; Sirolimus promotes the reaction [Caffeine results in increased cleavage of MAP1LC3B protein]; SIRT3 protein promotes the reaction [Caffeine results in increased cleavage of MAP1LC3B protein] |
CTD |
PMID:30555576 |
|
NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690
|
|
G |
Map2k7 |
mitogen activated protein kinase kinase 7 |
multiple interactions |
ISO |
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of MAP2K7 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of MAP2K7 mRNA] |
CTD |
PMID:20230807 |
|
NCBI chr12:2,591,312...2,604,211
Ensembl chr12:2,591,219...2,604,222
|
|
G |
Map3k12 |
mitogen activated protein kinase kinase kinase 12 |
multiple interactions |
ISO |
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of MAP3K12 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of MAP3K12 mRNA] |
CTD |
PMID:20230807 |
|
NCBI chr 7:133,630,267...133,648,464
Ensembl chr 7:133,630,835...133,640,789
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
increases expression multiple interactions decreases phosphorylation |
ISO |
Caffeine results in increased expression of MAPK1 protein modified form Caffeine inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK1 protein] Caffeine results in decreased phosphorylation of MAPK1 protein |
CTD |
PMID:17145898 PMID:21081844 PMID:22974838 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk15 |
mitogen-activated protein kinase 15 |
increases expression |
EXP |
Caffeine results in increased expression of MAPK15 mRNA |
CTD |
PMID:20864626 |
|
NCBI chr 7:107,694,907...107,714,640
Ensembl chr 7:107,694,964...107,714,645
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
increases expression multiple interactions decreases phosphorylation |
ISO |
Caffeine results in increased expression of MAPK3 protein modified form Caffeine inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK3 protein] Caffeine results in decreased phosphorylation of MAPK3 protein |
CTD |
PMID:17145898 PMID:21081844 PMID:22974838 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Marchf11 |
membrane associated ring-CH-type finger 11 |
decreases expression |
EXP |
Caffeine results in decreased expression of MARCHF11 mRNA |
CTD |
PMID:20864626 |
|
NCBI chr 2:76,898,330...76,999,690
Ensembl chr 2:76,898,386...76,999,691
|
|
G |
Mc2r |
melanocortin 2 receptor |
multiple interactions |
ISO |
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of MC2R mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of MC2R mRNA] |
CTD |
PMID:20230807 |
|
NCBI chr18:62,001,980...62,015,567
Ensembl chr18:62,004,948...62,015,488
|
|
G |
Mcm3 |
minichromosome maintenance complex component 3 |
increases expression |
ISO |
Caffeine results in increased expression of MCM3 protein |
CTD |
PMID:20025956 |
|
NCBI chr 9:23,219,169...23,237,314
Ensembl chr 9:23,219,169...23,237,314
|
|
G |
Mdh2 |
malate dehydrogenase 2 |
decreases expression |
ISO |
Caffeine results in decreased expression of MDH2 protein |
CTD |
PMID:31195006 |
|
NCBI chr12:20,894,269...20,907,225
Ensembl chr12:20,894,262...20,907,271
|
|
G |
Mef2a |
myocyte enhancer factor 2a |
increases expression multiple interactions |
EXP |
Caffeine results in increased expression of MEF2A mRNA; Caffeine results in increased expression of MEF2A protein Dantrolene inhibits the reaction [Caffeine results in increased expression of MEF2A mRNA]; Dantrolene inhibits the reaction [Caffeine results in increased expression of MEF2A protein] |
CTD |
PMID:25093688 |
|
NCBI chr 1:120,847,874...120,982,488
Ensembl chr 1:120,850,080...120,981,948
|
|
G |
Mef2c |
myocyte enhancer factor 2C |
multiple interactions increases expression |
EXP |
Dantrolene inhibits the reaction [Caffeine results in increased expression of MEF2C mRNA]; Dantrolene inhibits the reaction [Caffeine results in increased expression of MEF2C protein] Caffeine results in increased expression of MEF2C mRNA; Caffeine results in increased expression of MEF2C protein |
CTD |
PMID:25093688 |
|
NCBI chr 2:13,973,299...14,136,065
Ensembl chr 2:13,993,438...14,132,880
|
|
G |
Mgst1 |
microsomal glutathione S-transferase 1 |
decreases expression |
ISO |
Caffeine results in decreased expression of MGST1 mRNA |
CTD |
PMID:11793227 |
|
NCBI chr 4:171,029,666...171,044,893
Ensembl chr 4:171,029,630...171,044,892
|
|
G |
Micb |
MHC class I polypeptide-related sequence B |
multiple interactions |
ISO |
Caffeine inhibits the reaction [[Decitabine results in decreased methylation of MICB promoter] which results in increased expression of MICB protein] |
CTD |
PMID:18395517 |
|
NCBI chr 1:78,495,779...78,513,030
Ensembl chr 1:78,495,779...78,512,827
|
|
G |
Mir101a |
microRNA 101a |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of MIR101A mRNA |
CTD |
PMID:28843594 |
|
NCBI chr 5:115,966,332...115,966,406
Ensembl chr 5:115,966,328...115,966,410
|
|
G |
Mir122 |
microRNA 122 |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] affects the expression of MIR122 mRNA |
CTD |
PMID:28843594 |
|
NCBI chr18:58,758,703...58,758,787
|
|
G |
Mir192 |
microRNA 192 |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of MIR192 mRNA |
CTD |
PMID:28843594 |
|
NCBI chr 1:203,564,946...203,565,055
Ensembl chr 1:203,564,946...203,565,055
|
|
G |
Mki67 |
marker of proliferation Ki-67 |
multiple interactions decreases expression |
EXP |
Caffeine inhibits the reaction [aluminum chloride results in decreased expression of MKI67 protein] Caffeine results in decreased expression of MKI67 protein |
CTD |
PMID:26339337 PMID:30528684 |
|
NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762
|
|
G |
Mlxipl |
MLX interacting protein-like |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of MLXIPL mRNA |
CTD |
PMID:28843594 |
|
NCBI chr12:21,542,964...21,577,120
Ensembl chr12:21,543,576...21,577,112
|
|
G |
Mmp13 |
matrix metallopeptidase 13 |
increases expression |
EXP |
Caffeine results in increased expression of MMP13 mRNA |
CTD |
PMID:31874197 |
|
NCBI chr 8:4,497,960...4,508,239
Ensembl chr 8:4,497,960...4,508,239
|
|
G |
Mmp7 |
matrix metallopeptidase 7 |
multiple interactions |
ISO |
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of MMP7 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of MMP7 mRNA] |
CTD |
PMID:20230807 |
|
NCBI chr 8:4,848,186...4,855,908
Ensembl chr 8:4,848,186...4,855,902
|
|
G |
Mogat1 |
monoacylglycerol O-acyltransferase 1 |
decreases expression |
EXP |
Caffeine results in decreased expression of MOGAT1 mRNA |
CTD |
PMID:20864626 |
|
NCBI chr 9:79,980,963...79,988,513
Ensembl chr 9:79,956,649...79,988,513
|
|
G |
Mos |
MOS proto-oncogene, serine/threonine kinase |
increases expression |
ISO |
Caffeine results in increased expression of MOS protein |
CTD |
PMID:31195006 |
|
NCBI chr 5:16,859,957...16,861,264
Ensembl chr 5:16,859,957...16,861,264
|
|
G |
Mrm3 |
mitochondrial rRNA methyltransferase 3 |
decreases expression |
EXP |
Caffeine results in decreased expression of MRM3 mRNA |
CTD |
PMID:20864626 |
|
NCBI chr10:61,095,920...61,125,421
Ensembl chr10:61,095,952...61,102,630
|
|
G |
Mrpl19 |
mitochondrial ribosomal protein L19 |
decreases expression |
EXP |
Caffeine results in decreased expression of MRPL19 mRNA |
CTD |
PMID:20864626 |
|
NCBI chr 4:114,521,824...114,526,053
Ensembl chr 4:114,521,824...114,526,053
|
|
G |
Mrpl20 |
mitochondrial ribosomal protein L20 |
multiple interactions |
ISO |
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of MRPL20 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of MRPL20 mRNA] |
CTD |
PMID:20230807 |
|
NCBI chr 5:166,408,962...166,413,492
Ensembl chr 5:166,408,962...166,413,492
|
|
G |
mrpl9 |
mitochondrial ribosomal protein L9 |
multiple interactions |
ISO |
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of MRPL9 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of MRPL9 mRNA] |
CTD |
PMID:20230807 |
|
NCBI chr 2:182,082,012...182,086,758
Ensembl chr 2:182,076,369...182,087,095
|
|
G |
Mrps5 |
mitochondrial ribosomal protein S5 |
increases expression |
ISO |
Caffeine results in increased expression of MRPS5 protein |
CTD |
PMID:31195006 |
|
NCBI chr 3:114,821,046...114,837,291
Ensembl chr 3:114,821,046...114,837,291
|
|
G |
Msh2 |
mutS homolog 2 |
decreases expression |
EXP |
Caffeine results in decreased expression of MSH2 mRNA |
CTD |
PMID:12706856 |
|
NCBI chr 6:6,813,793...6,872,960
Ensembl chr 6:6,813,795...6,872,938
|
|
G |
Msmo1 |
methylsterol monooxygenase 1 |
decreases expression |
EXP |
Caffeine results in decreased expression of MSMO1 mRNA |
CTD |
PMID:20864626 PMID:25868845 |
|
NCBI chr16:24,980,680...24,997,927
Ensembl chr16:24,980,697...24,998,016
|
|
G |
Mt2A |
metallothionein 2A |
multiple interactions |
ISO |
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of MT2 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of MT2 mRNA] |
CTD |
PMID:20230807 |
|
NCBI chr19:10,832,009...10,832,783
Ensembl chr19:10,832,002...10,832,784
|
|
G |
Mtch1 |
mitochondrial carrier 1 |
multiple interactions |
ISO |
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of MTCH1 mRNA; Caffeine promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of MTCH1 mRNA] |
CTD |
PMID:20230807 |
|
NCBI chr20:7,389,942...7,413,426
Ensembl chr20:7,389,949...7,413,426
|
|
G |
Mtf2 |
metal response element binding transcription factor 2 |
multiple interactions |
ISO |
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of MTF2 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of MTF2 mRNA] |
CTD |
PMID:20230807 |
|
NCBI chr14:1,639,256...1,683,513
Ensembl chr14:1,640,746...1,683,524
|
|
G |
Mthfd2l |
methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2-like |
decreases expression |
EXP |
Caffeine results in decreased expression of MTHFD2L mRNA |
CTD |
PMID:20864626 |
|
NCBI chr14:17,089,947...17,170,036
Ensembl chr14:17,089,952...17,170,112
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
decreases activity |
ISO |
Caffeine results in decreased activity of MTOR protein |
CTD |
PMID:21081844 |
|
NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311
|
|
G |
Mtrr |
5-methyltetrahydrofolate-homocysteine methyltransferase reductase |
decreases expression |
EXP |
Caffeine results in decreased expression of MTRR mRNA |
CTD |
PMID:20864626 |
|
NCBI chr 1:34,866,991...34,899,425
Ensembl chr 1:34,867,089...34,899,425
|
|
G |
Mutyh |
mutY DNA glycosylase |
increases expression |
EXP |
Caffeine results in increased expression of MUTYH mRNA |
CTD |
PMID:20864626 |
|
NCBI chr 5:130,274,034...130,286,149
Ensembl chr 5:130,274,122...130,286,146
|
|
G |
Mvd |
mevalonate diphosphate decarboxylase |
decreases expression |
EXP |
Caffeine results in decreased expression of MVD mRNA |
CTD |
PMID:25868845 |
|
NCBI chr19:50,496,366...50,506,389
Ensembl chr19:50,496,367...50,507,971
|
|
G |
Mvk |
mevalonate kinase |
increases expression |
EXP |
Caffeine results in increased expression of MVK mRNA |
CTD |
PMID:25868845 |
|
NCBI chr12:42,141,391...42,158,858
Ensembl chr12:42,141,384...42,158,882
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
multiple interactions |
EXP |
Caffeine promotes the reaction [[2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine co-treated with Dietary Fats] results in increased expression of MYC mRNA] |
CTD |
PMID:18283038 |
|
NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
|
|
G |
Myh7 |
myosin heavy chain 7 |
increases expression multiple interactions |
EXP |
Caffeine results in increased expression of MYH7 mRNA Curcumin inhibits the reaction [Caffeine results in increased expression of MYH7 mRNA]; Curcumin promotes the reaction [KN 93 inhibits the reaction [Caffeine results in increased expression of MYH7 mRNA]]; Cyclosporine inhibits the reaction [Caffeine results in increased expression of MYH7 mRNA]; Dantrolene inhibits the reaction [Caffeine results in increased expression of MYH7 mRNA]; KN 93 inhibits the reaction [Caffeine results in increased expression of MYH7 mRNA]; KN 93 promotes the reaction [Curcumin inhibits the reaction [Caffeine results in increased expression of MYH7 mRNA]] |
CTD |
PMID:25093688 |
|
NCBI chr15:28,446,550...28,469,888
Ensembl chr15:28,446,550...28,468,217
|
|
G |
Myl6b |
myosin light chain 6B |
decreases expression |
ISO |
Caffeine results in decreased expression of MYL6B protein |
CTD |
PMID:31195006 |
|
NCBI chr X:40,572,012...40,572,991
|
|
G |
Myof |
myoferlin |
increases expression |
ISO |
Caffeine results in increased expression of MYOF protein |
CTD |
PMID:31195006 |
|
NCBI chr 1:235,673,666...235,822,413
Ensembl chr 1:235,673,666...235,822,334
|
|
G |
Nat2 |
N-acetyltransferase 2 |
increases acetylation affects metabolic processing |
ISO |
NAT2 protein results in increased acetylation of Caffeine NAT2 gene polymorphism affects the metabolism of Caffeine; NAT2 protein affects the metabolism of Caffeine |
CTD |
PMID:14586384 PMID:14586387 PMID:14747882 PMID:15199075 PMID:15327588 PMID:15558239 PMID:15980104 PMID:24221535 More...
|
|
NCBI chr16:22,207,362...22,238,513
Ensembl chr16:22,208,194...22,238,520
|
|
G |
Ncl |
nucleolin |
increases expression |
ISO |
Caffeine results in increased expression of NCL protein |
CTD |
PMID:31195006 |
|
NCBI chr 9:86,999,588...87,008,112
Ensembl chr 9:86,998,019...87,008,136
|
|
G |
Ndufb5 |
NADH:ubiquinone oxidoreductase subunit B5 |
multiple interactions |
ISO |
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of NDUFB5 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of NDUFB5 mRNA] |
CTD |
PMID:20230807 |
|
NCBI chr 2:115,519,248...115,533,589
Ensembl chr 2:115,519,154...115,533,589
|
|
G |
Ndufs4 |
NADH:ubiquinone oxidoreductase subunit S4 |
multiple interactions |
ISO |
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of NDUFS4 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of NDUFS4 mRNA] |
CTD |
PMID:20230807 |
|
NCBI chr 2:45,951,327...46,061,829
Ensembl chr 2:45,951,313...46,061,846
|
|
G |
Nefh |
neurofilament heavy chain |
affects expression |
EXP |
Caffeine affects the expression of NEFH mRNA |
CTD |
PMID:22954530 |
|
NCBI chr14:79,830,362...79,840,347
Ensembl chr14:79,830,362...79,840,351
|
|
G |
Neurog2 |
neurogenin 2 |
increases expression |
ISO |
Caffeine results in increased expression of NEUROG2 mRNA |
CTD |
PMID:31711903 |
|
NCBI chr 2:216,092,641...216,095,276
Ensembl chr 2:216,093,363...216,094,154
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions |
ISO |
Caffeine inhibits the reaction [Lipopolysaccharides affects the localization of NFKB1 protein] |
CTD |
PMID:22974838 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO |
Caffeine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased phosphorylation of NFKBIA protein] |
CTD |
PMID:26852703 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nisch |
nischarin |
multiple interactions |
EXP |
Caffeine inhibits the reaction [[moxonidine binds to and results in increased activity of NISCH protein] which results in decreased susceptibility to Ethanol] |
CTD |
PMID:22613216 |
|
NCBI chr16:6,364,370...6,400,675
Ensembl chr16:6,364,374...6,400,668
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
Caffeine inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased abundance of Nitric Oxide]; Caffeine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of NOS2 mRNA]; Caffeine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of NOS2 protein]; Caffeine inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; Caffeine inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein] |
CTD |
PMID:22974838 PMID:26852703 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nos3 |
nitric oxide synthase 3 |
multiple interactions |
EXP |
[Isoproterenol co-treated with Caffeine] results in decreased expression of NOS3 mRNA |
CTD |
PMID:29447158 |
|
NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166
|
|
G |
Notch1 |
notch receptor 1 |
multiple interactions |
ISO |
NOTCH1 protein mutant form inhibits the reaction [Caffeine promotes the reaction [[Doxorubicin co-treated with Nocodazole co-treated with Hydroxyurea] results in increased cleavage of CASP3 protein]] |
CTD |
PMID:31597699 |
|
NCBI chr 3:9,277,955...9,323,531
Ensembl chr 3:9,278,086...9,323,531
|
|
G |
Nphs2 |
NPHS2 stomatin family member, podocin |
decreases expression |
EXP |
Caffeine results in decreased expression of NPHS2 mRNA |
CTD |
PMID:25986755 PMID:31306741 |
|
NCBI chr13:68,448,720...68,461,312
Ensembl chr13:68,448,926...68,461,313
|
|
G |
Npl |
N-acetylneuraminate pyruvate lyase |
multiple interactions |
ISO |
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of NPL mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of NPL mRNA] |
CTD |
PMID:20230807 |
|
NCBI chr13:65,655,099...65,697,464
Ensembl chr13:65,655,118...65,697,372
|
|
G |
Nppa |
natriuretic peptide A |
multiple interactions increases expression |
EXP |
Caffeine analog inhibits the reaction [2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine inhibits the reaction [Phenylephrine results in increased expression of NPPA mRNA]]; Dantrolene inhibits the reaction [Caffeine results in increased expression of NPPA mRNA] |
CTD |
PMID:15452191 PMID:25093688 |
|
NCBI chr 5:158,429,042...158,430,351
Ensembl chr 5:158,429,042...158,430,351
|
|
G |
Nppb |
natriuretic peptide B |
increases expression multiple interactions |
EXP |
Caffeine results in increased expression of NPPB mRNA Dantrolene inhibits the reaction [Caffeine results in increased expression of NPPB mRNA] |
CTD |
PMID:25093688 |
|
NCBI chr 5:158,416,813...158,418,175
Ensembl chr 5:158,416,866...158,418,168
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions |
ISO |
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of NQO1 mRNA |
CTD |
PMID:28843594 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Nr3c1 |
nuclear receptor subfamily 3, group C, member 1 |
increases expression |
EXP |
Caffeine results in increased expression of NR3C1 mRNA; Caffeine results in increased expression of NR3C1 protein |
CTD |
PMID:22583948 PMID:30423288 PMID:30528684 PMID:30776459 PMID:31306741 PMID:32663519 More...
|
|
NCBI chr18:31,271,681...31,393,320
Ensembl chr18:31,271,681...31,393,375
|
|
G |
Nr3c2 |
nuclear receptor subfamily 3, group C, member 2 |
increases expression |
EXP |
Caffeine results in increased expression of NR3C2 mRNA |
CTD |
PMID:22959462 |
|
NCBI chr19:30,715,648...31,059,885
Ensembl chr19:30,715,648...31,059,885
|
|
G |
Nr5a1 |
nuclear receptor subfamily 5, group A, member 1 |
increases methylation decreases expression |
EXP |
Caffeine results in increased methylation of NR5A1 promoter Caffeine results in decreased expression of NR5A1 mRNA; Caffeine results in decreased expression of NR5A1 protein |
CTD |
PMID:24717552 |
|
NCBI chr 3:22,464,786...22,486,328
Ensembl chr 3:22,465,502...22,486,328
|
|
G |
Nrf1 |
nuclear respiratory factor 1 |
decreases expression |
EXP |
Caffeine results in decreased expression of NRF1 mRNA |
CTD |
PMID:20864626 |
|
NCBI chr 4:58,664,932...58,772,328
Ensembl chr 4:58,664,957...58,825,328
|
|
G |
Nsf |
N-ethylmaleimide sensitive factor, vesicle fusing ATPase |
multiple interactions |
ISO |
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of NSF mRNA; Caffeine promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of NSF mRNA] |
CTD |
PMID:20230807 |
|
NCBI chr10:88,727,912...88,857,375
Ensembl chr10:88,727,912...88,857,386
|
|
G |
Nt5e |
5' nucleotidase, ecto |
decreases activity multiple interactions |
EXP |
Caffeine results in decreased activity of NT5E protein caffeic acid inhibits the reaction [Caffeine results in decreased activity of NT5E protein]; Caffeine promotes the reaction [caffeic acid results in decreased activity of NT5E protein] |
CTD |
PMID:28465162 |
|
NCBI chr 8:89,271,046...89,314,918
Ensembl chr 8:89,270,696...89,314,881
|
|
G |
Nupr1 |
nuclear protein 1, transcriptional regulator |
multiple interactions |
ISO |
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of NUPR1 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of NUPR1 mRNA] |
CTD |
PMID:20230807 |
|
NCBI chr 1:181,213,292...181,215,327
|
|
G |
Oat |
ornithine aminotransferase |
increases expression |
ISO |
Caffeine results in increased expression of OAT mRNA |
CTD |
PMID:11793227 |
|
NCBI chr 1:187,347,862...187,367,644
Ensembl chr 1:187,347,865...187,367,682
|
|
G |
Olig3 |
oligodendrocyte transcription factor 3 |
increases expression |
ISO |
Caffeine results in increased expression of OLIG3 mRNA |
CTD |
PMID:31711903 |
|
NCBI chr 1:14,081,259...14,083,336
Ensembl chr 1:14,081,328...14,082,149
|
|
G |
Orm1 |
orosomucoid 1 |
increases expression |
ISO |
Caffeine results in increased expression of ORM1 protein |
CTD |
PMID:20025956 |
|
NCBI chr 5:76,766,637...76,776,149
Ensembl chr 5:76,772,941...76,776,154
|
|
G |
Oxsr1 |
oxidative stress responsive kinase 1 |
increases expression |
EXP |
Caffeine results in increased expression of OXSR1 mRNA |
CTD |
PMID:20864626 |
|
NCBI chr 8:118,972,754...119,062,102
Ensembl chr 8:118,972,754...119,062,027
|
|
G |
P3h3 |
prolyl 3-hydroxylase 3 |
multiple interactions |
ISO |
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of P3H3 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of P3H3 mRNA] |
CTD |
PMID:20230807 |
|
NCBI chr 4:157,646,238...157,662,035
Ensembl chr 4:157,646,243...157,695,509
|
|
G |
Pak1 |
p21 (RAC1) activated kinase 1 |
decreases expression |
EXP |
Caffeine results in decreased expression of PAK1 mRNA |
CTD |
PMID:29343424 |
|
NCBI chr 1:152,111,172...152,226,390
Ensembl chr 1:152,111,188...152,226,383
|
|
G |
Pak2 |
p21 (RAC1) activated kinase 2 |
multiple interactions increases activity |
ISO |
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of PAK2 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PAK2 mRNA] Caffeine results in increased activity of PAK2 protein |
CTD |
PMID:19325779 PMID:20230807 |
|
NCBI chr11:68,708,070...68,766,622
Ensembl chr11:68,707,969...68,768,816
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
affects cleavage decreases response to substance multiple interactions increases cleavage |
ISO EXP |
Caffeine affects the cleavage of PARP1 protein PARP1 protein results in decreased susceptibility to Caffeine Caffeine inhibits the reaction [Doxorubicin results in increased cleavage of PARP1 protein] [Caffeine co-treated with Alprazolam] results in increased activity of PARP1 protein; [PARP1 protein results in decreased susceptibility to Caffeine] promotes the reaction [N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride results in increased expression of CDKN1A mRNA]; Caffeine promotes the reaction [Capsaicin results in increased cleavage of and results in increased activity of PARP1 protein]; Caffeine results in increased cleavage of and results in increased expression of PARP1 protein Caffeine results in increased cleavage of PARP1 protein |
CTD |
PMID:16522534 PMID:19242509 PMID:19490937 PMID:21229324 PMID:21840268 PMID:22226932 PMID:30377735 More...
|
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pax3 |
paired box 3 |
decreases expression |
ISO |
Caffeine results in decreased expression of PAX3 mRNA |
CTD |
PMID:31711903 |
|
NCBI chr 9:79,567,455...79,664,042
Ensembl chr 9:79,568,634...79,664,042
|
|
G |
Pcare |
photoreceptor cilium actin regulator |
decreases expression |
ISO |
Caffeine results in decreased expression of PCARE protein |
CTD |
PMID:31195006 |
|
NCBI chr 6:23,749,700...23,758,419
Ensembl chr 6:23,749,757...23,758,169
|
|
G |
Pcna |
proliferating cell nuclear antigen |
affects expression |
EXP |
Caffeine affects the expression of PCNA mRNA; Caffeine affects the expression of PCNA protein |
CTD |
PMID:29343424 |
|
NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995
|
|
G |
Pcsk9 |
proprotein convertase subtilisin/kexin type 9 |
decreases expression |
EXP |
Caffeine results in decreased expression of PCSK9 mRNA |
CTD |
PMID:25868845 |
|
NCBI chr 5:121,211,278...121,233,688
Ensembl chr 5:121,211,278...121,233,688
|
|
G |
Pde11a |
phosphodiesterase 11A |
decreases expression |
EXP |
Caffeine results in decreased expression of PDE11A mRNA |
CTD |
PMID:20864626 |
|
NCBI chr 3:60,913,562...61,297,154
Ensembl chr 3:60,913,562...61,297,158
|
|
G |
Pde5a |
phosphodiesterase 5A |
decreases expression |
EXP |
Caffeine results in decreased expression of PDE5A mRNA |
CTD |
PMID:20864626 |
|
NCBI chr 2:210,858,515...211,003,480
Ensembl chr 2:210,858,063...210,999,701
|
|
G |
Pdhx |
pyruvate dehydrogenase complex, component X |
decreases expression |
EXP |
Caffeine results in decreased expression of PDHX mRNA |
CTD |
PMID:20864626 |
|
NCBI chr 3:89,372,472...89,396,759
Ensembl chr 3:89,371,497...89,431,773
|
|
G |
Pdia6 |
protein disulfide isomerase family A, member 6 |
multiple interactions |
ISO |
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of PDIA6 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PDIA6 mRNA] |
CTD |
PMID:20230807 |
|
NCBI chr 6:40,062,980...40,080,223
Ensembl chr 6:40,062,926...40,080,613
|
|
G |
Pfdn1 |
prefoldin subunit 1 |
multiple interactions |
ISO |
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of PFDN1 mRNA; Caffeine promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PFDN1 mRNA] |
CTD |
PMID:20230807 |
|
NCBI chr18:28,014,145...28,067,148
Ensembl chr18:28,014,145...28,067,064
|
|
G |
Pfkm |
phosphofructokinase, muscle |
affects expression |
ISO |
Caffeine affects the expression of PFKM protein |
CTD |
PMID:25486098 |
|
NCBI chr 7:129,221,679...129,259,192
Ensembl chr 7:129,221,653...129,259,192
|
|
G |
Pgk2 |
phosphoglycerate kinase 2 |
decreases expression |
ISO |
Caffeine results in decreased expression of PGK2 protein |
CTD |
PMID:31195006 |
|
NCBI chr 9:20,480,367...20,481,933
Ensembl chr 9:20,480,203...20,571,481
|
|
G |
Pgr |
progesterone receptor |
increases expression |
EXP |
Caffeine results in increased expression of PGR mRNA |
CTD |
PMID:20864626 |
|
NCBI chr 8:6,073,216...6,131,552
Ensembl chr 8:6,072,673...6,131,344
|
|
G |
Phb1 |
prohibitin 1 |
multiple interactions |
ISO |
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of PHB mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PHB mRNA] |
CTD |
PMID:20230807 |
|
NCBI chr10:80,605,268...80,618,043
Ensembl chr10:80,605,251...80,618,042
|
|
G |
Phex |
phosp | |